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SUMMARY
Introduction
Electrocardiographic evidence of left ventricular 
hypertrophy (LVH) in hypertensive patients is 
associated with increased mortality, and in particular 
with an increased incidence of sudden death. 
Multivariate analysis of the Glasgow Blood Pressure 
Clinic mortality data has shown that the risk 
associated with this electrocardiographic abnormality 
is in excess of that attributable to the associated 
hypertension, suggesting an independent contribution of 
left ventricular hypertrophy to mortality. The 
mechanism of this increased risk is unknown although 
sudden death in such patients is frequently attributed 
to myocardial infarction.
Other forms of cardiac hypertrophy, in particular 
hypertrophic cardiomyopathy, are also associated with 
sudden death; in hypertrophic cardiomyopathy, 
ambulatory electrocardiographic monitoring has revealed 
a high prevalence of ventricular arrhythmias including 
episodes of non-sustained ventricular tachycardia; 
furthermore, follow-up studies have demonstrated that 
such arrhythmias are predictive of subsequent sudden 
death.
Thus it was postulated that a tendency to ventricular 
arrhythmia, rather than a predisposition to myocardial
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infarction, might explain the excess mortality 
associated with left ventricular hypertrophy in 
hypertensive patients.
Studies
1. Validation of the diagnosis of left ventricular 
hypertrophy in the Glasgow Blood Pressure Clinic.
Before interpreting the Glasgow Blood Pressure Clinic 
mortality data too widely, some form of validation of 
the electrocardiographic diagnosis of left ventricular 
hypertrophy was required.
Detection of left ventricular hypertrophy in the clinic 
was based on the reports of many clinicians over a 
period of fifteen years without standardised criteria. 
Using echocardiography as the "gold standard" for 
detection of LVH in vivo, the sensitivity of the ECG 
reporting system was 62% with a specificity of 77%.
The sensitivity compares favourably with other series, 
although the specificity is low.
In an attempt to improve the ECG diagnosis of left 
ventricular hypertrophy, four different sets of 
electrocardiographic criteria were examined. Overall, 
the criteria of Sokolow-Lyon and Romhilt-Estes were the 
most sensitive and specific. However, when patients 
were subdivided into "obese" and "non-obese," it was 
demonstrated that body build had different effects on
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different criteria. The clinical significance of this 
is that stratification of patients by body build might 
improve the electrocardiographic diagnosis of left 
ventricular hypertrophy.
2. Prevalence of ventricular arrhythmias in 
hypertensive patients with and without 
electrocardiographic left ventricular hypertrophy.
To determine whether ventricular arrhythmias occur 
commonly in hypertensive patients with left ventricular 
hypertrophy, forty-eight hour ambulatory ECG monitoring 
was carried out in fifty normotensive control subjects 
and in one hundred hypertensive patients comprising 
fifty with electrocardiographic left ventricular 
hypertrophy (Sokolow-Lyon criteria) and fifty without. 
To control for any possible effect of hypertension 
itself on arrhythmia frequency, the two hypertensive 
groups were matched with each other for initial and 
achieved blood pressure; in addition, all three groups 
were matched for age, sex and smoking habit.
Ventricular arrhythmias were uncommon in the control 
group; all grades of arrhythmia occurred more commonly 
in the hypertensives, particularly in those with left 
ventricular hypertrophy, of whom 28% had at least one 
episode of ventricular tachycardia (three or more 
consecutive ventricular complexes) compared with 8% of 
those hypertensives without left ventricular
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hypertrophy. Among those with left ventricular 
hypertrophy and ST-T changes (the so-called LVH and 
"strain" pattern), over 50% had at least one episode of 
ventricular tachycardia.
3. Influence of diuretic therapy on arrhythmia 
frequency.
In view of the suggestion from several studies that 
diuretic-induced hypokalaemia may predispose to 
ventricular arrhythmias and sudden death, the 
distribution of ventricular arrhythmias was examined 
separately in those patients whose antihypertensive 
treatment included a diuretic. Although diuretic 
therapy was clearly associated with a lower serum 
potassium concentration, there was no suggestion that 
this degree of hypokalaemia increased arrhythmia 
frequency in patients with or without left ventricular 
hypertrophy.
4. Relationship of ventricular arrhythmia to coronary 
artery disease and to myocardial histology.
Further investigations, including coronary 
arteriography and left ventricular endomyocardial 
biopsy, were undertaken in those patients thought to be 
at increased risk of sudden death. Of seventeen 
patients with hypertension, left ventricular
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hypertrophy and ventricular tachycardia during 
ambulatory monitoring, nine (53%) were free of 
significant coronary artery disease (stenosis of 70% or 
greater in a major epicardial vessel) and none had 
triple vessel disease; this suggests that occult 
coronary disease is not the cause of the high 
prevalence of ventricular arrhythmias in hypertensive 
patients with left ventricular hypertrophy.
To examine the importance of myocardial factors in the 
pathophysiology of ventricular arrhythmias, left 
ventricular biopsies from eleven patients with left 
ventricular hypertrophy and ventricular tachycardia 
were analysed for fibrous tissue content by a point 
counting technique and compared with biopsies from 
sixteen patients also with left ventricular 
hypertrophy, but without ventricular tachycardia during 
ambulatory monitoring. Percentage fibrosis was 
significantly greater in those patients with 
ventricular tachycardia than in those without (13+3% 
vs. 2+1%, p<0.001) suggesting that the state of the 
myocardium, rather than the state of the coronary 
arteries, is important in the pathogenesis of 
ventricular arrhythmias in hypertensive patients with 
left ventricular hypertrophy.
5. Ventricular compliance in hypertensive LVH.
Finally, an echocardiographic study of the
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hypertrophied ventricle was undertaken. This 
demonstrated that diastolic compliance of the left 
ventricle declines as left ventricular mass rises. 
Filling of the ventricle will then become more 
dependent on atrial contraction. Thus the hypertrophied 
left ventricle may be more sensitive, on account of its 
abnormal filling pattern, to any arrhythmia involving 
loss of atrial transport function.
Conclusion
Thus high grade ventricular arrhythmias occur commonly 
in hypertensive left ventricular hypertrophy. Their 
prevalence is not attributable to occult coronary 
artery disease, nor to hypokalaemia, but is related to 
the presence of subendocardial fibrosis. This tendency 
to ventricular arrhythmia might explain why left 
ventricular hypertrophy is associated with a high 
mortality rate in excess of that attributable to the 
associated hypertension. It may be, therefore, that 
forms of therapy other than those aimed at reduction of 
blood pressure, perhaps including anti-arrhythmic drug 
therapy, will be required to reduce mortality in this 
high risk group.
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CHAPTER 1
A CASE HISTORY
A fifty-four year old gentleman was referred by his 
general practitioner to a medical outpatient clinic for 
investigation and treatment of hypertension. The 
patient was entirely asymptomatic, the elevated blood 
pressure having been found at a routine clinical 
examination. Apart from a cholecystectomy, there was no 
past history of serious illness and he was a 
non-smoker.
Clinical examination at the outpatient clinic revealed 
a blood pressure of 212/127 mm Hg recumbent and a 
thrusting but non-displaced cardiac apex beat; the 
optic fundi showed arteriolar narrowing but no 
haemorrhages or exudates. The remainder of the clinical 
examination was normal. In view of the high pressure, 
he was admitted to hospital for a period of inpatient 
assessment.
The following investigations were carried out:
1. chest X-ray - heart size at the upper limit of 
normal with a left ventricular configuration.
2. electrocardiogram - left ventricular hypertrophy by 
chest lead criteria with lateral ST-T changes ("LVH and 
strain"). The ECG is illustrated in figure 1.
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Figure 1
ECG at presentation (BP212 / 1 27mmHg)
3. full blood count - normal
4. blood urea - normal
5. serum electrolytes - normal
6. blood glucose - normal
7. fasting lipids - normal
8. urinary catecholamines - normal
9. intravenous pyelogram - Prompt excretion seen 
bilaterally. No evidence of renal artery stenosis or 
parenchymal renal disease.
Thus there appeared to be no evidence of an underlying 
cause for his hypertension and the diagnosis, by 
exclusion, was essential hypertension.
His blood pressure was initially difficult to control 
but satisfactory levels were eventually achieved on a 
combination of propranolol, minoxidil and frusemide. He 
was discharged home and was reviewed regularly over the 
next eight years at the outpatient clinic; his general 
health was good and his blood pressure control 
excellent, average readings being around 130/85 mm Hg. 
Then, at the age of sixty-three, he died suddenly and 
unexpectedly. There had been no premonitory symptoms. 
His general practioner, believing a myocardial 
infarction to be the most likely cause of death, 
entered this as the cause of death on the death 
certificate, although the patient had never experienced 
chest pain. A post-mortem examination was not 
performed.
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In summary, this gentleman’s only risk factor for 
ischaemic heart disease was hypertension. Despite 
impeccable control of blood pressure, he had died 
suddenly and prematurely and his death had been 
attributed to a myocardial infarction.
Discussion
This case history was the stimulus to the studies to be 
described in this thesis. At about the time of this 
man’s death, the first analysis of mortality from the 
Glasgow Blood Pressure Clinic was being discussed; this 
demonstrated that mortality was particularly high in 
hypertensive patients with electrocardiographic 
evidence of left ventricular hypertrophy (1). A review 
of the literature revealed that left ventricular 
hypertrophy was a major, although often neglected risk 
factor for cardiovascular mortality. The pathogenesis 
of LVH was not entirely clear and it appeared that 
factors other than blood pressure may influence its 
development. Furthermore, data from the Framingham 
study had suggested that the risk associated with ECG 
LVH was in excess of that attributable to hypertension 
alone, suggesting an independent contribution of left 
ventricular hypertrophy to mortality (2). The mechanism 
of this excess risk was not clear.
Also around this time, it had been shown that in other 
forms of cardiac hypertrophy, notably hypertrophic
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cardiomyopathy, ventricular arrhythmias occur commonly 
during ambulatory electrocardiographic monitoring and 
are predictive of subsequent sudden death (3).
Thus it was postulated that a primary ventricular 
arrhythmia, rather than a myocardial infarction, might 
have been the cause of this patient's sudden death.
The studies to be described investigate the 
relationships between left ventricular hypertrophy and 
ventricular arrhythmias and suggest a possible 
explanation for the high mortality associated with left 
ventricular hypertrophy in hypertensive patients.
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CHAPTER 2
A REVIEW OF THE LITERATURE
2.1 INTRODUCTION
In this section, the development of left ventricular 
hypertrophy and its relationship to arterial pressure 
is discussed. Since the studies to be described in this 
thesis are essentially clinical, the literature on 
experimental left ventricular hypertrophy is dealt with 
briefly, with reference mainly to major reviews. There 
then follows a review of the incidence, prevalence, and 
diagnosis of left ventricular hypertrophy in man 
together with an analysis of the associated risk. The 
structural and functional adaptations of the 
hypertrophied ventricle are then reviewed, again with 
brief reference to experimental animal models. The 
complex relationships between hypertension, left 
ventricular hypertrophy, coronary artery disease and 
myocardial ischaemia are then examined. The evidence 
for recent changes in attitudes towards sudden cardiac 
death is presented with particular reference to left 
ventricular hypertrophy.
Finally, hypertrophic cardiomyopathy is described and 
similarities between this and hypertensive heart 
disease outlined.
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2.2 DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN 
HYPERTENSION.
Primitive cardiac muscle cells can be identified early 
in embryonic life and the mammalian heart begins to 
contract at about eleven days gestation (4). At first 
the myofibrils are randomly arranged but soon align 
themselves parallel to the direction of maximum force 
development. Hyperplasia (increase in cell number) and 
hypertrophy (increase in cell size) continue throughout 
foetal life (5). The rate of division of myocytes slows 
markedly at birth and stops at about four weeks in 
experimental models (5). Any increase in muscle cell 
mass after this period is, therefore, usually 
attributed to cellular enlargement rather than to cell 
division.
The major determinant of left ventricular hypertrophy 
(LVH) is the "afterload" i.e. the load against which 
the left ventricle must pump. The true afterload is 
determined not only by the arterial pressure but by 
other factors including the left ventricular wall 
thickness and left ventricular internal diameter and is 
more accurately reflected by the left ventricular wall 
tension or stress which effectively represents the 
amount of force generated per unit of myocardium. After 
heart rate, left ventricular wall stress is the next 
most important determinant of myocardial oxygen
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consumption and it has been suggested that the ultimate 
aim of cardiac hypertrophy is to maintain the wall
tension within normal limits (6). The wall stress, or
tension, can be calculated from the Law of Laplace 
which states that the wall tension (T) of a thin-walled 
sphere is related to the radius (r) of the sphere and 
to the pressure within it (P) (7):
T = P x r/2
This expression is modified as follows if the sphere 
has a significant wall thickness (WT):
T = P x r/2WT 
or P = T x 2WT/r
or P varies as 2WT/r
Thus, if the pressure increases and the left 
ventricular internal radius remains constant, left 
ventricular wall thickness must increase in order to 
prevent the wall tension from rising. Indeed, if the 
wall stress is to remain constant, then we would expect 
that the pressure (P) would be directly proportional to 
the ratio of left ventricular wall thickness (WT) to 
left ventricular radius (r).
In man, Grossman et al have studied this relatioship by 
comparing patients with chronic pressure overload and
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patients with chronic volume overload with normal 
control subjects (8). Compared to the controls, both 
patient groups had markedly increased left ventricular 
mass. Left ventricular systolic pressure was greatly 
increased in the presence of pressure, but not volume, 
overload and wall thickness was increased in both 
groups. However, the ratio of wall thickness to cavity 
radius was increased only in the pressure overload 
group. Using a modification of the Law of Laplace, 
calculated values for systolic wall stress were normal 
for both the pressure and volume overload groups. Thus 
the cardiac hypertrophy prevents an increase in 
systolic wall stress (force per unit myocardium) which 
would otherwise occur in the presence of raised 
pressure. Furthermore, other studies in man have shown 
that the ratio of left ventricular radius to wall 
thickness bears a constant relationship to systolic 
blood pressure which holds for both physiological and 
pathological forms of hypertrophy (9).
There is some evidence that this "normalisation" of 
wall stress allows the contractile machinery to operate 
at its most efficient length. Using electron microscopy 
to measure the length of individual sarcomeres, it has 
been shown that the sarcomere length in the 
hypertrophied ventricle corresponds to a point on the 
steep slope of the Frank-Starling curve in both 
chronically dilated (10) and hypertrophied hearts (11). 
It is evident that hypertrophy cannot occur
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instantaneously and that the relationship between wall 
stress, cavity radius and wall thickness will vary with 
time. If the pressure load is introduced acutely, as by 
banding of the aorta in dogs, then an initial increase 
in wall stress occurs followed by an increase in wall 
thickness so that the wall stress has returned to 
normal within three months (12).
Thus increased wall stress is probably the stimulus to 
hypertrophy of the myocardial cells although the 
mechanism at a cellular level has not been fully 
elucidated. Certainly increased manufacture of 
contractile proteins is detectable soon after wall 
stress is increased in experimental left ventricular 
hypertrophy. Schreiber et al have detected increased 
RNA activity (13) and increased production of myosin, 
mitochondria and microsomes (14) within hours of aortic 
banding in dogs. While the muscle stretch itself may be 
directly responsible for increased RNA transcription 
(15), cellular deficiency of ATP, the ultimate energy 
source within the cell, and accumulation of cyclic AMP 
in the face of increased workload (16,17) have been 
suggested as an alternative mechanism.
Whatever the cellular processes involved, it has been 
shown that the distribution of hypertrophy in 
experimental LVH is such that those areas subjected to 
the greatest stress show the greatest hypertrophy (18); 
this observation is in keeping with the concept that 
wall stress is the principal determinant of cardiac
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hypertrophy.
2.3 NON-PRESSURE MODULATORS OF LEFT VENTRICULAR 
HYPERTROPHY
If arterial pressure is the sole determinant of left 
ventricular hypertrophy, we might expect a close 
correlation between arterial pressure and left 
ventricular mass. Early studies suggested that this was 
so. Animal studies of experimental renovascular 
hypertension in rats demonstrated this with respect not 
only to the development, but also the reversal, of 
cardiac hypertrophy (19). Early studies of left 
ventricular hypertrophy in man also suggested a close 
relationship between systolic blood pressure and the 
presence of left ventricular hypertrophy (20). However, 
this has been challenged by a more recent clinical 
study in which only a weak correlation between left 
ventricular mass and the level or duration of 
hypertension was found (21). In other forms of 
experimental hypertension, for example the 
spontaneously hypertensive rat (SHR), Sen has drawn 
attention to the poor relationship between arterial 
blood pressure and degree of left ventricular 
hypertrophy (22). There are several possible 
explanations for this.
First, casual blood pressure recordings may not reflect 
mean blood pressure over the course of the day. When 
blood pressure is measured continuously over 24 hours 
using an intra-arterial canula, a closer relationship
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does emerge between blood pressure and left ventricular 
mass (23). This finding has been confirmed by Rowlands 
(24) who showed a significant correlation between left 
ventricular mass index (LVMI) assessed 
echocardiographically and mean intra-arterial systolic 
blood presure over 24 hours but no significant 
correlation between LVMI and casual systolic blood 
pressure. Second, arterial pressure is not the only 
determinant of the pressure load against which the 
heart must work; better, although less easily measured 
determinants of this load are the aortic impedance and 
the left ventricular myocardial wall stress which is 
dependent on the diameter of the left ventricular 
cavity and the left ventricular wall thickness as well 
as the blood pressure.
Even when these factors are taken into account, the 
coorrelation between blood pressure and LVH remains 
relatively poor, suggesting that factors other than the 
level and duration of blood pressure might modify the 
development and regression of LVH.
The following factors are believed to influence the 
development of LVH independently of blood pressure:
A. Age
The effects of ageing on cardiac structure in both 
experimental animals and in man have been extensively 
reviewed (25,26). It appears that progressive
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hypertrophy of the ventricular wall occurs with 
increasing age even in the absence of significant 
hypertension (25). It is well established, however, 
that arterial pressure does rise progressively with age 
even though it may not exceed some arbitrary upper 
limit of normal, and it is thus difficult to separate 
this effect from the rise in left ventricular mass.
With ageing, the arterial tree also becomes "stiff" or 
non-compliant, causing a rise in aortic input impedance 
which could, conceivably, stimulate left ventricular 
hypertrophy even in the absence of a detectable rise in 
blood pressure. In practice, it is likely that both 
mechanisms contribute to the increase in left 
ventricular wall thickness with age which is of the 
order of 25% over a period of fifty years (27).
B. Race
Racial differences in the pathophysiology of 
hypertension have been reviewed by Gillum (28). Several 
studies, including the Hypertension Detection and 
Follow-Up Program (HDFP) (29) and the Evans County 
Georgia Study (30) have demonstrated that black 
hypertensive patients develop more electrocardiographic 
evidence of cardiac involvement for a given elevation 
of blood pressure than do white hypertensives. In 
addition, Dunn has shown that mean left ventricular 
mass measured by echocardiography is higher in black
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"than in white hypertensives even when the two groups 
are matched for age, sex and mean arterial pressure
(31). This finding has recently been confirmed by 
Hammond in an echocardiographic study which 
demonstrated that increased left ventricular mass was 
twice as prevalent in black as in white hypertensives
(32). In contrast, enlargement of the left ventricular 
chamber was more common in white hypertensives 
suggesting that volume overload was more common in 
whites. The same authors also noted differences in the 
prevalence of LVH between men and women; however, most 
studies define separate sex-specific normal ranges for 
left ventricular mass and thus sex is not usually 
regarded as a determinant of LVH.
C. Physical Exercise
Athletes who perform repeated isometric exercise, such 
as weight-lifters or shot-putters, require brief 
increases in cardiac output against a high systolic 
aortic pressure that can reach 300 mm Hg; consequently, 
they develop left ventricular hypertrophy with only 
slight chamber enlargement (33). The hypertrophy may be 
quite marked and an echocardiographic study has 
demonstrated that there is often disproportionate 
thickening of the septum mimicking hypertrophic 
cardiomyopathy (33). Although this is often regarded as 
"physiological" hypertrophy, there have been no
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long-term studies on the fate of such individuals. 
Athletes engaging in endurance exercise such as 
long-distance running or swimming also develop some 
thickening of the left ventricular wall and thus raise 
their left ventricular mass; however, the principal 
cardiac adaptation in this case is an increase in left 
ventricular volume and thus in stroke volume to allow 
development of a greater cardiac output during exercise 
(34,35). Similar changes have been documented in 
experimental animals. Carew and Covell have shown that 
both wall thickness and left ventricular cavity size 
are increased by exercise in greyhounds (36) while 
Pfeffer et al have shown that an intensive swimming 
programme increases left ventricular cavity size and 
left ventricular mass in rats (37).
D. The sympathetic nervous system
The role of catecholamines in left ventricular 
hypertrophy has been reviewed recently (38). Most of 
the work has been in experimental models of 
hypertension and centres around four main areas of 
research.
First, LVH can be induced by the chronic infusion of 
catecholamines. Isoprenaline was first used in 1959 
(39) and noradrenaline in 1970 (40) to induce LVH in 
dogs. Laks and Marady induced left ventricular 
hypertrophy in rats by infusing subpressor doses of
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noradrenaline (41), and suggested that noradrenaline 
might be the "myocardial hypertrophy hormone" (42). 
Yamori et al also produced left ventricular hypertrophy 
in rats by infusion of noradrenaline despite concurrent 
administration of an alpha adrenergic blocker which 
prevented any rise in blood pressure (43). The same 
group noted that beta adrenergic receptor blockade 
significantly reduced the degree of hypertrophy that 
resulted from noradrenaline infusion (43).
Second, several investigators have measured both total 
myocardial catecholamines and catecholamine 
concentration in experimental LVH. These investigations 
have yielded different results in different 
experimental models. Myocardial hypertrophy secondary 
to a pure pressure load, such as constriction of the 
aorta appears to reduce myocardial noradrenaline 
concentration (44) although total content of 
noradrenaline is normal until a late stage when cardiac 
failure supervenes. In other animal models of 
hypertension, similar changes were noted in 
renovascular hypertension in rats (38) but not in 
spontaneously hypertensive rats (SHR) in which total 
ventricular catecholamine content was increased (38). 
These results are difficult to interpret; it has been 
suggested that left ventricular hypertrophy occurring 
in the SHR could be a form of primary cardiomyopathy 
(45) since it occurs early and may precede the 
hypertension. This is a difficult point to establish
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experimentally and, if correct, it could explain the 
difference between SHR and other experimental models of 
LVH since primary hypertrophic cardiomyopathy in man 
may also be associated with excess catecholamines (46).
The third area of research concerns the contractile 
response of isolated hypertrophied myocardium to 
inotropic stimulation. It has been demonstrated that 
the response to beta adrenergic stimulation is reduced 
in both SHR (47) and experimental renovascular 
hypertension (48). Initially this was thought to be due 
to a reduction in cardiac beta adrenergic receptors in 
the hypertrophied myocardium but a number of 
intracellular alterations have now been identified in 
the chain of events leading from the beta receptor to 
to activation of adenylate cyclase (49). These hearts, 
however, remain capable of responding to different 
types of stress. Saragoca and Tarazi (48) have 
suggested that the reduction in inotropic 
responsiveness represents a shift in the heart's 
reserve mechanisms, with less dependence on beta 
adrenergic stimulation as a means of increasing cardiac 
output during stress and more dependence on the 
Frank-Starling mechanism.
Finally, experimental work has been directed at the 
regression of LVH. In spontaneously hypertensive rats, 
drugs that reduce circulating catecholamines, such as 
methyldopa, cause regression of LVH while those that
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activate the sympathetic system, such as thiazides, do 
not, despite the fact that both drugs control blood 
pressure (38). Indeed, in this animal model, reversal 
of hypertrophy was found to be related to ventricular 
catecholamine levels but not to degree of blood 
pressure control, although as noted earlier, the 
pathogenesis of hypertrophy may be different in the SHR 
when compared with other experimental models.
In man, evidence for the importance of the sympathetic 
system has centred on the effects of different 
anti-hypertensive agents on the reversal of LVH. 
Devereux has shown that blood pressure control with 
diuretics, which activate the sympathetic nervous 
system, did not produce regression of LVH while 
treatment with beta-blockers, either alone or in 
combination with captopril, did reduce LVH for the same 
degree of blood pressure control (50). Others, however, 
have found that reduction of blood pressure does 
regress LVH regardless of the effects on the 
sympathetic nervous system; for example, the 
Hypertension Detection and Follow-Up Program (HDFP) 
demonstrated that aggressive treatment of blood 
pressure, usually with diuretics, both reduced the rate 
of development of electrocardiographic LVH and produced 
some regression of ECG LVH when this was present at 
entry (51). Echocardiographic analysis of a subgroup of 
the HDFP study also demonstrated significant regression 
of LVH (52) and this has been confirmed in at least one
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other study where diuretics were used as the sole 
anti-hypertensive agent (53).
E. Renin angiotensin system
A direct stimulating action of angiotensin II on 
protein synthesis in myocardial cells has been 
suggested (54). In experimental hypertension, changes 
in plasma renin activity have been shown to correlate 
with changes in left ventricular mass during drug 
treatment of hypertension in spontaneously hypertensive 
rats (55). Sen et al have demonstrated that treatment 
with minoxidil controls blood pressure but increases 
plasma renin activity and left ventricular mass while 
treatment with propranolol reduces plasma renin 
activity and left ventricular mass without 
significantly reducing blood pressure (55). In a later 
study, the same authors demonstrated that an 
angiotensin converting enzyme inhibitor effectively 
prevented and, if already present, reversed left 
ventricular hypertrophy in spontaneously hypertensive 
rats (56).
In human studies, however, the marked haemodynamic 
effects of angiotensin make it difficult to dissociate 
pressure-induced changes in left ventricular mass from 
possible direct myocardial effects.
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F. Expansion of intravascular volume
Conditions associated with volume overload such as 
chronic anaemia (57), renal failure (58) and obesity 
(59) increase the preload rather than the afterload 
with respect to the left ventricle. The initial 
response to increased preload is an increase in the 
diameter of the ventricle. However, according to the 
Law of Laplace, the wall stress increases as the 
diameter increases and this in itself is a stimulus to 
hypertrophy. However, the ratio of left ventricular 
wall thickness to chamber diameter is said to remain 
constant in obese hypertensives in contrast to the 
situation in the non-obese hypertensive in whom 
thickening of the ventricular wall occurs without any 
increase in chamber size (59).
G. Other humoral factors
Many other hormones, including thyroxine (60), growth 
hormone (60) and parathormone (61) have been invoked as 
inducers of cardiac hypertrophy because, in each case, 
excess circulating hormone is associated with increased 
left ventricular mass. As with other vaso-active 
hormones, however, it is difficult to separate their 
effects on blood pressure from any possible direct 
effect on the myocardium.
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Summary
In summary, the mechanism of cardiac hypertrophy is not 
fully understood. While arterial pressure is the prime 
stimulus to the development of hypertrophy, it is clear 
that this can be modified by various genetic and 
neuro-endocrine factors. In some experimental 
situations, such neuro-endocrine factors can produce 
cardiac hypertrophy in the absence of measurable 
hypertension. Whether this occurs in man is not known 
although it is possible that hypertrophic 
cardiomyopathy, which can be difficult to distinguish 
from hypertensive heart disease, represents one end of 
a spectrum in the relationship between blood pressure 
and cardiac hypertrophy.
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2.4 DIAGNOSIS OF LEFT VENTRICULAR HYPERTROPHY IN MAN
Left ventricular hypertrophy can often be detected on 
clinical examination when palpation of the praecordium 
reveals a "heaving" or "thrusting1’ cardiac apex often 
accompanied by a soft fourth heart sound. However, 
clinical examination is highly subjective and is thus 
not used for the diagnosis of LVH in epidemiological 
studies.
The two most commonly used investigations for detection 
of left ventricular hypertrophy are electrocardiography 
and echocardiography. Chest radiography was also used 
previously but cannot differentiate cardiac enlargement 
secondary to ventricular hypertrophy from that 
secondary to chamber dilatation and will not be 
discussed further. At this point, however, it is 
worthwhile defining three terms, two of which are 
derived from the use of radiography to identify LVH, 
which are commonly confused:
1. Concentric LVH
This is the normal response of the ventricle to a 
pressure load such as hypertension or aortic stenosis. 
It implies thickening of the left ventricular wall 
without dilation of the left ventricular cavity; the 
wall thickness to cavity ratio, therefore, is 
increased.
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2. Eccentric LVH
This is the normal response to a volume load and 
implies hypertrophy with dilation of the cavity such 
that the wall thickness to cavity ratio remains 
constant. This occurs pathologically in mitral and 
aortic incompetence and also physiologically in 
endurance athletes.
This state was defined as "eccentric" during the 
Framingham study because the dilated heart becomes 
"eccentric" with respect to the thorax on chest X-ray.
3. Asymmetrical hypertrophy
This implies disproportionate thickening of the 
interventricular septum such that the ratio of septal 
thickness to left ventricular posterior wall thickness 
exceeds an arbitrary value of 1.3:1. It is typical, but 
not diagnostic, of hypertrophic cardiomyopathy and may 
also occur in young hypertensives and in some athletes.
Diagnosis of left ventricular hypertrophy by 
electrocardiography.
Even in the earliest days of electrocardiography, 
Einthoven (62) and Lewis (63) recognised that specific
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electrocardiographic patterns occurred in association 
with, hypertrophy of the cardiac chambers. However, it 
was not until 1942 when, to allow prognosis in 
hypertension to be estimated for insurance purposes, 
Gubner and Ungerleider defined specific criteria for 
left ventricular hypertrophy (64). Their criteria were 
based not on any post-mortem verification of left 
ventricular hypertrophy but on a comparison of EGG 
patterns in groups of patients with and without 
hypertension. At that time, only the standard limb 
leads were available; they considered left ventricular 
hypertrophy to be present when the sum of the R wave in 
lead I and the S wave in lead III exceeded 25mm, the 
ECG being standardised at 10mm=lmV. In addition, the 
presence of ST segment depression was noted and they 
suggested that the combination of increased voltages 
and ST segment depression, labelled "strain", was 
associated with marked hypertrophy. Furthermore Gubner 
and Ungerleider suggested that the increased amplitude 
of the QRS complex was most likely to be directly 
attributable to increased left ventricular mass and 
that changes in the ST segment and T wave were a 
manifestation of subendocardial ischaemia. Although 
their criteria are less commonly used, the principles 
behind them persist. In 1949, Sokolow and Lyon 
published a study comparing the ECG characteristics of 
147 patients with abnormal ECGs and a clinical 
diagnosis of hypertension, aortic valvular disease or
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coarctation of the aorta with 151 normal subjects (65). 
The amplitude of each P,Q,R,S and T wave from all 
twelve leads of each tracing was calculated. Their main 
conclusions involved the use of unipolar chest leads 
for the diagnosis of left ventricular hypertrophy. They 
found the characteristic and diagnostic changes, in 
order of frequency, to be:
a) a depressed ST segment and asymmetric inversion of 
the T wave in lead V5 or V6. In early cases, the T wave 
could be low, biphasic or flat in association with a 
depressed ST segment.
b) increase in voltage of the QRS complex with the R 
wave in V5 or V6 exceeding 26mm and/or the the sum of 
the R wave in V5 and the S wave in VI exceeding 35mm.
c) the onset of intrinsic deflection (i.e. the 
ventricular activation time) exceeding 0.05 seconds in 
lead V5 or V6.
These criteria are far from ideal but remain the most 
commonly used criteria for the detection of left 
ventricular hypertrophy in the clinical setting 
although over thirty different sets of criteria have 
since been derived. In 1960, Allenstein and Mori 
evaluated eight sets of ECG criteria for left 
ventricular hypertrophy in a post-mortem study (66).
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Left ventricular hypertrophy was considered to foe 
present if the left ventricular wall thickness exceeded 
10 mm. Most of the ECG criteria examined had low 
sensitivity; that is, they were unable reliably to 
detect left ventricular hypertrophy. However, the 
criteria of Sokolow and Lyon had acceptably high 
sensitivity but low specificity i.e. they produced a 
large number of "false positives". It was then noted 
that most of the false positives were related to the 
presence of ST segment and T wave abnormalities; if 
these were ignored, and reliance placed only on the QRS 
voltage criteria, then the specificity of the 
Sokolow-Lyon criteria was significantly increased. In 
another post-mortem study of 100 cases, Scott found 
that the Sokolow-Lyon criteria were the most reliable 
for the detection of left ventricular hypertrophy 
although specificity was not measured (67). In 1964, 
Carter and Estes (68) re-established the importance of 
ST-T changes in the diagnosis of left ventricular 
hypertrophy when they demonstrated that post-mortem 
heart weight correlated not only with QRS amplitude but 
also with QRS duration, left ventricular activation 
time, ST segment depression and left axis deviation. 
These findings were developed into a point scoring 
system for diagnosis of LVH by Romhilt and Estes in 
1967 (69).
By the 1970s, it was apparent that there were major 
limitations to the ECG diagnosis of left ventricular
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hypertrophy. First, many of the criteria had been 
derived from populations in which the prevalence and 
severity of LVH were high and they performed poorly 
when applied to other groups including normal 
populations. Second, factors other than left 
ventricular mass were shown to affect the sensitivity 
and specificity of different ECG criteria. Murphy (70) 
showed that the type of cardiac disease was important, 
praecordial voltage criteria being sensitive for left 
ventricular hypertrophy secondary to hypertension or 
valvular heart disease but insensitive for hypertrophy 
in patients with ischaemic heart disease. Geometric 
considerations also were seen to be important since 
left ventricular hypertrophy accompanied by chamber 
enlargement produced greater praecordial voltages than 
hypertrophy without chamber enlargement (71,72).
In an attempt to improve the ECG diagnosis of LVH, more 
complex methods of analysis including multiple logistic 
linear regression equations were used to derive new 
criteria which could then be prospectively validated. 
Using such methods, Casale et al derived ECG criteria 
that have greater predictive accuracy than the more 
commonly used Sokolow-Lyon criteria and Romhilt-Estes 
point scoring system (73). They point out, however, 
that further improvement in ECG performance for 
detection of LVH could be achieved if patients are 
stratified for age and sex and different criteria 
applied to different groups.
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Diagnosis of left ventricular hypertrophy by 
echocardiography.
The application of echocardiography to the measurement 
of left ventricular wall thickness in man was first 
described in 1972 (74). The method was initially 
validated against angiographic measurements made in the 
same patients, but in 1977 Devereux and Reichek 
published results of a comparison of antemortem 
echocardiographic measurements and post-mortem left 
ventricular weight in thirty-four subjects, all of whom 
had undergone echocardiography within 120 days of death 
(75). Using a simple formula which assumes the 
ventricle to be a cube, they obtained a correlation 
co-efficient between echocardiographic ventricular mass 
obtained from M-mode tracings and anatomic left 
ventricular weight of 0.96. Other studies have 
confirmed that estimation of left ventricular mass is a 
more sensitive index of LVH than simple measurement of 
wall thickness (76). Methods using different geometric 
equations for estimation of left ventricular mass have 
been described but are no more accurate (77).
Recently, two dimensional echocardiography has become 
widely available and methods of estimating mass from 
the two-dimensional image described (78,79). Although 
these have theoretical advantages over M-mode 
estimates, in which the ventricle is assumed to be
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regular in shape, studies in hypertensive patients have 
not shown any differences between the two techniques. 
Not surprisingly, the two dimensional method is more 
accurate in the small proportion of patients who have 
left ventricular aneurysms or other major causes of 
geometric distortion of the ventricle.
Overall, the principal advantages of the echocardiogram 
over the electrocardiogram are its superior 
sensitivity, allowing detection of milder degrees of 
cardiac hypertrophy, and its ability to quantify left 
ventricular mass and thus detect sequential changes in 
response to treatment. In their post-mortem study, 
Devereux and Reichek found the sensitivity of the 
echocardiogram for detection of LVH to be 93%; ECG 
criteria performed less well with a sensitivity of 50% 
for the Romhilt-Estes point scoring system and 21% for 
the Sokolow-Lyon voltage criteria. The specificity of 
both sets of ECG criteria and of echocardiography was 
95% (75). The disadvantages of echocardiography are 
that it is less widely available than 
electrocardiography, more time-consuming and more 
expensive. In addition, it is not possible to obtain 
high quality tracings in all subjects; patients who are 
obese, are cigarette smokers or have chronic lung 
disease are often technically difficult subjects and as 
many as 10-20% of patients may be unsuitable for 
detailed echocardiographic examination.
In summary, the electrocardiogram and echocardiogram
are both commonly used for the detection of left 
ventricular hypertrophy. For epidemiological purposes, 
ECG criteria utilising multiple logistic linear 
regression equations and stratification of patients by 
age and sex holds promise for increased sensitivity. In 
the clinical setting, however, the praecordial voltage 
criteria of Sokolow-Lyon and the point scoring system 
of Romhilt-Estes remain in common use. Both have 
reasonable specificity (approximately 90%) but low 
sensitivity, varying from 20% to 70% in different 
series. The echocardiogram has practical disadvantages, 
especially in large-scale studies, but is quantitative 
rather than qualitative and is more sensitive for 
detection of mild degrees of hypertrophy than the ECG.
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2.5 INCIDENCE AND PREVALENCE OF LEFT VENTRICULAR 
HYPERTROPHY
Both the ECG and the echocardiogram have been used to 
study the prevalence of LVH.
Assessed by electrocardiography.
Electrocardiography is the most widely used technique 
for the diagnosis of LVH. Most of our knowledge 
concerning the prevalence and incidence of 
electrocardiographic LVH has been derived from the 
Framingham study (2,80,81,82) which is unique in 
general population surveys in terms of the number of 
subjects, duration of follow-up and completeness of 
data. The Framingham study is a longitudinal study of 
5209 men and women aged 30-62 from a representative 
general population sample with a follow-up period 
exceeding twenty years. As well as routine examination, 
blood pressure measurement and chest X-ray, a thirteen 
lead electrocardiograph was taken at entry and then at 
each biennial return visit. Information relating to all 
major medical events was obtained from hospital records 
and from attending physicians; in addition, death 
certificates and medical examiners reports were 
reviewed. The drop-out rate from the study was low; of 
the initial cohort of 5209 persons, 4678 were still 
alive sixteen years later and of these, 86% attended
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for the examination. Even those who failed to attend 
were not entirely lost to follow-up since local 
hospital admissions were monitored and relatives 
interviewed. Thus the authors' claim that loss to 
examination is unlikely to have led to any substantial 
loss of information relating to the appearance of new 
cardiovascular disease seems to be justified. 
Electrocardiographic left ventricular hypertrophy was 
divided into "definite" and "possible," the former 
being the presence of voltage amplitude criteria with 
ST-T abnormalities and the latter being voltage 
amplitude criteria alone. The voltage criteria 
fulfilled could be any one of the following:
RI + SIII >, 25mm
RaVl ^ 11mm
RaVf + SaVf ^ 20mm
SV1 + RV5  ^35mm
any single praecordial deflection ^ 20mm
The overall prevalence of "definite" ECG LVH (i.e. LVH 
with repolarisation changes) was 1.5%. Prevalence rose 
sharply with age; LVH with repolarisation changes was 
uncommon at age 35 but affected 10% of subjects by the 
age of seventy and was slightly more common in men than 
in women. The prevalence of "possible" LVH (i.e. 
voltage criteria without repolarisation changes) was 
similar to that of "definite" LVH and also increased
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with age.
The longitudinal nature of the study also allows us to 
estimate an incidence rate. Over a period of twelve 
years, 3% of the original cohort developed definite ECG 
LVH and 4.5% of those without any evidence of LVH at 
entry developed voltage criteria. Thus ECG evidence of 
LVH was either present at entry, or developed during 
twelve years of follow-up, in 10% of this normal 
population group. Those with "possible" LVH were twenty 
times more likely to develop "definite" LVH than those 
without any LVH at entry. This is to be expected since 
voltage criteria with ST-T changes simply indicate 
greater hypertrophy than voltage changes alone (83,84). 
Thus the "possible" group from Framingham can be 
regarded as having moderate left ventricular 
hypertrophy while the "definite" group have more 
advanced hypertrophy. As Kannel points out, the 
development of ECG LVH occurs at a rate greater than 
that suggested by the prevalence data because of the 
high mortality associated with this ECG finding (81).
As expected, the Framingham study demonstrated a strong 
association between blood pressure and ECG LVH. The 
higher the blood pressure, the more likely was the 
patient to have, or to develop, ECG LVH. Over 50-6 of 
those with systolic blood pressure readings exceeding 
200 mm Hg had ECG LVH and the relationship was in 
general more striking with respect to systolic than to 
diastolic blood pressure. Abnormalities of
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repolarisation, including ST segment depression and T 
wave inversion were also more common as pressure rose.
A further analysis, derived from the original 
Framingham study, is of relevance here. In 1982, Savage 
et al reported on the prevalence of LVH in a "second 
generation" Framingham cohort comprising offspring and 
spouses of the initial subjects (mean age 44, range 
17-77 years) (85). The prevalence of LVH with 
repolarisation changes was only 0.2% compared with 1.5% 
in the original cohort; although the two groups were 
not ideally matched, this result has been widely 
interpreted as signifying a considerable reduction in 
the prevalence of left ventricular hypertrophy over a 
period of twenty years and has been attributed to the 
use of effective anti-hypertensive therapy (85).
Assessed by echocardiography
The Framingham data have also been used to define the 
prevalence of echocardiographic left ventricular 
hypertrophy (85,86). Using previously derived 
sex-specific upper limits of normal for left 
ventricular mass, the overall prevalence of 
echocardiographic left ventricular hypertrophy was 10-5 
reflecting the greater sensitivity of the 
echocardiogram for detection of left ventricular 
hypertrophy when compared with the ECG. As with ECG 
LVH, the prevalence of echocardiographic LVH rose
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sharply with age, being present in 6% of those under 
the age of fifty compared with 33% of men and 50% of 
women over the age of eighty. Prevalence also rose 
sharply with blood pressure.
In a recent review, Devereux noted that between 26% and 
48% of all hypertensive patients had echocardiographic 
LVH (87). Hammond et al have also recently reported on 
the prevalence of echocardiographic LVH among patients 
with uncomplicated hypertension (32). Again using 
sex-specific values for left ventricular mass, they 
identified LVH in 12% of patients with borderline 
hypertension (140-159 mm Hg systolic or 90-94 mm Hg 
diastolic after being recumbent for twenty minutes) and 
20% of patients with sustained hypertension (^160 
systolic or ,^95 diastolic).
In summary, the prevalence of left ventricular 
hypertrophy rises with age as well as with blood 
pressure. On average, between one-quarter and one-half 
of all hypertensive patients have echocardiographic LVH 
and approximately half of those will have ECG LVH.
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2.6 LEFT VENTRICULAR HYPERTROPHY AND RISK
As with incidence and prevalence of left ventricular 
hypertrophy, the Framingham study is the major source 
of data relating left ventricular hypertrophy to 
mortality and morbidity (2,80,81,82). The first paper 
relating specifically to left ventricular hypertrophy 
and risk was published in 1969 (80); this demonstrated 
that LVH with and without ST-T changes was associated 
with increased mortality in both men and women. For 
example, 60% of men and 41% of women with LVH and ST-T 
changes died during the first fourteen years of the 
study compared with 25% and 12% of age-matched groups 
without LVH. A similar pattern was seen in all age 
groups. Although the absolute risk of death was 
greatest in in the oldest age group, the relative risk 
of dying (risk in those with LVH divided by the risk in 
those without) was greatest in the youngest age group. 
As expected, the increase in mortality was confined to 
cardiovascular causes of death.
The initial findings have been confirmed in a more 
recent publication based on a twenty year follow-up 
period (2). Calculation of age-adjusted mortality rates 
demonstrates that LVH with repolarisation changes is 
associated with an increase in total mortality by a 
factor of 5.0 in men and 4.7 in women compared with a 
normal ECG, and increased cardiovascular mortality by a 
factor of 8.5 in men and 9.6 in women (2). LVH without
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ST T changes is associated with approximately a 
two-fold increase in total mortality and a three-fold 
increase in cardiovascular mortality. In all groups 
most of the excess mortality is attributed to coronary 
heart disease and sudden death.
A criticism of the Framingham study, and of other 
epidemiological studies, is that sudden death has in 
the past been considered to be almost synonomous with 
acute myocardial infarction. An example of this in the 
Framingham analysis is seen in the relationship between 
ECG LVH and the "risk of clinical manifestations of 
coronary disease" which include angina, myocardial 
infarction and sudden death (2). There is, however, 
some evidence from the data of a particularly strong 
association between left ventricular hypertrophy and 
sudden death. Compared to a normal ECG, LVH in men is 
associated with a two-fold increase in angina, a 
three-fold increase in myocardial infarction and an 
almost six-fold increase in sudden death. This suggests 
either that the case fatality rate for myocardial 
infarction is increased by the presence of LVH or that 
not all of the sudden deaths in LVH patients are 
attributable to myocardial infarction. This is 
discussed further in chapter 2.9.
The Framingham data demonstrate also that 
cardiovascular morbidity is substantially increased by 
the presence of LVH. In addition to an increase in 
myocardial infarction and cardiac failure, there is an
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increased incidence of stroke and occlusive peripheral 
vascular disease (2).
Since left ventricular hypertrophy is related both to 
the duration and to the severity of hypertension, it is 
not surprising that it should be associated with 
increased cardiovascular morbidity and mortality. 
However, the Framingham data suggest that LVH is an 
independent risk factor for mortality since the 
presence of LVH, for a given level of blood pressure, 
carries three times the risk of hypertension without 
LVH. Furthermore, multivariate analysis demonstrates a 
significant net effect of ECG LVH with ST-T changes on 
mortality that is independent of associated risk 
factors including blood pressure, smoking habit, plasma 
glucose, and serum cholesterol (81). In contrast, the 
authors suggest that the increased risk of LVH without 
ST-T changes is entirely attributable to the associated 
hypertension.
In summary, ECG LVH is a major risk factor for 
cardiovascular morbidity and mortality. The Framingham 
data demonstrate that the risk associated with LVH in 
the presence of ST-T changes is not wholly attributable 
to associated risk factors, suggesting an independent 
contribution of LVH, at least when accompanied by ST-T 
changes, to mortality.
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2.7 STRUCTURE AND FUNCTION OF THE HYPERTROPHIED 
VENTRICLE
Changes in both the structure and function of the left 
ventricle occur with the development of hypertrophy.
A. Structural changes
Since division of myocytes ceases at the age of three 
months in man (87), any increase in left ventricular 
muscle mass implies hypertrophy of the individual 
myocytes. It should be noted, however, that the 
myocytes may become polyploid and thus increased 
chromosomal material has been reported in hypertrophy 
(88).
Although there is no division of myocytes, hyperplasia 
of the connective tissue cells and increase in collagen 
content do occur with cardiac hypertrophy (89). Whether 
this increase in collagen is appropriate to, or in 
excess of, the accompanying hypertrophy is 
controversial and depends partly on the method used to 
estimate collagen production. Sasaki measured 
hydroxyproline content as an index of collagen 
systhesis in hypertrophied human myocardium and found 
this to be increased (90). Caspari measured collagen 
concentration in normal and hypertrophied hearts with 
and without aortic valve disease (91) and reported 
that, in the absence of valve disease, collagen content
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was increased in hypertrophied hearts while collagen 
concentration (expressed as mg. collagen per g. dry 
weight) was normal. In the presence of aortic stenosis, 
however, both content and concentration of collagen 
were increased. Although the authors suggest that 
collagen concentration is affected by the nature of the 
stimulus to hypertrophy, the individual heart weights 
are not recorded. Thus an alternative explanation would 
be that the degree of hypertrophy was greater in the 
hearts with aortic stenosis, and that there is a 
"critical weight" above which increased collagen 
production occurs.
When volume fraction of collagen was measured by point 
counting, this was found to be raised (92). Increase in 
collagen occurs particularly in the subendocardial area 
(92) and it has been suggested that tissue hypoxia is 
the stimulus to collagen production, since in vitro 
studies have shown that hypoxia stimulates collagen 
synthesis by fibroblasts (93). An alternative 
explanation is that increased collagen content in the 
subendocardium reflects an increase in, or altered 
distribution of, left ventricular wall stress (8). 
Whatever the mechanism, it appears that hyperplasia of 
fibroblasts and increased collagen synthesis, 
particularly in the subendocardium, both occur with the 
development of myocardial hypertrophy.
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B. Functional changes
Systolic function of the hypertrophied ventricle
The contractile properties of hypertrophied myocardium 
have been studied in the intact heart in both man and 
experimental animals and at a cellular level in 
experimental hypertrophy.
The "end stage" of hypertensive heart disease involves 
dilatation of the previously hypertrophied left 
ventricle with clinical development of heart failure. 
Clearly, myocardial contractility is reduced at this 
stage; there is much debate, however, as to whether 
contractility is reduced at an earlier stage when the 
ventricle is hypertrophied but not dilated.
In experimental hypertension, several studies have 
demonstrated normal or even elevated indices of 
systolic function in the intact hypertrophied, but not 
dilated, ventricle (94,95,96). The indices measured in 
these studies include the the maximum tension developed 
(94), the ventricular stroke work and minute work (95) 
and the pressure developed by the ventricle (96). In 
adddition, several studies of isolated papillary muscle 
have been reported (97,98,99,100). Tension developed 
per unit weight was significantly greater than normal 
in hypertrophied rat muscle (98) and non-significantly 
greater than normal in hypertrophied cat papillary 
muscle (97). Two other studies have reported depressed
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function in isolated papillary muscle preparations 
(99,100). Possible explanations for these apparently 
contradictory results include the use of different 
indices of contractility, differences in the time 
relationship between application of the pressure load 
and measurement of systolic function, and the 
abruptness of onset of the pressure load. The 
importance of differences in experimental design has 
been shown by Williams and Potter who demonstrated that 
the contractile function of cat papillary muscle was 
reduced 6 weeks after banding of the pulmonary artery 
but had returned to normal by twenty-four weeks (101) 
and by Bishop and Melsen who showed that acute volume 
loading of the right ventricle in cats leads to local 
necrosis and fibrosis and subsequently to impaired 
systolic function (102).
Thus a gradually increasing pressure load, as in 
systemic hypertension, may be associated with normal or 
even increased contractility during the early stages.
In man, assessment of systolic function is difficult 
because all commonly used indices of systolic function 
are dependent on the loading conditions of the heart.
In other words, there is no measure of myocardial 
contractility that is independent of preload and 
after load. As Grossman points out in a review of the 
subject (103), the studies that have reported impaired 
myocardial contractility in ventricles subjected to 
pressure overload have utilised indices of systolic
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function that are themselves affected by alterations in 
loading conditions. To investigate an index of systolic 
function that would be independent of preload, Fifer 
examined the rate of stress development, as opposed to 
total sress, in patients with severe aortic stenosis 
and found no evidence of reduced myocardial 
contractility (104). Several other experiments appear 
to support this view. Gunther and Grossman (105) 
studied fourteen patients with pressure overload 
hypertrophy and found a close inverse correlation 
between systolic wall stress and ejection fraction 
suggesting that the apparent reduction in ejection 
fraction was related to increased afterload. When 
ejection fraction was plotted against wall stress for 
normal subjects, it was found that the points fell 
along the same line as for patients with aortic 
stenosis while those for patients with congestive 
cardiomyopathy fell below this line. The authors held 
that this was consistent with the absence of an 
intrinsic contractile abnormality in patients with left 
ventricular hypertrophy secondary to aortic stenosis. 
They further cite the well documented "normalisation" 
of left ventricular function after aortic valve 
replacement as further evidence that there is no 
intrinsic reduction of contractility in hypertrophied 
myocardium (105).
Much of the debate as to whether ventricular 
hypertrophy in hypertension is a physiological response
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to increased afterload or a pathological process 
centres on biochemical changes that have been detected 
in experimental LVH. Schwartz et al have shown that the 
rate of hydrolysis of ATP, an index of energy 
utilisation, is reduced in hypertrophied hearts from 
hypertensive rats (106); this contrasted with the 
increased rate of ATP hydrolysis found in the 
"physiological" hypertrophy in the thyroxine treated 
rat (107). Changes have also been noted in the 
structure and properties as well as the quantity of 
myosin produced with appearance of new iso-enzymes in 
experimental LVH (106,107). However, the relevance of 
these results to human cardiac hypertrophy is not 
known. As with assessment of structural changes, 
factors such as the nature and duration of the pressure 
load applied may affect the results. Indeed, in a 
recent study using a gradually increasing pressure load 
in the pig (108), chosen as an experimental model 
specifically because its myosin iso-enzyme pattern most 
closely resembles that of man, no changes were seen in 
myosin iso-enzyme pattern nor in myosin ATPase activity 
despite an increase in left ventricular mass to almost 
170% of the control value.
Thus most of the recent evidence suggests that there is 
no intrinsic disorder of contractility in left 
ventricular hypertrophy secondary to hypertension, 
earlier reports of impaired contractile function may in 
part reflect the lack of suitable techniques for
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assessing contractility independently of loading 
conditions.
2. Diastolic function of the hypertrophied ventricle
Until recently, interest in cardiac function focused 
mainly on the pumping ability of the heart, and little 
attention was paid to the function of the heart during 
diastole. Realisation that abnormalities of diastolic 
function can significantly influence pumping ability 
has led to increased interest in diastolic function.
Normal diastolic function
Diastolic function of the left ventricle is dependent 
on many factors of which two of the most important are 
the completeness of ventricular relaxation and the 
passive elastic properties of the ventricular wall 
(109). Relaxation of ventricular muscle is not a 
passive process; the active uptake of calcium ions by 
the sarcoplasmic reticulum is necessary to lower the 
calcium concentration around the myofibrils and thus 
allow the cleavage of actin-myosin crossbridges leading 
to relaxation (110). The uptake of calcium by the 
sarcoplasmic reticulum requires ATP as an energy source 
and it has been suggested that as much as 15% of the 
total energy expenditure of the heart may be used in 
the process of "active” relaxation (111). Following
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this period of ventricular relaxation, there is a 
period of passive ventricular filling, the rate and 
degree of which are determined not only by the filling 
pressure (i.e. the pressure gradient between left 
atrium and left ventricle during diastole) but also by 
the passive elastic properties of the ventricle.
Abnormalities of diastolic function
Abnormalities of either the process of active 
ventricular relaxation or the passive elastic 
properties of the ventricle may adversely affect 
diastolic function.
If the ventricle becomes ischaemic, then there may be 
insufficient energy available for resorption of calcium 
by the sarcoplasmic reticulum and thus ventricular 
relaxation will be slowed and may be incomplete 
(112,113). It has been suggested that this "impaired 
relaxation" rather than depressed contractility may 
account, at least in part, for the high filling 
pressures found in acute myocardial ischaemia 
(114,115).
The passive elastic properties of the ventricle may be 
influenced by several factors including the thickness 
and composition of the ventricular wall. Increased 
ventricular wall thickness is associated with increased 
stiffness of the ventricle, as is the deposition of 
abnormal material such as scar tissue or amyloid (109).
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All of these mechanisms may be operating in the 
hypertrophied ventricle of a hypertenive patient in 
which the ventricular wall thickness is increased, 
diffuse myocardial fibrosis is present and 
subendocardial ischaemia can occur even in the absence 
of coronary artery disease.
The functional importance of these diastolic 
abnormalities is that the pattern of ventricular 
filling changes. In a heart of normal compliance, 
approximately 80% of ventricular filling occurs during 
the "passive" phase of ventricular filling before the 
onset of atrial systole. There is then a period of 
reduced flow across the mitral valve followed by the 
final "kick" as the left atrium contracts shortly 
before the onset of ventricular systole. In the 
hypertrophied ventricle with reduced diastolic 
compliance, the flow across the mitral valve during the 
early period of diastole is reduced; as a result, 
atrial systole becomes increasingly important for the 
maintainance of normal ventricular filling.
Several studies have specifically investigated 
diastolic filling properties of the ventricle in 
hypertension using a variety of relatively noninvasive 
techniques including apex cardiography, 
echocardiography and radionuclide ventriculography. 
Dreslinski et al used the echocardiographic left atrial 
emptying index (LAEI) to compare hypertensives with and 
without LVH and normotensive controls (116). The LAEI
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is a measure of the amount of ventricular filling that 
occurs during the first one third of diastole divided 
by the total amount of ventricular filling. Thus a 
high value (approximately 0.75-1.00) indicates normal 
compliance of the ventricle and a low value indicates 
reduced compliance. As expected, they found compliance 
was reduced in those hypertensives with LVH although 
compliance was also reduced in those hypertensives 
without LVH and in whom echocardiographic indices of 
systolic function were normal (116). The technique of 
radionuclide ventriculography has also been used to 
assess diastolic function. Here the red blood cells 
are "labelled" using radioactive technetium and the 
radioactive counts are detected using a gamma camera 
placed over the chest. Commonly used indices of 
ventricular diastolic function derived from this 
technique are the peak filling rate (of the ventricle) 
and the time to peak filling (measured from the 
beginning of diastole). Studies in hypertension have 
shown that the peak filling rate is reduced and the 
time to peak filling prolonged in hypertensives when 
compared with normal subjects (117); again, these 
abnormalities were present even when systolic function 
was completely normal in the hypertensive group.
Summary
In summary, while there is debate as to whether
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systolic function is normal or impaired, in the 
hypertrophied but undilated left ventricle, the recent 
evidence suggests that systolic function may well be 
normal. In contrast, the available evidence suggests 
that diastolic function of the ventricle is abnormal at 
an early stage in hypertensive heart disease and 
deteriorates further as hypertrophy progresses. The 
practical significance of this is that filling of the 
ventricle becomes increasingly dependent on effective 
atrial contraction as left ventricular mass rises. 
Sudden loss of effective atrial contraction in a 
hypertrophied heart, caused for example by the onset of 
atrial fibrillation or a ventricular arrhythmia, will 
be accompanied by a marked reduction in ventricular 
filling and presumably in cardiac output. Thus impaired 
diastolic filling might render the heart more 
vulnerable to an arrhythmia that involves loss of 
atrial transport function.
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2.8 LEFT VENTRICULAR HYPERTROPHY, MYOCARDIAL ISCHAEMIA 
AND CORONARY ARTERY DISEASE
Introduction
The terms "coronary artery disease" and "myocardial 
ischaemia" are sometimes wrongly used synonomously. In 
left ventricular hypertrophy, there is evidence that 
myocardial ischaemia can occur for reasons other than 
coronary artery disease. In this section, the 
relationships between left ventricular hypertrophy, 
cardiac ischaemia and coronary artery disease are 
discussed.
1. Left ventricular hypertrophy and myocardial 
ischaemia.
It has been known for many years that patients with 
left ventricular hypertrophy as a result of either 
hypertension or aortic valve disease can develop 
typical exercise-induced angina pectoris accompanied by 
electrocardiographic changes of ischaemia even when the 
major coronary vessels are widely patent (118,119). In 
addition, post mortem histological examination in such 
patients often reveals patchy myocardial necrosis, 
particularly in the subendocardium (120), and an 
intracoronary collateral circulation (121), the 
stimulus for which has presumably been ischaemia. There
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is convincing evidence, therefore that myocardial 
ischaemia can and does occur in hypertrophied 
ventricles in the absence of coronary artery disease, 
implying an imbalance of oxygen supply and demand. 
Initial studies of myocardial blood flow in patients 
with left ventricular hypertrophy suggested that 
coronary blood flow and myocardial oxygen consumption 
(corrected for ventricular mass) were normal (122,123) 
although Malik et al suggested that coronary flow was 
reduced in the hypertrophied ventricle but that oxygen 
consumption was unchanged due to increased oxygen 
extraction (124).
The available techniques, however, had two major 
limitations; they could only be performed at rest and 
were therefore unable to detect exercise-induced 
ischaemia and they measured only total myocardial blood 
flow and could not detect localised ischaemia due to 
regional differences in perfusion. Recent studies using 
animal models to investigate total and regional 
perfusion both at rest and after different types of 
stress have demonstrated significant abnormalities in 
the hypertrophied ventricle. Rembert et al (125) used 
radioactive microspheres to assess transmural 
variations in perfusion in dogs with left ventricular 
hypertrophy after aortic banding. They found resting 
subendocardial blood flow to be reduced in the 
hypertrophied hearts, the ratio of subendocardial to 
subepicardial blood flow being 1.10+0.08 compared to
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1.25+0.07 in control animals. These findings have been 
confirmed by another group who reported an inverse 
correlation between left ventricular mass and the 
subendocardial to subepicardial blood flow ratio (126). 
One group failed to show reduced subendocardial flow at 
rest but the degree of cardiac hypertrophy in this 
study (127) was less than in Rembert’s study in which 
left ventricular mass was increased by 80-100% (125). 
Other investigators have studied the ability of 
myocardial blood flow to increase in response to 
various vasodilator stimuli including pharmacologial 
agents such as adenosine (128) or dipyridamole 
infusions both at resting heart rates and at higher 
heart rates induced either by exercise (129) or rapid 
atrial pacing (128). In general, these studies have 
shown that the vasodilator capacity, or "vascular 
reserve" of the coronary circulation, is reduced in 
experimental left ventricular hypertrophy (127,128). In 
studies that have measured regional perfusion using 
microspheres or similar techniques, redistribution of 
perfusion away from the subendocardium with reduction 
in the ratio of subendocardial to subepicardial flow 
has been observed particularly at rapid heart rates 
(129).
Why is the subendocardium particularly vulnerable to 
ischaemia? Several mechanisms have been suggested all 
of which may combine to ensure that the subendocardial 
area is the first to be affected when myocardial oxygen
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demand exceeds supply. First, subendocardial muscle 
uses approximately 20-s more oxygen per unit mass than 
the remaining myocardium (130). Since coronary 
autoregulation regulates myocardial blood flow in 
response to local metabolic needs, the high 
subendocardial flow presumably represents increased 
energy requirements as a result of the greater systolic 
stress in the deeper layers of the ventricular wall. 
Thus the high energy requirement of the subendocardial 
zone immediately renders it susceptible to ischaemia.
A second factor involves the coronary vascular reserve,
i.e. the ability to increase coronary blood flow by 
vasodilatation. It has been shown that when a 
progressive imbalance develops between myocardial 
supply and demand, maximum vasodilatation occurs 
earliest in the left ventricular subendocardial area 
(131,132); thereafter subendocardial flow becomes 
pressure dependent. Thus coronary vascular reserve is 
lost in the subendocardial but not the subepicardial 
layer; any further increase in oxygen requirement will 
then result in subendocardial ischaemia.
Third, physical factors may be important in determining 
subendocardial susceptibility to ischaemia. This 
subject has been reviewed by Hoffman (133); if blood 
vessels were rigid, then the flow rate would be 
determined only by the arteriovenous pressure 
difference and by the properties of the fluid and 
vessel. However, blood vessels are compressible and
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tissue pressure can affect their diameter and thus 
influence flow. For some years, high tissue pressure 
during systole has been invoked as a contributing 
factor to subendocardial ischaemia. Several 
investigators had shown that tissue pressure in the 
subendocardial zone during systole was high and 
approximated to intracavitary systolic pressure but 
decreased centrifugally to low values in the 
subepicardial area (133). Thus it was suggested that 
myocardial flow to the subendocardium occurred only in 
diastole while subepicardial flow could occur during at 
least part of systole. Recent evidence, however, 
suggests that most of the myocardium receives no flow 
during systole (134,135) and thus systolic tissue 
pressures may not be relevant to myocardial perfusion. 
However, diastolic tissue pressure also displays a 
gradient from the subendocardial area outwards and it 
is possible that the high tissue pressures found in the 
deeper layers of the hypertrophied ventricle may 
restrict subendocardial flow during diastole (133).
How far can these observations be applied to man? 
Coronary vascular reserve has been studied in man by 
measuring the hyperaemic reaction to intra-coronary 
injection of contrast medium in patients with and 
without left ventricular hypertrophy (136). As in the 
animal models, coronary vascular reserve was markedly 
reduced in those patients with left ventricular 
hypertrophy. Assessment of transmural differences in
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myocardial flow in man has proved more difficult and 
there are no suitable in vivo techniques available. 
However, the occurrence of typical angina pectoris with 
accompanying ST segment depression in patients with 
cardiac hypertrophy and normal coronary arteries, when 
taken with the experimental evidence, strongly suggests 
that subendocardial ischaemia does occur during 
exercise and measurement of coronary sinus lactate 
concentration has provided biochemical confirmation of 
ischaemia (83). While this technique cannot pinpoint 
the site of ischaemia, the distribution of myocardial 
fibrosis at post mortem suggests that ischaemia is 
predominantly subendocardial. It remains to be seen 
whether newer imaging techniqes, such as Positron 
Emission Tomography and Magnetic Resonance Imaging will 
be able to demonstrate regional differences in 
perfusion in vivo.
As in the various experimental models, the factors that 
are likely to be responsible for the susceptibility of 
the subendocardium to ischaemia include a high 
metabolic demand, early loss of vasodilator capacity 
during stress and high tissue diastolic pressures which 
impede myocardial perfusion.
2. Left ventricular hypertrophy and coronary artery 
disease.
An association between hypertension and myocardial
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infarction was first noted by Sir Thomas Lewis when he 
observed that thrombosis of a coronary artery occurred 
most commonly in men over the age of fifty with signs 
of arterial disease "and as often as not high blood 
pressure" (137). It is now well established that 
hypertension is a major risk factor for myocardial 
infarction (138); the higher the arterial pressure, the 
greater the risk (2). Hypertension appears to 
accelerate the process of atherosclerosis and a greater 
percentage of the surface area of the coronary 
arteries, and other major arteries, is affected by 
atherosclerosis in hypertensive when compared to 
normotensive individuals (139).
There is some evidence that pressure itself is the 
mediator of vascular damage since atherosclerosis of 
the pulmonary arteries is usually only seen in 
pulmonary hypertension (140). In the presence of other 
risk factors, such as elevated serum cholesterol 
concentration, the severity of atherosclerosis is 
increased in experimental animal models (141) and there 
is evidence in man that the potential for 
atherosclerosis in hypertension is reduced if the serum 
cholesterol level is low (142).
Thus there is a strong association between hypertension 
and coronary artery disease. However, does an 
association exist between left ventricular hypertrophy 
and coronary artery disease? Since there is a 
correlation, albeit a poor one, between blood pressure
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and left ventricular mass, we would expect some 
relationship between LVH and coronary disease. Is there 
any evidence, however, that LVH, which is an 
independent risk factor for cardiovascular mortality, 
is also an independent risk factor for coronary artery 
disease? This is of considerable practical importance 
because the excess mortality that is associated with 
LVH is frequently attributed to coronary artery 
disease.
Several post-mortem studies have examined the 
relationship between coronary artery disease and left 
ventricular hypertrophy (143,144); without exception, 
cardiac hypertrophy has been a common finding in 
patients dying from ischaemic heart disease. Buja and 
Willerson (143) reported that 85% of hearts from 
subjects dying of ischaemic heart disease weighed over 
400g (normal range 300-350g). This hypertrophy, 
however, need not be due to associated hypertension; 
any factor that increases afterload or preload, such as 
congestive cardiac failure or valvular disease, will 
lead to cardiac hypertrophy. Even in the absence of 
frank cardiac failure, previous infarction will lead to 
compensatory hypertrophy of the remaining myocardium 
and ischaemia itself may be the stimulus to myocardial 
hypertrophy either by increasing wall stress or by the 
direct action of intracellular ischaemia to reduce ATP 
concentration and stimulate myosin synthesis (16,17). 
Dean and Gallacher (144) have examined the relationshxp
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between cardiac hypertrophy and coronary artery disease 
in a series of fifty post-mortem hearts. Overall, there 
was a weak correlation between the extent of coronary 
artery disease and total heart weight although in the 
subgroup of ten patients with left ventricular 
hypertrophy secondary to either hypertension or 
valvular disease, there was no correlation. Gould et al 
studied eighty-five patients including a group with 
congestive cardiomyopathy and normal coronary arteries 
and a group with triple vessel disease but with a 
similar degree of left ventricular dysfunction, and 
found that left ventricular mass was similarly 
increased in both groups suggesting that the left 
ventricular dysfunction rather than the coronary artery 
disease was the cause of the cardiac hypertrophy (145). 
They concluded that left ventricular mass rose in 
proportion to the left ventricular end-diastolic 
volume.
Summary
Thus there is considerable evidence that myocardial 
ischaemia occurs in left ventricular hypertrophy even 
when the coronary arteries are free of significant 
disease; there is also evidence that myocardxal 
ischaemia from any cause, including coronary artery 
disease, may stimulate left ventricular hypertrophy. 
There is, however, little to suggest that left
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ventricular hypertrophy per se predisposes to coronary 
artery disease. This is important because, as noted 
previously, left ventricular hypertrophy is an 
independent risk factor for cardiovascular mortality, 
and particularly for sudden death. One possible 
explanation is that the case fatality rate for 
myocardial infarction is greater in patients with 
pre-existing left ventricular hypertrophy either 
because of an increased tendency to ventricular 
arrhythmia or because of greater infarct size as a 
result of reduced coronary reserve. An alternative 
explanation is that left ventricular hypertrophy 
predisposes to sudden death by a mechanism other than 
coronary artery disease.
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2.9 RELATIONSHIP BETWEEN SUDDEN DEATH, CORONARY ARTERY 
DISEASE AND LEFT VENTRICULAR HYPERTROPHY.
A. The definition of sudden cardiac death.
Investigators have subdivided sudden death into 
categories according to whether the death was 
instantaneous or whether the patient experienced a 
change in symptoms within two hours or one hour of 
death. A recent World Health Organisation Scientific 
Group declined to define the word "sudden1 but instead 
recommended that data surrounding the terminal event 
should be collected including the presence of prior 
pain or myocardial infarction, time of onset of 
symptoms, whether death was witnessed etc (146). 
Accurate registration of sudden death is difficult not 
only because of difficulties in definition but because 
"sudden death" is not recognised as a "cause" of death 
by the Registrar General for the purpose of death 
certification. Since most sudden deaths occur in the 
community, the death certificate is usually completed 
by the general practitioner. Faced with the problem of 
a sudden death in a patient whom he has been attending, 
the general practitioner can either decline to certify 
on the grounds that the cause of death is not known, or 
he can put forward a "best guess" regarding the cause 
of death, such as myocardial infarction or 
cerebrovascular accident. Estimates suggest that sudden
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cardiac death accounts for approximately 75,000 deaths 
per annum in the United Kingdom, the rate in 
industrialised countries being 30 per million 
population per week (146).
B. Mechanism of sudden death.
It is now widely accepted that ventricular 
tachyarrhythmias are responsible for most cases of 
sudden cardiac death. In a study of four hundred and 
twenty-six "would be" victims of sudden death, 
Liberthson reported that the initial cardiac rhythm 
recorded was ventricular fibrillation in 72% of cases 
(147). Two other studies confirmed that ventricular 
firbrillation was present in approximately two-thirds 
of sudden death victims at the time of attempted 
resuscitation (148,149).
However, the increased availability over the last five 
years of twenty-four hour Hoi ter monitoring has 
demonstrated that ventricular fibrillation is not 
invariably the initial arrhythmia in cases of sudden 
cardiac death. In 1982, Nikolic documented six cases of 
sudden death that occurred during ambulatory 
monitoring. The terminal arrhythmia was ventricular 
fibrillation in five but this had been immediately 
preceded by either ventricular tachycardia or other 
complex ventricular ectopic activity in five (150).
This finding has been confirmed by at least two other
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studies (151,152).
If there is a delay of several minutes from the time of 
cardiac arrest, it is likely that the rhythm will have 
degenerated from ventricular tachycardia to ventricular 
fibrillation thus making the latter the most commonly 
detected arrhythmia in out—of—hospital cardiac arrest.
C. Sudden death and coronary artery disease.
In 1974, WB Kannel, author of many of the Framingham 
papers, wrote:
"Sudden death is a common and possibly incidental
expression of lethal coronary heart disease.....
The inescapable conclusion is that the prevention 
of sudden death requires the prevention of 
coronary attacks." (82)
This statement reflected a widely held belief that 
sudden death was almost invariably a result of acute 
myocardial infarction. Subsequent post-mortem studies 
of the coronary arteries of sudden death victims tended 
to confirm this viewpoint. Liberthson, reporting on a 
series of two hundred and twenty sudden cardiac deaths, 
found at least one coronary artery stenosis in 94% of 
victims, and 60% had three or four vessel disease
(147). In a series of fifty-nine, Friedman found only 
four that were free of any coronary artery stenosis and
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again triple vessel disease was the norm (153). 
in view of the known association between myocardial 
infarction and ventricular fibrillation, it was 
generally assumed that the fatal arrhythmia resulted 
from an ischaemic insult to the myocardium. However, 
several observations suggested that this relationship 
was not as straightforward as it at first appeared. 
First, it was noted that survivors of out-of-hospital 
cardiac arrest did not invariably develop signs of 
myocardial infarction. In Liberthson's series, only 
39% of defibrillated survivors developed 
electrocardiographic evidence of myocardial infarction
(147). In a series of three hundred and fifty-two 
cardiac arrests, Myerburg found that only 36% of the 
survivors had evidence of definite myocardial 
infarction although 79% had coronary artery disease
(148). In a study by Baum, transmural infarction was 
confirmed in only 17% of one hundred and forty-six 
patients resuscitated from ventricular fibrillation 
(154) and the authors point out that sudden cardiac 
death should not be equated with myocardial infarction. 
The second unexpected finding was the low incidence of 
acute coronary thrombosis found at post mortem in 
victims of sudden cardiac death. This has varied from 
4% to 59% in different studies, but on average only 
22-30% of cases of sudden cardiac death have an acute 
coronary thrombosis (155). In contrast, acute coronary 
thrombosis is almost invariably present in patients
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with acute myocardial infarction. The recent increase 
in the use of thrombolytic therapy early in the course 
of myocardial infarction has necessitated early 
coronary arteriography which has demonstrated acute 
coronary thrombosis in the vast majority of patients 
with acute myocardial infarction (156); thus it has 
been suggested that sudden cardiac death and acute 
myocardial infarction should be regarded as different 
diseases (157). The third unexpected finding was the 
high prevalence of old healed myocardial infarction in 
those patients dying suddenly. Most studies 
demonstrated that at least 50% of sudden death victims 
had an old myocardial infarction (153). Thus there is a 
stronger association between sudden death and old 
myocardial injury than between sudden death and acute 
myocardial infarction. As Reichebach points out (158), 
the observations suggest that acute coronary thrombosis 
and recent myocardial infarction do not occur with 
sufficient frequency to be considered causally related 
to the sudden collapse. It is now generally accepted 
that sudden cardiac death is more commonly the result 
of pre-existing myocardial disease than of acute 
myocardial infarction, and that the ventricular "scar" 
somehow predisposes to ventricular arrhythmia.
D. Sudden death and left ventricular hypertrophy.
Electrocardiographic evidence of left ventricular
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hypertrophy is strongly associated with sudden death.
In the Framingham study, 36% of sudden deaths were 
preceded by ECG LVH compared with 19% of non-sudden 
deaths and 6% of cancer deaths (81). ECG LVH was 
associated with a five-fold increase in sudden death 
and, indeed, the association between ECG LVH and sudden 
death was more striking than the association between 
hypertension and sudden death. Post mortem evidence 
confirms that left ventricular hypertrophy is common in 
victims of sudden cardiac death (82). Although it 
could be argued that ischaemia secondary to coronary 
artery disease may be a stimulus to cardiac 
hypertrophy, Perper found no correlation between heart 
weight and the degree of coronary artery disease in 
victims of sudden death (159) suggesting that the 
hypertrophy itself is not simply a reflection of more 
severe coronary artery disease and may itself 
predispose to sudden death. In a post-mortem study of 
one hundred and fifty-one sudden death victims,
Rissanen identified a subgroup of eighteen patients 
without coronary artery thrombosis in whom death had 
been instantaneous and was presumed to be due to 
primary ventricular arrhythmia (160). Cardiac 
hypertrophy and a history of hypertension were more 
common in this "primary arrhythmia" group than in those 
with evidence of myocardial infarction and coronary 
atherosclerosis was less common. Of the eighteen, 
seven (5%) had no coronary artery disease whatsoever;
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two had aortic stenosis and two had hypertension and 
left ventricular hypertrophy with no other abnormal 
findings.
In summary therefore, there appears to be an 
association between left ventricular hypertrophy and 
sudden death that is independent of coronary artery 
disease.
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2.10 HYPERTROPHIC CARDIOMYOPATHY - A MODEL FOR 
HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY?
Introduction
Hypertrophic cardiomyopathy was first described by 
Donald Teare in 1958, as a condition characterised by 
striking myocardial hypertrophy, particularly involving 
the interventricular septum, in the absence of left 
ventricular dilatation (161). Early interest in the 
condition focused on the presence of a pressure 
gradient within the left ventricle (162) with 
development of a high pressure apical region and a low 
pressure outflow region. As a result, names such as 
idiopathic hypertrophic subaortic stenosis (IHSS) and 
Teare1s original term, hypertrophic obstructive 
cardiomyopathy (HOCM), came into common use.
Since it is now clear that the majority of patients do 
not in fact have an intraventricular pressure gradient, 
the term hypertrophic cardiomyopathy is preferred for 
the condition of left ventricular hypertrophy in the 
absence of any other cause, such as aortic stenosis or 
hypertension (163). Following the early interest in 
systolic pressure gradients, it is now generally 
accepted that systolic function in hypertrophic 
cardiomyopathy is excellent. Systolic outflow from the 
ventricle is unusually rapid and ejection fraction, a 
commonly used index of systolic function, is often
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high. Diastolic function, however, is impaired (163). 
The ventricle is abnormally stiff leading to impaired 
ventricular filling and a high left ventricular end 
diastolic pressure. This in turn leads to elevated 
left atrial, pulmonary venous and pulmonary capillary 
wedge pressures. As in left ventricular hypertrophy 
secondary to hypertension, both echocardiography and 
radionuclide ventriculography have been used to 
demonstrate the impairment of diastolic ventricular 
filling. One study suggested that ventricular 
compliance in hypertrophic cardiomyopathy was a dynamic 
process, possibly related to chronic subendocardial 
ischaemia, since diastolic function appears to improve 
acutely after administration of the calcium antagonist 
nifedipine (164).
The condition is inherited, usually as an autosomal 
dominant trait with a high degree of penetrance. Thus 
examination of the relatives of a patient with 
hypertrophic cardiomyopathy will often reveal 
hypertrophic cardiomyopathy, although the condition may 
be mild and detectable only by echocardiography (165).
Aetiology of hypertrophic cardiomyopathy.
The aetiology of this condition is unknown. The 
various suggestions include increased responsiveness of 
the heart to circulating catecholamines (46), an 
intrinsic abnormality of collagen (166), abnormal
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intramural coronary arteries leading to myocardial 
ischaemia and secondary fibrosis in the absence of 
epicardial coronary disease (166) and abnormally rapid 
conduction through the atrioventricular node leading to 
asynchronous ventricular contraction and resultant 
cardiac hypertrophy (166).
Pathology of hypertrophic cardiomyopathy.
The major pathological findings of hypertrophic 
cardiomyopathy have been reviewed by Maron and Epstein 
(163) and by Wynne and Braunwald (167). Marked 
hypertrophy of the ventricles in the absence of 
dilatation is characteristic. Commonly, there is 
disproportionate thickening of the interventricular 
septum when compared with the free wall of the left 
ventricle (163). If the ratio of interventricular 
septal thickness to free wall thickness exceeds 1.3, 
this is termed asymmetrical septal hypertrophy (ASH). 
ASH was previously regarded as being pathognomonic of 
hypertrophic cardiomyopathy. However, it is now 
recognised that hypertrophy secondary to hypertension 
may sometimes preferentially affect the septum and that 
some patients with inherited hypertrophic 
cardiomyopathy may have symmetrical hypertrophy (168); 
the diagnosis, therefore, of hypertrophic 
cardiomyopathy cannot be made on the basis of 
asymmetric septal hypertrophy alone.
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Histologically the condition is characterised by 
hypertrophied, bizarrely-shaped and abnormally arranged 
myocytes and attempts have been made to quantify the 
degree of cellular disorganisation (169). Electron 
microscopy has demonstrated that this disorganisation 
and disarray is not restricted to the cellular level 
but also involves the myofibrils and myofilaments 
within the myocardial cells (170).
There is some debate as to the distribution of these 
changes within the ventricle. Maron stated that these 
abnormalities were common in the septum and rare in the 
free wall of the left ventricle (170), although this 
has been questioned in a review of the subject by Olsen 
(171). In affected areas, foci of disorganised cells 
are found interspersed in areas of hypertrophied, but 
otherwise normal, muscle. Such changes were previously 
thought to be specific for hypertrophic cardiomyopathy. 
However, it is now recognised that they can occur in 
other forms of cardiac hypertrophy, including 
hypertrophy secondary to hypertension or aortic valve 
disease, although there does appear to be a 
quantitative relationship between the degree of 
cellular disorganisation and the underlying disease 
process, the degree of disorganisation being far 
greater in hypertrophic cardiomyopathy than in 
secondary cardiac hypertrophy (169).
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Prognosis in hypertrophic cardiomyopathy.
Patients with hypertrophic cardiomyopathy are 
prediposed to sudden death; indeed this is a common 
presentation of the condition, the annual rate of 
sudden death being approximately 3% in adults and 5% in 
children (172). Post-mortem examination confirms the 
diagnosis of hypertrophic cardiomyopathy but rarely 
identifies the cause of death. Various possible 
mechanisms of sudden death have been suggested 
including haemodynamic causes, such as dynamic 
obstruction of the outflow tract in response to a 
sudden change in preload or afterload and diseases of 
the conducting system involving either accessory 
atrio-ventricular bypass pathways, intermittant heart 
block or sinus arrest (172).
However, it is generally believed that the most likely 
mechanism of sudden death is the development of 
ventricular tachycardia followed by ventricular 
fibrillation. This mechanism was first suggested by 
Goodwin and Krikler in 1976 (173). Since then, several 
studies have demonstrated a high prevalence of complex 
ventricular arrhythmias in patients with hypertrophic 
cardiomyopathy (3,174). McKenna (3) reported that 28% 
of patients with hypertrophic cardiomyopathy had at 
least one episode of ventricular tachycardia during a 
72 hour period of ambulatory ECG monitoring. Savage 
(174) reported a figure of 19% although the lower
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prevalence may be because monitoring was for 
twenty-four rather than forty-eight hours.
The mechanism of ventricular arrhythmia in hypertrophic 
cardiomyopathy is unknown. The presence of cellular 
disorganisation itself does not appear to be important 
since this histological finding is rare in children who 
die suddenly (172). Histological evidence of 
myocardial ischaemia, due to inadequate myocardial 
blood flow, is common even in the absence of coronary 
disease (175) and may provide a focus for ventricular 
arrhythmias. James et al suggested that septal clefts 
might provide a "re-entry" circuit for ventricular 
arrhythmias (166). Thus there are possible explanations 
for initiation and propagation of ventricular 
tachycardia although the precise mechanisms remain to 
be elucidated.
Whatever the mechanism, two studies have demonstrated a 
significant link between ventricular tachycardia 
detected during ambulatory monitoring and subsequent 
sudden death. This is in contrast to studies of 
haemodynamic and ECG parameters which were unable to 
discriminate between survivors and decedents (167). 
McKenna et al carried out ambulatory ECG monitoring in 
eighty-six unselected patients with hypertrophic 
cardiomyopathy, of whom twenty-four had at least one 
episode of ventricular tachycardia (3). During a mean 
follow-up period of 2.6 years, seven patients died 
suddenly of whom five had VT. Thus 21% of the patients
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with VT died suddenly compared with 3% of the patients 
without VT. Maron et al found very similar results in 
a study of ninety-nine patients (176); sudden death 
occurred in 24% of patients with and 3% of those 
without VT. In this study, only VT was associated with 
sudden death whereas McKenna et al also reported an 
association, although less strong, between sudden death 
and both multiform ventricular extrasystoles and 
ventricular couplets.
Influence of treatment on mortality.
If ventricular arrhythmias are the cause of sudden 
death in hypertrophic cardiomyopathy, and not merely 
markers of the condition, then effective 
anti-arrhythmic therapy should improve prognosis in 
hypertrophic cardiomyopathy.
Trials involving beta blockers and the calcium 
antagonist verapamil have failed to show any reduction 
in the incidence of ventricular arrhythmia.
Furthermore, conventional anti-arrhythmic agents, 
including quinidine, disopyramide and mexilitene, have 
been found to be poorly tolerated and unsuccessful in 
reducing complex ventricular arrhythmias (172).
However, the Class III anti-arrhythmic agent amiodarone 
has successfully reduced ventricular arrhythmia 
frequency and early evidence suggests that it does 
improve prognosis (177).
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Hypertrophic cardiomyopathy and hypertensive left 
ventricular hypertrophy.
There are some similarities between hypertrophic 
cardiomyopathy and hypertensive left ventricular 
hypertrophy. Both are characterised by myocardial 
hypertrophy, subendocardial ischaemia and ultimately 
myocardial fibrosis; both are associated with sudden 
death. In hypertrophic cardiomyopathy, there is 
persuasive evidence to suggest that the mechanism of 
sudden death is primary ventricular arrhythmia, usually 
ventricular tachycardia which then degenerates to 
ventricular fibrillation. Furthermore there is some 
evidence, although less conclusive, that effective 
anti-arrhythmic therapy may reduce mortality. In 
hypertensive left ventricular hypertrophy, there is 
evidence that left ventricular hypertrophy defined by 
standard ECG criteria is an independent risk factor for 
cardiovascular mortality and in particular for sudden 
death. In other words, LVH is associated with an 
increased risk that cannot be explained by the presence 
of hypertension or other associated risk factors.
It is possible, therefore, that the excess risk 
associated with left ventricular hypertrophy in 
essential hypertension may be related to ventricular 
arrhythmia and that, as in hypertrophic cardiomyopathy, 
such arrhythmias may be related to metabolic and
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structural abnormalities associated with hypertrophy 
itself rather than to co-existent atherosclerotic 
disease of the major coronary arteries.
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CHAPTER 3
AIMS OF THIS THESIS
Broadly, the aim was to investigate a possible 
mechanism which might explain the high mortality in 
hypertensive patients with left ventricular 
hypertrophy.
Since the high mortality associated with this ECG 
finding in the Glasgow Blood Pressure Clinic was a 
major stimulus to my studies, I have included a 
description of the clinic and an analysis of the 
relationship between electrocardiographic left 
ventricular hypertrophy, associated risk factors and 
cardiovascular mortality. During the past eighteen 
months, I have been one member of a group investigating 
this relationship with the statistical assistance of 
Dr. G Murray. Other members of the group include Dr C 
Isles, Dr FG Dunn, Dr AF Lever, Dr AR Lorimer and Dr HJ 
Dargie. In this thesis, I have included only those 
parts of the analysis with which I was closely involved 
(chapter 4).
The aims of the subsequent studies were as follows:
1. To validate the reporting of LVH in the Glasgow 
Blood Pressure Clinic. Since mortality data from the 
Glasgow Blood Pressure Clinic are based on an ECG
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reporting system without "standardised" criteria, some 
form of validation of the electrocardiographic 
diagnosis of LVH in the Glasgow Blood Pressure Clinic 
was required; this I have done by calculating the 
sensitivity and specificity of the ECG reporting system 
using echocardiography as a "gold standard" for the 
assessment of hypertrophy (chapter 5).
Having completed this, two further analyses of the ECG 
and echocardiographic data have been undertaken to 
attempt to both standardise and improve the ECG 
diagnosis of LVH (chapter 6):
a) a comparison of the sensitivities and specificities 
of four commonly used sets of ECG criteria for LVH.
b) analysis of the influence of body build on various 
ECG criteria for LVH to determine whether knowledge of 
a patient's height and weight could perhaps be used to 
improve the ECG diagnosis of LVH.
2. To determine the prevalence of ventricular 
arrhythmias in hypertensive patients with LVH and to 
compare this with both a hypertensive control group 
without ECG LVH and a normotensive control group. If, 
as in hypertrophic cardiomyopathy, a tendency to 
ventricular arrhythmia is important in the high 
mortality associated with LVH, then ventricular 
arrhythmias might occur more commonly in hypertensives
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with ECG LVH than in those without (chapter 7).
3. To examine the influence of diuretic therapy and 
serum potassium concentration on ventricular 
arrhythmias in hypertensives with and without left 
ventricular hypertrophy (chapter 8).
4. To examine the relationship between ventricular 
arrhythmias and coronary artery disease in hypertensive 
patients with left ventricular hypertrophy and thus 
determine whether such arrhythmias are a manifestation 
of coronary artery disease (chapter 9).
5. To examine the relationship between ventricular 
arrhythmias and myocardial histology in patients with 
left ventricular hypertrophy and thus determine whether 
factors other than coronary artery disease might be 
important in the genesis of ventricular arrhthmia 
(chapter 10).
6. To examine the function of the hypertrophied left 
ventricle with particular reference to ventricular 
filling; since loss of diastolic compliance is believed 
to be the major functional abnormality in hypertrophic 
cardiomyopathy, this may also occur in hypertensive 
heart disease and may "sensitise" the heart to the 
effects of an arrhythmia that leads to loss of atrial 
contraction (chapter 11).
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CHAPTER 4
LEFT VENTRICULAR HYPERTROPHY AND MORTALITY IN THE 
GLASGOW BLOOD PRESSURE CLINIC
Introduction
While the level of blood pressure is an important risk 
factor for cardiovascular mortality in hypertensive 
patients, other variables, including cigarette smoking, 
a history of angina, myocardial infarction or stroke, 
impaired renal function and ECG evidence of left 
ventricular hypertrophy, may influence outcome 
(1,2,178,179). Data from the Framingham study have 
suggested that ECG LVH with ST-T changes is an 
independent predictor of outcome while the risk 
associated with ECG LVH without ST-T changes can be 
wholly attributed to the associated hypertension (81). 
The purpose of this study was to examine the 
relationship between ECG LVH with and without ST-T 
changes and mortality in the Glasgow Blood Pressure 
Clinic. The clinic provides an unusual opportunity for 
an analysis of this type because of the high prevalence 
of LVH, the high mortality, the long duration of 
follow-up and the completeness of the mortality data.
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Materials and methods
1. Patients
The Glasgow Blood Pressure Clinic was set up in 1968 to 
record standardised information on hypertensive 
patients attending four Glasgow hospitals (the Western 
Infirmary, Glasgow Royal Infirmary, Stobhill Hospital 
and the Southern General Hospital). Patients are 
referred either from their general practitioner, other 
hospitals or other departments within the four main 
hospitals. Although patients with all grades of 
hypertension are referred, there is a bias towards 
those whose hypertension is complicated or is difficult 
to control. The system of recording information in he 
clinic has been described previously (1,180) as has the 
high mortality in clinic patients when compared with 
other hypertensive groups (1).
Between 1968 and January 1983, 4283 patients were 
referred to the clinic of whom 3783 had non-malignant 
hypertension and a diastolic blood presssure greater 
than 90 mm Hg before treatment. 85% of this group (3216 
patients) had an ECG within three months of initial 
attendance at the clinic. These patients have been 
followed for a mean of 6.5 years and it is on this 
group that calculations of risk are based.
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2. Blood pressure
Blood pressure was measured using a standard 
sphygmomanometer in either the lying or seated 
position. Phase V was taken as diastolic pressure. 
Average blood pressure for men at entry to the clinic 
was 181/111 mm Hg falling to 158/96 mm Hg during 
treatment. Corresponding values for women were 185/109 
mm Hg and 161/96 mm Hg.
3. ECG analysis
Standard twelve lead electrocardiograms were recorded 
at a paper speed of 25 mm/sec. These were then reported 
by physicians in each of the four hospitals and the 
presence of left ventricular hypertrophy with or 
without ST-T changes, myocardial ischaemia and 
myocardial infarction noted using "conventional" 
criteria. The criteria, however, were not standardised 
among the reporting clinicians. (This is discussed in 
chapter five).
4. Record linkage and mortality data.
To ensure completeness of mortality data, all patients 
were flagged with the Registrar General for Scotland. 
Provided that death occurred in the United Kingdom, 
copies of all relevant death certificates with the
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cause of death coded according to the International 
Classification of Diseases were returned to the clinic. 
Causes of death were then analysed in five groups using 
the 9th revision of this classification (181): 
ischaemic heart disease (codes 410-414), 
cerebrovascular disease (codes 430-438), other vascular 
disease (codes 390-456 excluding the above), cancer 
(codes 140-208 and 235-239) and all other causes (any 
other code).
5. Statistical methods
Age-specific mortality rates were calculated as 
deaths/1000 patient years of observation, based on the 
age at death and on years spent by each patient in each 
decile (182). Comparison between groups was made using 
Chi-squared analysis. The relation between LVH and 
survival was also determined by stepwise multiple 
regression using the Cox proportional hazards model 
(183) to control for the possible influence of age, 
sex, smoking habit, initial blood pressure, past 
history of vascular disease, raised blood urea, retinal 
arteriovenous nipping and referral to the clinic before 
1976.
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Results
1. Prevalence of LVH and relation to blood pressure.
LVH was present in 34.5% of men and 21.5% of women at 
presentation (table 1). In addition to voltage evidence 
of LVH, 12.9% of men and 8.9% of women had ST-T changes 
(the 1 strain" pattern). While ECG LVH was more common 
in men, ST-T changes alone were seen more commonly in 
women. Evidence of myocardial infarction was seen in 
6.0% of men and 3.4% of women.
In an analysis confined to patients who were untreated 
at the time of presentation (n=2664), the prevalence of 
LVH increased with the height of the initial diastolic 
blood pressure in both sexes (figure 2) although men 
had more ECG LVH than women at every level of initial 
blood pressure. Table 2 shows the mean reduction in 
diastolic blood pressure between the initial and the 
final clinic visit for the different ECG categories. 
Absolute reduction was similar for those with and 
without LVH, those with LVH having slightly higher 
final blood pressures than those without.
2. Risk of LVH
The mortality rate and relative risk associated with 
ECG LVH and other major ECG abnormalities are shown in 
table 3 (for men) and table 4 (for women). Thus LVH by
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TABLE 1
FREQUENCY AND TYPE OF MAJOR ECG ABNORMALITIES
MEN
(n=1609)
WOMEN
(n=1609)
NORMAL ECG 34.1% 44.4%
LVH WITHOUT ST-T CHANGES 21.6% 12.6%
LVH WITH ST-T CHANGES 12.9% 8.9%
ST-T CHANGES ONLY 13.2 % 17.1%
MYOCARDIAL INFARCTION 6.0% 3.4%
TABLE 2
LEVEL OF INITIAL AND ACHIEVED DIASTOLIC BP IN RELATION TO ECG AT PRESENTATION
ECG ABNORMALITY INITIAL DBP ACHIEVED DBP CHANGE IN DBP
(mmHg) (rimHg) (mnHg)
NORMAL 108 94 14
LVH ONLY 114 98 16
LVH AND ST-T CHANGES 116 100 16
ST-T CHANGES ONLY 113 98 15
MYOCARDIAL INFARCTION 114 98 16
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Figure 2
Prevalence of ECG LVH in relation to blood 
pressure at presentation.
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TABLE 3
MORTALITY AND RELATIVE RISK OF LVH AND OTHER ECG ABNORMALITIES IN MEN
ALL CAUSE IHD CVA
n MR RR P n MR RR P n MR RR P
NORMAL ECG 73 27.6 1.0 19 6.0 1.0 15 7.2 1.0
LVH WITHOUT ST-T CHANGES 92 43.2 1.6 *** 35 16.2 2.7 19 13.3 1.8 **
LVH WITH ST-T CHANGES 80 56.9 2.1 *** 33 23.8 4.0 *** 18 12.5 1.7 *
ST-T CHANGES ONLY 74 46.7 1.7 *** 42 27.2 4.5 6 3.7 0.5 **
MYOCARDIAL INFARCTION 44 73.1 2.6 •k irk 21 31.9 5.3 *** 11 23.5 3.2 ir k
n = number of deaths
MR = age-adjusted mortality rate (deaths/1000 patient years)
RR = relative risk i.e. mortality rate for a given ECG abnormality
divided by mortality rate for a normal ECG
* = p<0.05
** = p<0.01 - compared with a normal ECG
*** = pcO.OOl -
TABLE 4
MORTALITY AND RELATIVE RISK OF LVH AND OTHER ECG ABNORMALITIES IN WOMEN
ALL CAUSE I HD CVA
n MR RR P n MR RR P n MR RR P
NORMAL ECG . 65 13.7 1.0 24 4.9 1.0 15 3.1 1.0
LVH WITHOUT ST-T CHANGES 49 33.1 2.4 *** 15 9.6 2.0 * 17 12.3 4.0
k ir k
LVH WITH ST-T CHANGES 39 36.2 2.6 i r k 12 11.5 2.3 * 11 10.1 3.3
ir k
ST-T CHANGES ONLY 56 22.9 1.6 i r k * 23 9.9 2.0 * 10 4.2 1.4
MYOCARDIAL INFARCTION 18 39.9 2.9 7 19.4 4.0
* 4
r
-
H• 2.0
n = number of deaths
MR = age-adjusted mortality rate (deaths/1000 patient years)
RR = relative risk i.e. mortality rate for a given ECG abnormality
divided by mortality rate for a normal ECG
* = p<0.05
** = p<0.01 - compared with a normal ECG
*** = p<0.001 -
voltage alone was associated with a 57% increase in 
mortality in men (27.6 vs 43.2 deaths per thousand 
patient years, pCO.OOl) and a 142% increase in women 
(13.7 vs 33.1 deaths per thousand patient years, 
pCO.OOl). LVH with ST-T changes was associated with an 
even greater increase in mortality, the rate being 56.9 
per thousand patient years for men and 36.2 per 
thousand patient years for women. The highest mortality 
rates for both sexes were seen in patients with ECG 
evidence of myocardial infarction (73.1 and 39.9 per 
thousand patient years respectively) but the 
contribution of LVH to total mortality in the clinic 
was greater than that of myocardial infarction because 
it was more common. As expected, the increased risk was 
largely confined to vascular causes of death.
The "independence" of LVH as a risk factor was then 
tested by regression analysis using the Cox 
proportional hazards model. Initially, the following 
covariates were tested by univariate analysis for their 
relation to mortality: age, smoking habit, past history 
of vascular disease, referral to the clinic before 
1976, initial mean arterial blood pressure, retinal 
arteriovenous nipping, raised blood urea and ECG LVH 
with and without ST-T changes. Retinal arteriovenous 
nipping and referral to the clinic before 1976 were 
included because both had emerged as risk factors in a 
previous analysis from the Glasgow Blood Pressure 
Clinic (1). In univariate analyses, all were
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significantly related to outcome in both sexes 
(pCO.OOl).
Controlling for mean arterial blood pressure at 
presentation, the relative risk associated with ECG LVH 
(compared to patients with a normal ECG) was 1.80 for 
men and 1.97 for women; relative risk for those with 
LVH and ST-T changes was 2.87 for men and 2.09 for 
women. Furthermore, 95% confidence limits drawn around 
these values did not cross unity in any of the four 
groups analysed (figure 3). When multivariate analysis 
was repeated controlling simultaneously for age, mean 
arterial blood pressure at presentation, smoking habit, 
previous vascular disease and raised blood pressure, 
LVH, both with or without ST-T changes, again emerged 
as a strong and independent risk factor for mortality 
(figure 4).
Discussion
The first main finding was that LVH with or without 
ST-T changes was common among patients referred to the 
clinic, being present in no fewer than one-third of the 
men and one-fifth of the women. The high prevalence 
contrasts with the much lower rates found in general 
population surveys such as Framingham (2) and in large 
groups of patients with mild to moderate hypertension 
(184,185). This presumably reflects referral to the 
clinic of patients with more severe, more resistant, or
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more complicated forms of hypertension. In this study, 
the prevalence of LVH was related to the height of the 
initial blood pressure as was the case in the 
Framingham and HDFP studies (2,184). LVH was more 
common in men but higher blood pressure was not the 
explanation. Men must develop more ECG LVH than women 
for some other reason, therefore. Differences in body 
build affect ECG voltages, particularly when 
praecordial leads are used. In general, women have more 
centrally distributed fat than than men and this may 
reduce the sensitivity of the ECG for detection of LVH 
in women. In support of this, the sex difference in LVH 
prevalence is much less marked when LVH is assessed 
echocardiographically (85).
The second main finding relates to the risk associated 
with LVH. Mortality in the clinic has previously been 
noted to be high (1), but patients with ECG LVH when 
first seen were twice as likely to die as those without 
LVH. This was true for men and women separately (tables 
3 and 4) and although absolute mortality was greater in 
men, relative risk was the same for both sexes. LVH 
with ST-T changes was associated with a high mortality 
risk almost comparable to that of a previous myocardial 
infarction. Multivariate analysis confirmed that LVH 
with or without ST-T changes was a highly significant 
and independent predictor of outcome. This is in 
contrast to the Framingham data which showed that while 
"definite" LVH (LVH with ST-T changes) was an
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Figure 3
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more complicated forms of hypertension. In this study, 
the prevalence of LVH was related to the height of the 
initial blood pressure as was the case in the 
Framingham and HDFP studies (2,184). LVH was more 
common in men but higher blood pressure was not the 
explanation. Men must develop more ECG LVH than women 
for some other reason, therefore. Differences in body 
build affect ECG voltages, particularly when 
praecordial leads are used. In general, women have more 
centrally distributed fat than than men and this may 
reduce the sensitivity of the ECG for detection of LVH 
in women. In support of this, the sex difference in LVH 
prevalence is much less marked when LVH is assessed 
echocardiographically (85).
The second main finding relates to the risk associated 
with LVH. Mortality in the clinic has previously been 
noted to be high (1), but patients with ECG LVH when 
first seen were twice as likely to die as those without 
LVH. This was true for men and women separately (tables 
3 and 4) and although absolute mortality was greater in 
men, relative risk was the same for both sexes. LVH 
with ST-T changes was associated with a high mortality 
risk almost comparable to that of a previous myocardial 
infarction. Multivariate analysis confirmed that LVH 
with or without ST-T changes was a highly significant 
and independent predictor of outcome. This is in 
contrast to the Framingham data which showed that while 
"definite" LVH (LVH with ST-T changes) was an
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independent risk factor for mortality, "possible" LVH 
(LVH without ST-T changes) was not associated with a 
risk in excess of that attributable to hypertension 
alone (81). A limitation of the multivariate analysis 
is that it controls for initial rather than achieved 
arterial pressure. However, as table 2 demonstrates, 
the mean absolute reduction in blood pressure was 
similar for those with and without LVH and thus it 
seems likely that the relative risk of LVH would be 
unaffected had it been possible to control for 
achieved, as well as initial, blood pressure.
Why LVH should be an independent risk factor for 
mortality is not known. Since it is independent of the 
major risk factors for coronary artery disease, namely 
cigarette smoking, high blood pressure and cholesterol, 
we must postulate either that LVH itself accelerates 
the process of coronary atherosclerosis or that LVH is 
contributing to mortality through a mechanism other 
than coronary artery disease and myocardial infarction. 
In conclusion, ECG LVH is common in patients from the 
Glasgow Blood Pressure Clinic and is associated with a 
high mortality that is in excess of that attributable 
to other co-existent risk factors. The mechanism of 
this excess risk is unknown.
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CHAPTER 5
ECHOCARDIOGRAPHIC VALIDATION OF ECG REPORTING IN THE 
GLASGOW BLOOD PRESSURE CLINIC.
Introduction
The analysis of mortality in the Glasgow Blood Pressure 
Clinic with respect to ECG LVH was based on the 
original ECG reports made by a number of junior and 
senior physicians over a period of almost twenty years 
using "conventional" but not standardised criteria for 
left ventricular hypertrophy. It was necessary, 
therefore, that some form of validation of this 
reporting system be carried out before firmly accepting 
the findings. Echocardiography is now regarded as the 
"gold standard" for assessment of left ventricular 
hypertrophy in vivo and thus it was used to calculate 
the sensitivity and specificity of the "routine" ECG 
reporting service for the diagnosis of LVH.
Materials and methods
Before examining the hypertensive subjects, it was 
necessary first to define a normal range for left 
ventricular mass based on a normotensive control 
population. Since myocardial mass is generally greater 
in men than in women and also varies with body build,
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the normal range was defined in terms of left 
ventricular mass index (expressed as g/m2 body surface 
area) for men and women separately.
In total, one hundred and fifty subjects, comprising 
fifty normal controls and one hundred hypertensive 
patients were studied. The subjects were derived from 
"screening" of fifty-nine normal controls and one 
hundred and twenty-one hypertensives, the remainder 
being excluded usually because of inability to obtain 
an echocardiogram of sufficient quality for analysis.
Study groups
1. Control group
This comprised fifty normal subjects, the majority 
being either employees of the hospital or ambulance 
service or friends or relatives of members of the 
cardiac department. None had a history of current 
cardiac symptoms or of previous cardiac disease. None 
had a history of hypertension or were taking 
antihypertensive medication. In view of the wide range 
of blood pressures found in any "normal" population, it 
was decided that individuals should be excluded only if 
their supine blood pressure, after resting for at least 
ten minutes, exceeded 160 mm Hg systolic or 105 mm Hg 
diastolic; this did not apply to any of the fifty 
controls. However, subjects were excluded if the
PAGE 105
resting electrocardiogram showed evidence of left 
ventricular hypertrophy; four of the fifty-nine 
subjects screened were excluded for this reason. 
Baseline data, relating to age, sex and blood pressure 
levels for the fifty controls are given in table 5.
2. Hypertensive group
One hundred hypertensive patients were studied. For the 
purposes of the study on arrhythmia frequency (to be 
described in chapter 7), two matched groups of 
hypertensives were studied. Thus fifty patients had ECG 
evidence of left ventricular hypertrophy by the 
criteria of Sokolow and Lyon (SVl+RV5^35mm)(65) and 
fifty did not. The majority (seventy-eight patients) 
attended the Glasgow Blood Pressure Clinic at the 
Western Infirmary and the remaining twenty-two attended 
the cardiology outpatient clinic also at the Western 
Infirmary. All one hundred had essential hypertension; 
none had a history or electrocardiographic changes of 
myocardial infarction or bundle branch block and none 
had clinical evidence of valvular heart disease. 
Baseline data relating to age, sex and blood pressure 
levels for the two hypertensive groups are shown in 
tables 6 and 7. An important feature of the study of 
arrhythmia prevalence was that the hypertensive groups 
with and without ECG LVH should be matched for both 
initial and achieved blood pressure. Initial (i.e.
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pre-treatment) blood pressure readings were obtained 
from the Glasgow Blood Pressure Clinic records and from 
the clinic referral letters for those patients 
attending the cardiac clinic. Each patient in the group 
with ECG LVH was matched with a hypertensive without 
LVH for age (within five year age bands), smoking habit 
(current smoker or non-smoker), initial systolic blood 
pressure (within 10 mm Hg) and achieved systolic blood 
pressure (within 5 mm Hg). In addition, the two 
hypertensive groups were matched in the same way with 
the control group for age, sex and smoking habit. All 
of the hypertensives were receiving regular 
antihypertensive medication which included one or more 
of beta blocker, diuretic and vasodilator; treatment 
was continued throughout the period of investigation. 
The baseline data for the hypertensive and control 
groups are summarised in table 8. There were no 
significant differences in age, sex distribution or 
smoking habit between the groups. Blood pressure 
levels, despite treatment, were higher in the 
hypertensive groups than in the controls.
Methods 
1. Blood Pressure
Systolic and diastolic blood pressure was measured in 
all one hundred and fifty subjects after ten minutes
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TABLE 5
BASELINE DATA - NORMAL CONTROLS
SUBJECT AGE SEX SBP DBP
NUMBER (years) (im Hg) (mm Hg)
1 55 F 120 73
2 26 F 116 89
3 64 F 122 76
4 48 F 128 87
5 43 F 134 90
6 54 F 136 76
7 45 F 110 70
8 32 M 106 77
9 52 F 110 80
10 41 M 116 86
11 32 M 118 86
12 67 M 132 82
13 33 M 92 64
14 61 M 144 88
15 76 M 156 92
16 65 M 124 78
17 64 M 128 84
18 62 M 110 76
19 50 M 132 98
20 63 M 134 76
21 44 M 158 84
22 68 M 98 82
23 53 M 120 76
24 45 M 126 94
25 67 F 136 94
26 51 M 124 80
27 69 F 102 68
28 76 M 132 76
29 52 M 157 84
30 42 M 118 80
31 50 M 159 94
32 56 M 132 88
33 53 M 160 98
34 57 M 158 98
35 57 M 156 92
36 54 F 134 78
37 73 M 135 88
38 59 M 122 86
39 58 F 112 65
40 30 F 110 74
41 76 M 134 84
42 68 M 128 79
43 73 M 138 90
44 71 M 139 82
45 69 F 122 78
46 69 F 118 74
47 68 M 130 84
48 67 F 137 94
49 74 M 140 102
50 66 M 136 84
SBP = SYS. BLOOD PRESSURE (mmHg) 
DBP = DIA. BLOOD PRESSURE (mmHg)
NO.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
TABLE 6
BASELINE DATA - HYPERTENSIVES WITHOUT ECG LVH
INITIAL BP ACHIEVED BP DURATION 
(mm Hg) (mm Hg) OF THERAPY
SEX AGE SBP DBP SBP DBP (YEARS)
F 67 201 70 138 94 3
M 67 200 130 156 82 6
M 58 152 98 132 94 11
M 64 166 98 150 88 4
F 54 204 107 158 92 10
M 61 154 86 128 94 4
M 69 200 115 164 90 10
M 68 208 108 164 70 3
M 29 146 90 145 103 4
M 71 152 88 134 88 11
F 62 260 114 154 92 4
M 59 187 110 168 84 2
F 36 195 116 165 88 6
M 62 210 108 136 90 6
M 58 180 88 148 86 10
M 48 182 92 192 92 3
M 64 190 80 188 80 5
F 58 200 110 126 82 2
F 63 190 118 128 86 3
F 77 170 96 176 81 11
F 76 164 92 212 92 4
F 42 194 90 161 65 11
M 32 164 104 162 104 11
M 59 156 103 132 78 5
F 44 162 108 126 68 • 8
M 39 170 104 128 92 9
M 32 174 117 140 80 7
M 79 210 100 164 92 10
M 71 190 140 176 82 4
M 58 149 81 158 85 10
F 60 150 95 158 88 2
M 57 172 108 136 74 2
F 65 179 87 172 92 5
M 65 212 110 168 86 11
F 50 150 86 128 82 6
M 43 210 136 154 82 2
M 47 184 112 160 94 2
F 46 182 108 168 94 12
F 67 210 130 146 94 3
M 55 178 106 142 94 10
M 57 186 108 148 98 8
M 74 185 100 150 92 1
M 77 173 108 154 96 3
M 55 196 86 170 98 7
M 59 150 100 156 104 6
F 62 160 106 140 92 10
M 64 158 107 170 100 6
F 66 200 110 145 90 5
F 54 220 144 190 85 10
F 58 185 116 165 92 1
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
132
134
135
136
137
138
139
140
141
142
143
144
145
146
147
TABLE 7
BASELINE DATA - HYPERTENSIVES WITH ECG LVH
INITIAL BP ACHIEVED BP DURATION 
AGE (mm Hg) {m Hg) OF THERAPY
SEX (YEARS) SBP DBP SBP DBP (YEARS)
M 68 223 111 210 104 12
M 62 165 95 142 90 1
M 55 155 100 150 78 6
F 65 175 105 130 77 1
M 66 210 120 177 86 9
F 77 182 100 166 100 9
M 54 168 106 170 95 2
M 65 184 110 174 90 4
M 55 176 104 152 100 4
M 55 150 90 174 94 2
F 70 154 102 240 105 10
M 65 167 108 135 80 1
M 36 164 82 144 82 9
M 54 210 106 164 84 3
M 62 160 95 160 82 11
M 62 183 92 178 100 10
M 31 150 92 136 90 10
M 59 150 92 160 92 8
M 30 174 70 136 84 2
M 58 190 104 190 94 12
F 57 238 84 192 95 4
M 58 192 114 180 76 11
M 29 166 116 154 108 8
M 71 202 108 192 104 1
M 65 192 99 164 88 5
F 67 236 110 206 102 5
M 70 200 110 168 107 3
M 71 172 108 172 92 5
M 60 170 110 134 92 12
F 73 182 115 165 96 4
F 61 158 98 136 92 1
M 67 180 92 160 86 9
M 67 200 100 144 72 6
M 60 194 102 138 92 5
M 57 174 113 132 90 7
M 68 166 106 134 82 3
F 74 190 110 190 90 10
M 72 175 81 170 90 3
F 71 210 95 175 110 1
F 66 210 100 206 106 6
M 59 180 98 154 98 2
F 62 167 108 150 80 11
M 51 160 106 130 110 7
M 52 170 103 168 94 12
M 41 170 92 160 94 2
M 50 174 90 140 78 7
F 74 160 110 165 90 10
M 61 152 84 120 90 8
M 62 155 85 155 80 4
M 29 188 116 145 74 4
TABLE 8
CHARACTERISTICS OF CONTROL SUBJECTS AND HYPERTENSIVE PATIENTS
NORMOTENSIVE
CONTROLS
HYPERTENSIVES 
WITHOUT ECG LVH
HYPERTENSIVES 
WITH ECG LVH
(n=50) (n=50) (n=50)
AGE (YEARS) 57+2 58+2 59+2
M:F RATIO 34:16 31:19 34:16
INITIAL SYS BP (mm Hg) - 182+4 179+4
INITIAL DIA BP (mm Hg) - 104+2
**
101+2
**
ACHIEVED SYS BP (mm Hg) 129+2 155+3
**
162+3
**
ACHIEVED DIA BP (mm Hg) 83+2 88+2 91±3
DURATION OF THERAPY (years) 6.2+0.5 6.0+0.5
SMOKERS 58% 52% 42%
HEIGHT (cm) 168+1 167+2 168+2
WEIGHT (kg) 71+2 73+2 72+1
** p<0.01 - difference from controls
recumbency using a "Hawksley" random zero 
sphygmomanometer.
2. Electrocardiograms
Standard 12 lead electrocardiograms were recorded with 
a paper speed of 25 mm/sec and standardisation of 
lmV/cm. The ECGs were sent for reporting in the routine 
non-standardized manner and the report coded as in the 
Glasgow Blood Pressure Clinic office. Since the purpose 
of this analysis was to examine the validity of ECG 
reporting of LVH, the coding system described here has 
been simplified as follows to exclude other diagnoses:
1 = no ECG LVH
2 = ECG LVH without ST-T changes
3 = ECG LVH with ST-T changes
3. Echocardiograms
Echocardiography was carried out using an "IREX SYSTEM 
III" phased array ultrasound unit with a 2.5 MHz 
transducer and an aperture size of 16 mm. All 
echocardiograms were recorded by myself. M-mode 
recordings were made on six inch light-sensitive paper 
with a paper speed of 50 mm/sec. The ECG was recorded 
simultaneously. The two dimensional echocardiogram
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image was used to position the M-mode cursor 
appropriately. The recordings were coded for later 
analysis so that the electrocardiographic 
characteristics of the subject were not known to me at 
the time of analysis. Analysis was performed using a 
digitising tablet (KONTRON Ltd) and a micro-computer.
In addition, the reproducibility of echocardiographic 
measurements was assessed and both intra- and 
inter-observer variability in the calculation of left 
ventricular mass were estimated.
The measurements taken and calculations made were as 
follows:
A
(a) Left ventricular dimensions
*>
Left ventricular posterior wall thickness (LVPW),
interventricular septal thickness (IVS) arjjp left
ventricular cavity diameter (LVCD) were all measured
distal to the tips of the mitral valve leaflets. All
measurements were made at end-diastole which was taken 
A
to be j:he peak of the ’ R ’ wave on the ECG. The measured 
septal thickness included contributions from both right 
and left ventricular endocardium while the measured 
left ventricular wall thickness included left 
ventricular endocardium. Measurements were made over 
three consecutive cardiac cycles and mean values 
calculated. Figure 5 shows an M-mode recording from a 
normal subject illustrating the interventricular
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Figure 5
M-mode echoca r d i o g r a m  through the left 
v e n t r i c l e  distal to the tips of the mitral 
v a lve leaflets
y j/ Electrocardiogram
Right ventricle
Interventricular
septum
Left ventricle
Left ventricular 
posterior wall
t r r r i l 1 1 m T i  m  »h ■ n I 1 1 n I ■ n 1 I n nT» 1 »i * ■
septum, the left ventricular cavity and the left 
ventricular posterior wall.
(b) Left ventricular mass
As discussed earlier, several methods have been 
described for the calculation of left ventricular mass. 
In this analysis, the method used was the cube formula 
incorporating the Penn convention as described by 
Devereux (75). This method is currently the most widely 
used for estimation of left ventricular mass and has 
been validated against actual left ventricular weight 
in a post-mortem study (75).
The formula is as follows:
LV mass (g) = 1.04((IVSD+LVPWD+LVEDD)3 -(LVEDD)3) 
where 1.04 = density of myocardium
IVSD = interventricular septal thickness 
LVPWD = left ventricular posterior wall thickness 
LVEDD = left ventricular internal diameter
These measurements are not the same as in (a) but are 
made using the "Penn" convention in which endocardial 
echoes are excluded from the wall thickness 
measurements; calculations using this convention have 
been shown to correlate well with left ventricular 
weight at post-mortem (75).
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Thus,
IVSD = septal thickness excluding right and left 
ventricular endocardial echoes 
LVPWD = posterior wall thickness excluding 
endocardial and epicardial echoes 
LVEDD = left ventricular internal diameter including 
the septal and posterior wall endocardial 
echoes
Examples of M-mode echocardiograms from normal and 
hypertensive subjects are illustrated in figure 6. 
Measurements were again made over three consecutive 
cardiac cycles and mean values calculated. The left 
ventricular mass index was used to define 
echocardiographic LVH. This was obtained by dividing 
the left ventricular mass by the body surface area, 
estimated from height and weight using standard 
reference tables (186). Baseline data including left 
ventricular mass and left ventricular mass index values 
for the three groups are shown in tables 9, 10 and 11. 
Using the data from table 9, upper limits of normal, 
equivalent to the mean plus two standard deviations, of 
145 g/m2 for men and 110 g/m2 for women were derived. 
These are close to the values reported in other series 
(32).
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TABLE 9
LEFT VENTRICULAR MASS AND MASS INDEX - NORMAL CONTROLS
BODY SURFACE
NUMBER HEIGHT WEIGHT AREA LV MASS LVMI
(cm) (kg) (m2) (9) (9/m2)
1 158 71.2 1.81 139 76.9
2 160 53.7 1.55 102 65.6
3 155 58.0 1.61 145 90.3
4 153 40.8 1.32 113 85.8
5 156 71.7 1.81 138 76.3
6 164 63.0 1.71 127 74.3
7 160 61.0 1.67 132 79.2
8 178 79.5 1.99 214 107.6
9 157 57.1 1.60 139 87.4
10 170 72.7 1.87 196 104.9
11 182 71.9 1.90 214 112.9
12 171 60.2 1.69 66 39.1
13 170 72.7 1.87 125 66.9
14 179 78.4 1.98 206 104.2
15 166 72.0 1.85 194 105.1
16 180 78.2 1.98 138 69.8
17 152 75.2 1.84 214 116.3
18 172 74.0 1.89 188 99.3
19 173 87.4 2.08 187 90.0
20 182 78.0 1.98 244 123.1
21 178 74.4 1.92 201 104.7
22 180 75.8 1.95 130 66.8
23 180 76.2 1.95 207 106.1
24 184 76.2 1.96 147 75.1
25 164 77.2 1.62 133 82.0
26 176 74.6 1.92 186 97.2
27 179 65.8 1.80 177 98.5
28 162 64.0 1.72 205 119.6
29 163 59.0 1.65 212 128.8
30 170 69.0 1.82 186 102.4
31 182 99.3 2.26 160 70.9
32 166 71.6 1.84 189 102.7
33 165 67.1 1.77 110 62.2
34 187 88.4 2.14 210 98.1
35 170 53.5 1.58 234 148.0
36 152 79.0 1.61 187 116.0
37 179 65.8 1.80 102 56.8
38 173 91.6 2.13 213 99.9
39 142 86.0 1.53 92 59.9
40 144 43.8 1.35 111 82.9
41 174 76.2 1.93 256 132.8
42 176 76.3 1.94 209 108.4
43 168 69.1 1.81 220 121.6
44 168 70.9 1.84 173 94.1
45 155 61.1 1.65 165 69.1
46 159 55.8 1.59 214 94.8
47 171 75.5 1.90 165 86.6
48 155 71.3 1.65 117 70.8
49 167 68.6 1.64 165 100.4
50 168 70.9 1.84 154 83.9
TABLE 10
PERCENTAGE IDEAL WEIGHT AND LEFT VENTRICULAR MASS INDEX 
HYPERTENSIVES WITHOUT ECG LVH
%
NUMBER HEIGHT WEIGHT IDEAL LV MASS
(cm) (kg) WEIGHT (g)
51 149 88.2 172 240
52 168 88.4 172 332
53 167 65.3 107 227
54 168 73.5 115 325
55 166 73.4 124 183
56 177 75.8 106 150
57 173 71.0 106 118
58 177 68.0 96 180
59 168 61.6 96 160
60 174 82.2 123 202
61 139 86.2 164 317
62 175 74.3 106 392
63 157 55.4 104 164
64 180 96.2 133 384
65 174 72.2 108 165
66 177 89.8 126 292
67 173 92.5 139 271
68 160 63.8 116 137
69 167 61.4 103 93
70 158 74.0 138 241
71 147 54.0 112 122
72 157 64.4 119 148
73 177 88.2 124 196
74 181 90.6 125 217
75 160 54.0 96 137
76 187 95.6 120 128
77 161 53.8 91 89
78 166 61.2 96 299
79 175 77.6 110 243
80 165 70.2 110 277
81 167 75.0 125 110
82 162 77.0 129 280
83 167 76.8 130 129
84 184 85.3 115 209
85 159 60.6 110 203
86 164 85.5 143 132
87 166 92.0 145 291
88 165 80.0 136 143
89 157 79.4 148 229
90 170 85.6 136 183
91 179 85.4 128 219
92 178 75.2 144 268
93 166 98.0 170 113
94 169 63.4 100 176
95 152 64.0 122 310
96 155 63.0 120 193
97 167 81.6 126 321
98 161 75.4 137 184
99 152 74.5 143 438
100 167 64.2 107 172
LVMI
(9/m2)
120
160
130 
174
98 
78
64
99 
94
100
159
205
104
173
88
137
127
80
55
131 
80
87 
93
101
88 
57
57 
177 
124 
152
58 
147
67
100
123
65 
137
73
119
90
106
146
52
102
184
115
162
98 
239
99
TABLE 11
LEFT VENTRICULAR MASS AND MASS INDEX 
HYPERTENSIVES WITH ECG LVH
NO. HEIGHT WEIGHT
(cm) (kg)
101 171 72.4
102 173 75.6
103 161 68.5
104 154 52.7
105 172 89.4
106 180 89.4
107 180 87.2
108 149 58.0
109 168 71.4
110 171 75.6
111 165 71.0
112 152 60.0
113 181 64.0
114 161 73.0
115 189 88.0
116 165 81.2
117 167 51.4
118 181 85.6
119 157 54.6
120 178 74.2
121 158 75.0
122 160 47.6
123 172 55.6
124 176 70.8
125 178 88.3
126 155 91.2
127 161 64.0
128 172 86.0
129 187 86.4
130 153 69.5
131 158 67.6
132 157 71.3
133 167 66.4
134 182 74.0
135 167 61.8
136 175 75.6
137 161 67.8
138 177 72.0
139 151 56.0
140 162 73.8
141 189 102.0
142 159 57.1
143 176 71.6
144 166 85.6
145 169 77.0
146 168 89.0
147 156 66.4
148 172 80.2
149 165 63.0
150 176 69.8
IDEAL LV MASS LVMI
WEIGHT (g) (g/m2)
109 401 215
111 446 232
116 450 253
101 330 217
134 386 184
134 226 106
121 206 98
126 332 156
112 260 141
116 438 229
120 353 193
109 302 186
88 235 132
124 181 98
136 476 199
133 330 168
79 231 150
118 269 129
95 99 129
104 308 161
139 494 266
79 200 137
85 598 370
101 361 194
124 511 243
173 489 238
108 362 211
128 367 179
109 506 240
133 191 108
126 248 141
123 245 136
104 369 209
101 337 175
95 292 164
108 500 260
120 387 219
100 469 249
109 232 148
128 199 107
146 465 194
104 324 115
102 367 154
140 500 247
120 391 203
139 355 171
126 206 119
120 812 410
103 375 219
100 563 305
(c) Validation of echocardiographic measurements
In this study, it was not possible to calculate the 
precision of echocardiographic estimation of left 
ventricular mass since this would require knowledge of 
actual left ventricular weight.
However, we did assess the reproducibility of the 
technique. First, the reproducibility of acquiring the 
echocardiographic tracing was assessed by recording 
M-mode images across the left ventricle in the left 
parasternal view from a single subject on ten separate 
occasions over a period of three days. All tracings 
were recorded by one observer (JMM) and analysed by a 
second observer (AD) for septal thickness, posterior 
wall thickness, left ventricular cavity diameter and 
left ventricular mass as described above.
The results are shown in table 12. Thus the coefficient 
of variation (standard deviation divided by the mean 
and expressed as a percentage) was approximatly 6% for 
estimation of septal thickness, 3% for left ventricular 
end-diastolic diameter, 8% for posterior wall thickness 
and 3% for calculated left ventricular mass. On 
reviewing the tracings in the light of these results, 
it appeared that variation in the placement of the 
M-mode cursor with respect to the tips of the mitral 
valve leaflets accounted for much of the variability in 
the measured septal and posterior wall thickness.
We then assessed the intra- and inter-observer
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TABLE 12
REPRODUCIBILITY OF ECHOCARDIOGRAPHIC MEASUREMENTS IN A SINGLE SUBJECT
NO. IVS (cm) LVEDD (cm) LVPW (cm) LV MASS
1 1.47 4.58 0.69 175.4
2 1.51 4.48 0.61 171.0
3 1.31 4.44 0.76 164.3
4 1.42 4.51 0.69 165.6
5 1.54 4.52 0.66 171.8
6 1.60 4.13 0.77 163.6
7 1.41 4.54 0.60 160.7
8 1.51 4.42 0.66 169.5
9 1.53 4.39 0.65 168.3
10 1.33 4.68 0.72 175.1
MEAN 1.463 4.469 0.681 168.5
S.D. 0.094 0.146 0.057 4.95
COEFFICIENT 6.4% 3.3% 8.3% 2.9%
OF VARIATION
IVS = INTERVENTRICULAR SEPTUM 
LVEDD = LEFT VENTRICULAR END-DIASTOLIC DIAMETER 
LVPW = LEFT VENTRICULAR POSTERIOR WALL THICKNESS
TABLE 13
CALCULATION OF LEFT VENTRICULAR MASS 
ESTIMATION OF INTRA-OBSERVER VARIABILITY
NUMBER OBSERVER A OBSERVER A FIRST - SECOND DIFFERENCE
(FIRST) (SECOND) SQUARED
1 139 128 11 121
2 102 94 8 64
3 145 107 38 1444
4 113 115 -2 4
5 138 153 -15 225
6 127 126 1 1
7 132 149 -17 289
8 214 203 11 121
9 139 137 2 4
10 196 175 21 441
11 240 224 16 256
12 332 341 -9 81
13 227 251 -24 576
14 325 302 23 529
15 183 194 -11 121
16 150 153 -3 9
17 118 116 2 4
18 180 164 16 256
19 160 153 7 49
20 202 228 -26 676
21 410 383 27 729
22 446 453 -7 49
23 450 438 12 144
24 330 358 -28 784
25 386 390 -4 16
26 226 243 -17 289
27 206 218 -12 144
28 232 230 2 4
29 260 253 7 49
30 438 407 31 961
TOTAL " 13832 60 8440
MEAN 231 1
's' SQUARED (DIFFERENCE SQUARED/2n) = 8440/(2x30) = 140.7
•e' = 11.9
COEFFICIENT OF VARIATION (SD/MEAN) = (11.9/231) X 100% = 5.2%
TABLE 14
CALCULATION OF LEFT VENTRICULAR MASS 
ESTIMATION OF INTER-OBSERVER VARIABILITY
NUMBER OBSERVER A OBSERVER B FIRST - SECOND DIFFERENCE
SQUARED
1 139 110 29 841
2 102 88 14 196
3 145 167 -22 484
4 113 135 -22 484
5 138 136 2 4
6 127 147 -20 400
7 132 146 -14 196
8 214 193 21 441
9 139 144 -5 25
10 196 220 -24 576
11 240 159 81 6561
12 332 307 25 625
13 227 249 -22 484
14 325 313 12 144
15 183 188 -5 25
16 150 141 9 81
17 118 98 20 400
18 180 163 17 289
19 160 154 6 36
20 202 186 16 256
21 410 435 -25 625
22 446 407 39 1521
23 450 482 -32 1024
24 330 347 -17 289
25 386 371 15 225
26 226 245 -19 361
27 206 267 -61 3721
28 232 208 24 576
29 260 241 19 361
30 438 454 -16 256
TOTAL 13847
MEAN 231
's' SQUARED (DIFFERENCE SQUARED/2n) 
's'
COEFFICIENT OF VARIATION (SD/MEAN)
45 21507
0.75
= 21507/(2x30) = 358.5
= 18.9
= (18.9/231) X 100% = 8.2%
variability for calculation of left ventricular mass in 
a sample of thirty of the original one hundred and 
fifty tracings comprising ten from normal controls, ten 
from hypertensives without ECG LVH and ten from 
patients with ECG LVH. Each subgroup of ten patients 
was selected at random from the original cohorts of 
fifty normal controls, fifty hypertensives without ECG 
LVH and fifty hypertensives with ECG LVH. The thirty 
tracings were then analysed on two further occasions, 
once by the original observer (JMM) and once by a 
second observer who was unaware of the results of 
previous analyses. The results are shown in tables 13 
(intra-observer variability) and 14 (inter-observer 
variability). Thus the coefficient of variation was 
5.2% for a second analysis of the tracing by the same 
observer and 8.2% for analysis by a second observer.
We concluded that our echocardiographic measurements 
were sufficiently reproducible to be employed for the 
validation of the electrocardiographic diagnosis of 
left ventricular hypertrophy.
4. Calculation of sensitivity and specificity
The sensitivity and specificity values for the ECG 
reporting system were then calculated as follows:
TP
sensitivity (%) =   x 100
TP + FN
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TN
specificity (%) =   X 100
TN + FP
where:
TP = true positive = ECG +ve, ECHO +ve
FP = false positive = ECG +ve, ECHO -ve
TN = true negative = ECG -ve, ECHO -ve
FN = false negative = ECG -ve, ECHO +ve
Thus, for example, patients were considered to be "true 
positives" if they had an elevated left ventricular 
mass index (> 145g/sq. metre for males and >110g/sq. 
metre for females) and fulfilled the appropriate ECG 
criteria.
Results
All parametric data (age, blood pressure, 
echocardiographic measurements etc.) are expressed as 
mean + S.E.M. and differences between groups calculated 
using a two-tailed t-test for unpaired data.
Differences in non-parametric data (sex ratio, smoking 
habit, etc.) are calculated using a Chi-squared test. 
The echocardiographic dimensions of the two
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hypertensive groups and the normal control subjects are 
summarised in table 15. Mean left ventricular mass was 
significantly greater in those hypertensives without 
ECG LVH than in the controls. For those hypertensives 
with ECG LVH, mean LV mass was higher still, being 
approximately 50% greater than in those hypertensives 
without ECG LVH and double that of the normotensive 
controls.
Table 16 shows the ECG codes and echocardiographic 
findings in the study group of one hundred 
hypertensives. Sixty-nine patients had 
echocardiographic LVH of whom forty-three also had ECG 
LVH (true positives). This gives a sensitivity for the 
ECG reporting system of 43/69 = 62%. Specificity (true 
negatives / true negatives + false positives) was 24/31 
= 77%.
Those patients with ECG and echo evidence of LVH (true 
positives) had significantly more hypertrophy than 
those with echo LVH only (false negatives) (206+10 vs. 
151+6 g/m2, p<0.01)(table 17).
In twenty-six patients, the echo, but not ECG, criteria 
for LVH were fulfilled (false negatives). Compared to 
those patients with both ECG and echo evidence of LVH, 
left ventricular mass index was lower, thus confirming 
that the echocardiogram can detect milder degrees of 
LVH than the ECG. This group also differed from the 
three other groups in being more obese, their mean 
weight being 130+4% of their predicted ideal weight
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TABLE 15
ECHOCARDIOGRAPHIC DIMENSIONS FOR THE THREE GROUPS
INTRAVENTRICULAR 
SEPTUM (cm)
LEFT VENTRICULAR 
POSTERIOR WALL (cm)
LEFT VENTRICULAR 
CAVITY (cm)
LEFT VENTRICULAR 
MASS (g)
CONTROLS HYPERTENSIVES WITHOUT HYPERTENSIVES WITH
ECG LVH ECG LVH
(n=50) (n=50) (n=50)
**
1.04+0.04 1.33+0.09 1.63±p.06
**
++
**
+
0.93+0.03 1.13+0.06 1.38+0.07
4.71±0.08 4.59+0.13 4.83±0.12
* *** 
169+6 215+12 359+20
* p<0.02 -
** p<0.01 - difference from controls
*** p<0.001 -
+ p<0.02
++ pcO.Ol - difference between hypertensive groups 
+++ pcO.OOl
Note: significance assumed at level of p<0.02 (i.e. 0.05 divided by 3)
to take account of multiple comparisons (Bonferroni correction)
TABLE 16
EVIDENCE OF LVH BY ECG AND BY ECHO IN 100 HYPERTENSIVES
PATIENT NO. ECG CODE ECHO LVH PATIENT NO. ECG CODE
51 1 2 101 3
52 1 2 102 3
53 1 2 103 2
54 1 2 104 2
55 1 2 105 2
56 1 1 106 2
57 1 1 107 2
58 1 1 108 2
59 1 1 109 2
60 1 1 110 2
61 1 2 111 2
62 1 2 112 3
63 1 1 113 2
64 1 2 114 2
65 1 1 115 2
66 1 2 116 3
67 1 2 117 3
68 1 1 118 2
69 1 1 119 2
70 1 2 120 2
71 1 1 121 3
72 1 1 122 2
73 1 1 123 3
74 1 1 124 2
75 1 1 125 2
76 1 1 126 3
77 1 1 127 2
78 1 2 128 3
79 1 2 129 2
80 1 2 130 2
81 1 1 131 2
82 1 2 132 2
83 1 1 133 2
84 1 1 134 3
85 1 2 135 3
86 1 1 136 2
87 1 2 137 3
88 1 1 138 3
89 1 2 139 2
90 1 1 140 2
91 1 2 141 2
92 1 2 142 2
93 1 1 143 3
94 1 1 144 3
95 1 2 145 3
96 1 2 146 3
97 1 2 147 2
98 1 2 148 3
99 1 2 149 3
100 1 2 150 3
ECG : 1 = NO LVH ECH0 : 1 " N0 LVH
2 = LVH (VOLTAGE ONLY) 2 = LVH
3 = LVH AND ST-T CHANGES
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TABLE 17
CHARACTERISTICS OF FALSE NEGATIVES AND FALSE POSITIVES
TRUE FALSE FALSE TRUE
NEGATIVES NEGATIVES POSITIVES POSITIVES
n 24 26 7 43
M:F 15:9 16:10
*
7:0 27:16
% IDEAL WEIGHT 117+4 130+4 108+6 117+3
LVMI (g/m2) 81+4 151+6 125+6 206±10
* P<0.05 vs. TRUE NEGATIVES 
P<0.05 vs. TRUE POSITIVES 
P<0.01 vs. FALSE POSITIVES
(table 17).
Discussion
There are several potential sources of error in the 
existing reporting system. First, standardised ECG 
criteria are not used. While it is likely that most 
reporters will have used the chest lead criteria of 
Sokolow and Lyon, there are several variations of these 
criteria in common usage such as SV1 + RV5 > 35mm and 
SV1 or 2 + RV5 or 6 ^ 40mm although only the former is 
included in the original paper (65). Furthermore, some 
reporters may also have used criteria based on limb 
lead voltages.
Second, the ECGs were not reported "blind"; that is, 
the reporter was aware that the patient attended the 
blood pressure clinic and this may have introduced some 
bias towards the reporting of "borderline" LVH.
Third, the low sensitivity of the ECG for diagnosis of 
LVH is well known (187,188,189). Indeed, the value of 
62% obtained in this analysis is one of the highest 
sensitivities recorded; this is reflected by the 
specificity being lower than in most recorded series 
(188,189). The population studied, however, is not a 
random group of hypertensives and it is possible that 
the high sensitivity and low specificity are related to 
the high prevalence of left ventricular hypertrophy in 
the study group. Had left ventricular hypertrophy been
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less common in this group, then the sensitivity of ECG 
diagnosis might have been lower. In addition, the high 
sensitivity and low specificity reflect the use of 35 
mm as an arbitrary cut-off point. Had we defined LVH as 
RV5 + SV1 >, 37mm or even RV5 + SV1 } 40mm, sensitivity 
would have been lower and specificity higher.
In general, however, the sensitivity of the ECG is poor 
and almost 40% of patients with echocardiographic LVH 
are not detected by the electrocardiogram. ECG LVH is, 
however, a relatively specific finding (small number of 
false positives) and it did allow us to identify a 
subgroup of hypertensive patients at increased risk of 
cardiovascular mortality.
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CHAPTER 6
POSSIBLE IMPROVEMENT IN THE ELECTROCARDIOGRAPHIC 
DIAGNOSIS OF LEFT VENTRICULAR HYPERTROPHY 
Introduction
Many studies have shown that the ECG is an insensitive 
indicator of LVH (187,188,189). In attempts to improve 
this sensitivity, over thirty different sets of ECG 
criteria now exist (87). However, it seems unlikely 
that any single set of electrocardiographic criteria 
will reliably detect LVH in a heterogeneous population. 
Thus stratification of patients has been suggested, 
with different criteria being applied to different 
groups; for example, Casale et al recently suggested 
that stratification by age and sex can improve the 
diagnostic performance of the ECG for detection of LVH 
(73).
We have previously observed a number patients with 
marked echocardiographic left ventricular hypertrophy 
in whom the limb lead, but not chest lead, criteria 
were fulfilled. These patients were more often than not 
female, elderly and obese. An ECG from such a patient 
is shown in figure 7.
In this chapter, a further analysis of ECG criteria for 
LVH is described. The aims of this analysis were as
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Figure v
ECG showing LVH by limb lead, but 
not chest lead, criteria in an obese 
patient (weight 91kg, height 152cm).
I I I  I I I
aVr aVl aVf
V- V:
V, V,
follows:
1. to compare the sensitivity and specificity of four 
commonly used sets of electrocardiographic criteria for 
LVH (Sokolow-Lyon, Romhilt-Estes, Gubner-Ungerleider 
and RaVl), in the group of one hundred hypertensives 
described in chapter 5.
2. to divide the hypertensives into two groups on the 
basis of body build ("obese" and "non-obese") and to 
calculate the sensitivity and specificity of each set 
of criteria in the two groups and thus determine 
whether knowledge of a patient's height and weight 
could potentially be used to further improve the 
sensitivity of the ECG for detection of LVH.
Materials and methods
The electrocardiograms of the one hundred hypertensives 
described in chapter five were coded and carefully 
analysed, without knowledge of the echocardiographic 
findings, for evidence of left ventricular hypertrophy 
by the following criteria:
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1. Sokolow-Lyon (65)
RV5 + SV1 >,35 mm
2. Romhilt-Estes point scoring system (69)
POINTS
a) Voltage
largest R or S wave in limb leads >,20mm 3
or S wave in VI or V2 ^Omm
or R wave in V5 or V6 >30mm
b) ST-T depression
without digitalis 3
with digitalis 1
c) left atrial "strain" 3
i.e. terminal negativity of 'P' wave
in VI )>lmm in depth with duration of 
I>0.04 second
d) left axis deviation 2 
(mean axis of -30 degrees or less)
e) QRS duration ,^0.09 second 1
f) Intrinsicoid deflection 1
in V5/V6 ^,0.05second---------------------- -----
TOTAL SCORE =
4 POINTS = PROBABLE LVH
5 POINTS = DEFINITE LVH
3. Gubner-Ungerleider (64)
RI + SIII ,^25mm
4. RaVl } 12mm
Sensitivity and specificity were then calculated as 
before using echocardiography as the gold standard.
For the second part of the analysis, patients were 
subdivided into two groups, "obese" and "non-obese" 
according to whether or not their actual weight 
exceeded their predicted ideal weight by more than 20%. 
Predicted weight for age, sex and height was derived 
from standard reference tables (186) and is given in
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tables 10 and 11. Sensitivity and specificity values 
were then calculated separately for the obese and 
non-obese subgroups for all four sets of criteria.
Results
Sensitivities and specificities for the four different 
sets of electrocardiographic criteria are shown in 
table 18. The criteria of Sokolow-Lyon and 
Romhilt-Estes have similar values for sensitivity (57% 
and 54% respectively) and identical specificity (94%); 
the criteria based on limb lead voltages (RaVl and 
Gubner-Ungerleider) are reasonably specific (both 87%) 
but less sensitive (35% and 42% respectively) than 
either Sokolow or Romhilt-Estes.
For the obese hypertensives (n=49), the criteria of 
Gubner and Ungerleider were able to correctly detect 
LVH in 69% of those obese hypertensives with 
echocardiographic LVH (table 19) while the Sokolow 
criteria detected only 41%. Thus, in obese patients, 
the criteria of Gubner and Ungerleider are more 
sensitive for detection of LVH than the criteria of 
Sokolow and Lyon (69% vs 41%); this just achieves 
statistical significance at the 0.05 level when tested 
by Chi-sguared analysis. The height of the ’ R ? wave in 
aVl also appeared more sensitive than the Sokolow 
criteria for detection of LVH in the obese although 
this difference was not significant (p=0.2).
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Furthermore, this increase in sensitivity in obese 
patients was not achieved at the cost of a marked 
reduction in specificity, there being no significant 
differences in specificity between the four sets of 
criteria.
In the non-obese hypertensives, the situation was 
reversed (table 20). Here, sensitivity of the Sokolow 
criteria was three times greater than that of Gubner 
and Ungerleider (70% vs 19%, p<0.001). RaVl was 
slightly less sensitive than the criteria of Gubner and 
Ungerleider in both groups of hypertensives but 
followed a similar pattern, being significantly more 
sensitive (19/32 vs 5/37 p<0.002) in obese than in 
non-obese hypertensives. Estes criteria, which include 
contributions from both chest lead and standard lead 
voltages, showed intermediate sensitivity in both 
groups, being more sensitive than Sokolow in obese 
hypertensives and more sensitive than either Gubner and 
Ungerleider or RaVl in the non-obese.
Finally, table 21 shows what would happen if we divided 
the patients into "obese" and "non-obese" and then 
applied the most sensitive criteria to the two groups 
(Gubner and Ungerleider in the obese, Sokolow and Lyon 
in the non-obese). Thus the overall sensitivity of the 
ECG for detection of LVH could be increased from 57% 
(table 18) to 70% (table 21) (p=0.055) with only a 
small fall in specificity (94% to 90%) (NS).
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TABLE 18
SENSITIVITY AND SPECIFICITY OF VARIOUS ECG CRITERIA FOR LVH 
ALL HYPERTENSIVES (n=100)
SOKOLOW
TRUE POSITIVES 39
FALSE POSITIVES 2
FALSE NEGATIVES 30
TRUE NEGATIVES 29
SENSITIVITY 57%
SPECIFICITY 94%
ESTES RaVl GUBNER
38 24 29
2 4 4
31 45 40
29 27 27
55% 35% 42%
94% 87% 87%
TABLE 19
SENSITIVITY AND SPECIFICITY OF VARIOUS ECG CRITERIA FOR LVH 
OBESE HYPERTENSIVES (n=49)
SOKOLOW ESTES RaVl GUBNER
TRUE POSITIVES 13 15 19 22
FALSE POSITIVES 1 1 2 2
FALSE NEGATIVES 19 17 13 10
TRUE NEGATIVES 16 16 15 15
SENSITIVITY 41% 47% 60% 69%
SPECIFICITY 94% 94% 88% 88%
TABLE 20
SENSITIVITY AND SPECIFICITY OF VARIOUS ECG CRITERIA FOR LVH 
LEAN HYPERTENSIVES (n=51)
SOKOLOW ESTES RaVl GUBNER
TRUE POSITIVES 
FALSE POSITIVES 
FALSE NEGATIVES 
TRUE NEGATIVES
SENSITIVITY 70% 62%
SPECIFICITY 94% 93%
26 23 5 7
1 1 2 2
11 14 32 30
13 13 12 12
TABLE 21
EFFECT OF SELECTING CRITERIA ACCORDING TO BODY BUILD
OBESE LEAN TOTAL
(Gubner and Ungerleider) (Sokolow)
TRUE POSITIVES 22 + 26 48
FALSE POSITIVES 2 + 1 = 3
FALSE NEGATIVES 10 + 11 21
TRUE NEGATIVES 15 + 13 28
SENSITIVITY = 70%
SPECIFICITY = 90%
Discussion
In accordance with other studies, (187,188,189), this 
analysis has shown that current electrocardiographic 
criteria are insensitive and fail to detect almost 50% 
of those patients who fulfill echocardiographic 
criteria for left ventricular hypertrophy. Also in 
agreement with other studies (189), it has 
demonstratred that the criteria of Romhilt-Estes and 
Sokolow-Lyon are more sensitive than criteria based on 
standard limb lead voltages (RaVl and Gubner and 
Ungerleider). However, it has not previously been 
reported that criteria based on limb lead voltages are 
more sensitive than chest lead criteria for detection 
of LVH in obese hypertensives.
The likely explanation relates to the orientation of 
the heart within the thorax and indeed the relationship 
between body build and QRS voltage has previously been 
studied in normal individuals. Kilty and Lepeschkin 
correlated QRS voltages against ponderal index (as a 
measure of obesity) in 300 individuals free from 
cardiorespiratory disease (190). The ponderal index was 
derived by dividing height by the cube root of body 
weight; a low value, therefore, indicated obesity and a 
high value indicated lean build. They found a 
significant positive correlation between the sum of SV1 
and RV5 or 6 and ponderal index and a significant 
negative correlation between the sum of RI and SIII and
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ponderal index. The authors suggested that the fall in 
the SV1+RV5/6 sum and rise in the RI + SIII sum with 
increasing obesity was:
"most likely caused by a more transverse position 
of the heart resulting from a higher diaphragm 
position with increasing accumulation of adipose 
tissue in the abdomen."
This association between cardiac position and QRS 
voltages was noted by Sokolow and Lyon in their 
original paper (65). Although no mention is made of 
body build, it was noted that ''conventional" criteria 
for LVH (i.e. those based on limb lead voltages) 
detected LVH in "horizontal" hearts while their newly 
devised criteria, based on chest lead voltages, 
detected LVH in "vertical" hearts.
The clinical importance of these observations is that 
it may be possible to improve the diagnostic ability of 
the ECG to detect LVH if the patient's body build is 
taken into account.
Other variables, such as chest wall thickness (71) and 
the size and shape of the left ventricular cavity (72) 
have been shown to influence ECG voltages, and could be 
used to improve the ECG detection of LVH; however, 
unlike height and weight, such data are not routinely 
available in the outpatient clinic and criteria based 
on these variables are unlikely to pass into clinical
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use.
There are several limitations to this analysis. First, 
there is a complex relationship between obesity, 
hypertension and left ventricular hypertrophy (59). 
Obesity and hypertension are believed to have disparate 
cardiovascular effects; while essential hypertension is 
associated with increased afterload, obesity is 
associated with an expanded intravascular volume and 
increased preload (59). As far as is possible, these 
factors have been taken into account. Thus ventricular 
hypertrophy has been defined in terms of left 
ventricular mass index (g/m2) which makes allowance for 
dilatation of the left ventricular cavity when 
calculating left ventricular mass and also corrects for 
increased cardiac size in "big" people.
Second, the number of patients studied is too small to 
allow simultaneous stratification of patients according 
to age, sex and body build.
However, this analysis has demonstrated that criteria 
based on chest lead voltages, such as Sokolow-Lyon, are 
more sensitive for detection of LVH in patients of 
"average" weight than criteria based on limb lead 
voltages and that the reverse is true in obese 
patients. Casale has recently shown that stratification 
of patients by age and sex can improve ECG diagnosis of 
LVH (73) and it may be that stratification by age, sex 
and body build will lead to further improvement.
Clearly a prospective echocardiographic study of a
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large number of patients would be required to establish 
such criteria.
Interestingly, there is a suggestion that the 
clinicians reporting ECGs from the Glasgow Blood 
Pressure Clinic may have been using several sets of 
criteria since the sensitivity for detection of LVH was 
greater for the non-standardised system that for any of 
the four sets of criteria examined in this analysis.
The likely explanation is that LVH would be reported as 
being present by some observers if either chest lead or 
limb lead voltage criteria were fulfilled.
For the future documentation of LVH in the Glasgow 
Blood Pressure Clinic, a new form has been devised 
using standardised criteria in which limb lead, as well 
as chest lead, voltages are recorded.
7 t. x.i:
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CHAPTER 7
VENTRICULAR ARRHYTHMIAS IN HYPERTENSIVE PATIENTS WITH 
AND WITHOUT ECG LVH
Introduction
Both the Glasgow Blood Pressure Clinic data (1) and the 
Framingham study (80) have demonstrated that 
electrocardiographic left ventricular hypertrophy is 
associated with an increased cardiovascular mortality; 
in particular, it appears to be associated with an 
increased risk of sudden death (155) that is in excess 
of the risk attributable to hypertension or other 
associated cardiovascular risk factors (2).
One cause of this excess mortality could be a 
predisposition to ventricular arrhythmia and indeed 
increased ventricular ectopic activity has been found 
in hypertensive patients with LVH (191). However, in 
other conditions, the relationship between single 
ventricular extrasystoles and subsequent mortality is 
unclear while the relationship between complex 
ventricular arrhythmias, particularly ventricular 
tachycardia, appears more clear-cut. No data have been 
reported relating specifically to more complex 
ventricular arrhythmias in hypertensive patients with 
LVH.
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Aim
The aim of this analysis was to determine the frequency 
of both simple and complex ventricular arrhythmias in 
hypertensive patients with and without left ventricular 
hypertrophy, and to compare this with a control group. 
Since previous studies have made no allowance for a 
possible effect of hypertension itself on arrhythmia 
frequency, an important feature of this study was that 
the two hypertensive groups were matched with each 
other for both initial and achieved blood pressure as 
well as for other cardiovascular risk factors including 
age, sex and smoking habit.
Materials and methods
Patients
The one hundred hypertensive patients and fifty 
normotensive control subjects described in chapter 5 
were investigated for arrhythmia frequency. As 
mentioned in chapter 5, the one hundred hypertensives 
comprised two groups of fifty patients each, one with 
ECG LVH and one without. ECG LVH for this purpose was 
defined by chest lead voltage criteria according to 
Sokolow-Lyon (SV1+RV5 £35mm) (65). Baseline data 
relating to the two hypertensive groups and the normal 
controls have been summarised previously (tables 5-11
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and table 15). Those with electrocardiographic LVH were 
further subdivided according to whether the ECG also 
demonstrated major ST—T wave changes, defined as 
horizontal or down-sloping ST segment depression of 1mm 
or greater in leads V5 and V6 or T wave inversion in 
the same leads (n=21).
As noted earlier, the two hypertensive groups were 
matched with each other for both initial and achieved 
blood pressure.
Methods 
Ambulatory ECG monitoring
Ambulatory ECG recordings were made over two 
consecutive twenty-four hour periods using "TRACKER 
TR1" ambulatory tape recorders (Reynolds Medical 
Limited). The complete forty-eight hour record was 
printed using a "REYNOLDS TP1" full disclosure unit. 
After coding, the printouts were analysed manually. For 
analysis of ventricular extrasystoles, the tapes were 
subdivided into the following categories:
a) <10 extrasystoles per hour over 48 hours
b) 10-30 extrasystoles per hour over 48 hours
c) >30 extrasystoles per hour over 48 hours.
For analysis of complex ventricular arrhythmias, 
ventricular couplets were considered to be present if
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there were two or more couplets per 48 hours and 
ventricular tachycardia was defined as one or more 
episode of at least 3 consecutive ventricular beats at 
a heart rate greater than 120 beats per minute. 
Examples of the arrhythmias detected are shown in 
figure 8.
All one hundred and fifty printouts were analysed by 
two observers (myself and K.I.M.). Although there were 
minor differences in the total ectopic count between 
the two observers, there were no differences in the 
classification of printouts into the different 
categories:
i.e. a) <10, 10-30, >30 VEs per hour
b) couplets / no couplets
c) VT / no VT
RESULTS
Differences in non-parametric data (arrhythmia 
frequency, prevalence of ECG LVH etc.) are calculated 
using a Chi-squared test; differences in parametric 
data (age, left ventricular mass etc.) are expressed as 
mean + S.E.M. and differences between groups expressed 
usj.ng a two-tailed t-test for paired data.
t»
1. Frequency of ventricular arrhythmias
The frequency of ventricular arrhythmias is shown in
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Figure 8
Ve n t ricular arrhythmias detected
(a) Frequent ventricular extrasystoles (>30/hour)
urti(b) Ventricular couplets
mm M l f s lmm
Hi * 8 it
r."w m 1 § 1
(c) Ventricular tachycardia
TABLE 22
PREVALENCE OF VENTRICULAR ARRHYTHMIA DURING 48 HOUR ECG MONITORING 
(EXPRESSED PER 24 HOURS)
NORMAL CONTROL SUBJECTS
SUBJECT
NUMBER
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
17
18
19
20 
21 
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
NUMBER OF NUMBER OF
VENTRICULAR VENTRICULAR
EXTRASYSTOLES COUPLETS
0 0
3 0
0 0
0 0
35 0
0 0
0 0
7 0
0 0
0 0
48 0
0 0
55 0
7 0
4 0
0 0
0 0
0 0
3 0
1 0
0 0
0 0
0 0
31 0
0 0
0 0
2 0
3 0
8 0
0 0
706 3
0 0
0 0
0 0
0 0
0 0
0 0
0 0
6 0
0 0
87 2
0 0
5 0
0 0
14 0
0 0
0 0
3 0
0 0
0 0
EPISODES OF 
VENTRICULAR 
TACHYCARDIA
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
TABLE 23
PREVALENCE OF VENTRICULAR ARRHYTHMIA DURING 48 HOUR ECG MONITORING 
(EXPRESSED PER 24 HOURS)
HYPERTENSIVES WITHOUT ECG LVH
SUBJECT
NUMBER
NUMBER OF
VENTRICULAR
EXTRASYSTOLES
NUMBER OF
VENTRICULAR
COUPLETS
EPISIDES OF 
VENTRICULAR 
TACHYCARDIA
51 120
52 76
53 62
54 104
55 0
56 0
57 2
58 0
59 0
60 532
61 0
62 1318
63 0
64 1
65 112
66 8
67 240
68 4
69 0
70 4
71 0
72 0
73 0
74 0
75 0
76 0
77 0
78 3
79 62
80 0
81 0
82 1199
83 371
84 1
85 161
86 2
87 0
88 19
89 39
90 8
91 61
92 212
93 7086
94 0
95 0
96 262
97 54000
98 25
99 1
100 43
0
0
0
0
0
0
0
0
0
0
0
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3 
0
4 
2 
0 
0 
0 
0 
0 
0 
2 
0 
0 
7
546
0
2
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19
0
3
0
TABLE 24
PREVALENCE OF VENTRICULAR ARRHYTHMIA DURING 48 HOUR ECG MONITORING 
(EXPRESSED PER 24 HOURS)
HYPERTENSIVES WITH ECG LVH
NUMBER OF NUMBER OF EPISODES OF
VENTRICULAR VENTRICULAR VENTRICULAR
NUMBER EXTRASYSTOLES COUPLETS TACHYCARDIA
101 2748 1 2
102 14920 1271 14
103 2 2 0
104 4164 67 11
105 24 0 0
106 0 0 0
107 56 0 0
108 580 0 0
109 2 0 0
110
111
112
113
114
115
116
117
118
119
120 
121 
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
2748 1
14920 1271
2
4164 67
24
0
56
580
2
0 0
10 0
1027 1
2 0
74 1
16 2
4384 42
0 0
2 0
10 0
48 0
80 5
676 1
0 0
612 3
54 2
608 4
2 0
10 0
0 0
2 0
0 0
4 0
0 0
0 0
24 2
1104 0
21721 8653
2 0
6 0
540 0
42 4
1653 1
0 0
8 0
614 0
2 0
0 0
0 0
802 0
701 2
0
0
0
0
0
0
1
0
0
0
0
17
0
1
0
0
3
0
2
0
0
0
0
0
0
1
0
22
137 u u i  0 0
138 I 0 0
139 6 n 0
140 540 ? 1
141 «  |  o
142 1653 I 0U3, o  0
144 ? n 1145  0
146 n  0
147 °  0
148 0 n 1
149 802 0 4
150
TABLE 25
PREVALENCE OF SIMPLE AND COMPLEX VENTRICULAR ARRHYTHMIAS
<10 VPCs/hr 
10-30 VPCs/hr 
>30 VPCs/hr
VENTRICULAR
COUPLETS
VENTRICULAR
TACHYCARDIA
CONTROLS HYPERTENSIVES HYPERTENSIVES
WITHOUT WITH
ECG LVH ECG LVH
(n=50) (n=50) (n=50)
49 45 34
] ]
1 3 ] * 10 ] ***
] ] +
0 2 6
2 8 18
1 4 14 +
* P<0.05 -
- DIFFERENCE FROM CONTROLS 
*** P<0.001 -
+ P<0.05 - DIFFERENCE BETWEEN GROUPS 
WITH AND WITHOUT ECG LVH
had marked left ventricular hypertrophy by 
echocardiography (LV mass values of 271, 321 and 438g).
2. Relation of ventricular tachycardia to 
repolarisation abnormalities.
In table 26, the LVH group has been subdivided into 
those with and without ST-T changes. Twenty-one 
patients had LVH with ST-T changes of whom eleven (52%) 
had ventricular tachycardia, twelve (57%) had 
ventricular couplets (57%) and five (24%) had more than 
thirty ventricular extrasystoles per hour. Both 
ventricular tachycardia and ventricular couplets were 
significantly more common in those with than in those 
without ST-T changes. This is confirmed in table 27 
which demonstrates the principal differences between 
hypertensives with and without VT. There were no 
significant differences between the two groups in terms 
of age, sex ratio and smoking habit. Blood pressure 
levels were, on average, 10 mm Hg higher in those with 
VT although this achieved statistical significance for 
diastolic pressure only. The most striking differences 
between the two groups, however, relate to the presence 
of ECG LVH and to the degree of hypertrophy as assessed 
by echocardiography.
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TABLE 26
PREVALENCE OF ARRHYTHMIAS IN HYPERTENSIVES WITH AND WITHOUT ST-T CHANGES
HYPERTENSIVES HYPERTENSIVES
WITH ECG LVH WITH ECG LVH AND
(VOLTAGE ONLY) ST-T CHANGES
(n=29) (n=21)
>30 VPCs/hr 1 5
VENTRICULAR *
COUPLETS 6 12
VENTRICULAR *
TACHYCARDIA 4 14
* P< 0.05
TABLE 27
CHARACTERISTICS OF HYPERTENSIVES WITH VENTRICULAR TACHYCARDIA
HYPERTENSIVES
WITH
V.T.
(n=18)
HYPERTENSIVES
WITHOUT
V.T.
(n=82)
"p" VALUE
AGE (YEARS) 59+3 58+1 NS
M:F RATIO 12:6 53:29 NS
ACHIEVED SYS. BP (mm Hg) 162+6 152+2 NS
ACHIEVED DIA. BP (mm Hg) 98+5 88+2 p<0.05
SMOKERS 6 (33%) 38 (48%) NS
ECG LVH - VOLTAGE ONLY 14 (78%) 36 (43%) p<0.001
ECG LVH WITH ST-T CHANGES 11 (61%) 10 (12%) P<0.001
LEFT VENTRICULAR MASS (g) 390+29 261+15 P<0.001
3. Relation of ventricular tachycardia to heart rate.
Since the episodes of ventricular tachycardia were 
asymptomatic,, it was not possible to determine the 
subject’s activity at the time of the arrhythmia. It 
was possible, however, to determine mean heart rate 
during the thirty second period immediately prior to 
onset of the arrhythmia. As shown in figure 9, over 80% 
of episodes occurred when mean heart rate was less than 
one hundred beats per minute. This suggests that 
myocardial ischaemia secondary to increased cardiac 
workload was unlikely to be a major factor in the 
initiation of ventricular arrhythmia.
DISCUSSION
Ventricular arrhythmias do occur in individuals free of 
overt heart disease; this, together with the known 
spontaneous variability in ventricular ectopic 
frequency in short-term studies (192) and variability 
in simple and complex arrhythmias in long-term studies 
(193), has led to difficulties in the interpretation of 
studies of ventricular arrhythmia frequency.
In this study, we have attempted to control for some of 
these problems by including an age and sex matched 
control group. The prevalence of arrhythmia in the 
control group was of a similar order to that reported 
in asymptomatic individuals (194). Although spontaneous
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variability in arrhythmia frequency is a problem in 
longitudinal studies when trying to assess changes in 
ectopic frequency in response to an intervention, this 
should not introduce a systematic bias in a 
cross-sectional study such as this.
Thus the present study confirms the increased 
ventricular ectopic activity in hypertensive left 
ventricular hypertrophy described by Messerli (191) but 
demonstrates for the first time that ventricular 
tachycardia occurs significantly more often in 
hypertensive patients with LVH than in those without. 
Ventricular tachycardia occurred most commonly in those 
patients in whom overall mortality risk, as discussed 
in chapter 4, is highest, namely those with left 
ventricular hypertrophy and accompanying ST-T 
abnormalities on the resting ECG.
Experimentally, left ventricular hypertrophy 
predisposes to ventricular arrhythmia. It has been 
shown that spontaneously hypertensive rats have a lower 
threshold for ventricular fibrillation than controls 
(195) and that afterpotentials, which may predispose to 
arrhythmia, can be induced in hypertrophied rat 
myocardium but not in normal rat myocardium (196). In 
man, programmed electrical stimulation at the time of 
cardiac surgery has been used to determine 
vulnerability to ventricular tachyarrhythmias in 
patients with primary left ventricular hypertrophy 
(hypertrophic cardiomyopathy) and left ventricular
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hypertrophy secondary to aortic stenosis (197). 
Ventricular tachycardia could be induced in 82% of 
those patients with hypertrophic cardiomyopathy, 57% of 
those with aortic stenosis but in none of a "control" 
group with severe coronary artery disease but normal 
left ventricular function and no previous myocardial 
infarction.
In summary, this study has demonstrated that 
ventricular arrhythmias occur commonly in hypertensive 
left ventricular hypertrophy; their prevalence is not 
attributable to differences in age, sex, smoking habit 
or blood pressure but is related to the degree of 
cardiac hypertrophy. It is possible that this tendency 
to arrhythmia might be an important factor in the high 
mortality, and in particular, the high incidence of 
sudden death, in hypertensive patients with LVH.
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CHAPTER 8
INFLUENCE OF DIURETIC THERAPY AND HYPOKALAEMIA ON THE 
FREQUENCY OF VENTRICULAR ARRHYTHMIAS 
Introduction
In chapter seven, an increased frequency of ventricular 
arrhythmia was demonstrated in hypertensive patients 
with LVH and it was suggested that such arrhythmias 
might explain why LVH is an independent risk factor for 
mortality as described in chapter four.
Hypokalaemia is an alternative cause of ventricular 
arrhythmia and several studies have reported an 
association between diuretic-induced hypokalaemia and 
ventricular arrhythmia in treated hypertensive patients 
(198,199). Furthermore, a subgroup analysis of the 
Multiple Risk Factor Intervention Trial (MRFIT) 
suggested that mortality from coronary heart disease 
was increased in a group of patients with resting 
electrocardiographic abnormalities, including LVH, in 
whom "active" treatment included thiazide therapy for 
hypertension (200,201). This has been interpreted as 
suggesting that thiazide diuretics increase the 
incidence of fatal arrhythmias in hypertensive patients 
with abnormal ECGs.
In view of the importance of the MRFIT analysis, we 
have examined the prevalence of ventricular arrhythmias
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in those patients taking a diuretic as part of their 
antihypertensive regime and compared this to arrhythmia 
frequency in patients not taking a diuretic.
Materials and methods
The one hundred patients were as described in chapter 
five. The group was then subdivided according to 
whether or not the patients were taking a regular 
diuretic. Patients were initially included in the 
diuretic group whether or not they were taking oral 
potassium supplementation or a potassium sparing 
diuretic and the analysis was then repeated with these 
patients excluded.
A ten millilitre sample of venous blood was taken from 
a peripheral vein from each of the one hundred 
hypertensive subjects described in chapter five after 
at least ten minutes’ recumbency in a quiet room for 
estimation of serum potassium concentration.
Differences in arrhythmia prevalence between groups 
were calculated using a Chi-squared test and 
differences in serum potassium concentration calculated 
using a two-tailed t-test for unpaired data.
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Results
Fifty-six hypertensives were taking a diuretic as part 
of their treatment regimen at the time of assessment; 
four were taking oral potassium supplementation and 
three a potassium sparing diuretic. Forty-two were 
taking a thiazide diuretic (usually bendrofluazide) and 
fourteen were taking a loop diuretic (usually 
frusemide). Serum potassium concentration for this 
group was 3.5 + 0.3 mmol/1 compared to 4.2 +0.3 mmol/1 
for those not taking a diuretic (p<0.01). There were, 
however, no significant differences in the frequency of 
ventricular extrasystoles, couplets or tachycardia 
between the diuretic treated and non-diuretic treated 
groups (table 28).
To determine whether potassium supplements might 
"dilute" any difference in arrhythmia frequency between 
diuretic and non-diuretic treated patients, this 
analysis was repeated excluding those patients taking 
either potassium supplements or potassium sparing 
diuretics; again there were no differences in 
arrhythmia frequency between the two groups (table 29). 
The effect of diuretics on arrhythmia was then examined 
separately in those patients with and without LVH. 
Although all grades of ventricular arrhythmia were more 
common in those with LVH, there was no evidence that 
diuretic therapy, although clearly associated with a 
reduction in serum potassium concentration, was
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TABLE 28
DIURETIC TREATMENT AND ARRHYTHMIA FREQUENCY 
ALL HYPERTENSIVES
DIURETIC
(n=56)
I DIURETIC "p" VALUE 
(n=44)
SERUM K+ (mmol/I) 3.5+0.3 4.2+0.3 <0.01
VENTRICULAR 
EXTRASYSTOLES 
(>30 PER HOUR)
VENTRICULAR
COUPLETS
5 (9%) 3 (7%)
10 (18%) 9 (20%)
NS
NS
VENTRICULAR
TACHYCARDIA 11 (20%) 7 (16%) NS
TABLE 29
DIURETIC TREATMENT AND ARRHYTHMIA FREQUENCY 
ALL HYPERTENSIVES EXCLUDING THOSE ON TAKING K+ SUPPLEMENTATION
DIURETIC NO DIURETIC "p" VALUE
(n=49) (n=44)
SERUM K+ (mmol/I) 3.4+0.3 4.2+0.3 <0.01
VENTRICULAR
EXTRASYSTOLES 4 (8%) 3 (7%) NS
(>30 PER HOUR)
VENTRICULAR , x
COUPLETS 8 (16%) 9 (20%) NS
VENTRICULAR
TACHYCARDIA 10 (20%) 7 (16%) NS
TABLE 30
DIURETIC TREATMENT AND ARRHYTHMIA FREQUENCY 
HYPERTENSIVES WITH LEFT VENTRICULAR HYPERTROPHY
DIURETIC 
(n=29) (n=21)
SERUM K+ (mmol/1) 3.6±0.4 4.1+0.3 <0.
VENTRICULAR
EXTRASYSTOLES 3 (10%) 2 (10%) NS
(>30 PER HOUR)
VENTRICULAR
COUPLETS 7 (24%) 5 (24%) NS
VENTRICULAR
TACHYCARDIA 8 (24%) 6 (29%) NS
TABLE 31
DIURETIC TREATMENT AND ARRHYTHMIA FREQUENCY 
HYPERTENSIVES WITHOUT LEFT VENTRICULAR HYPERTROPHY
ii-iDIURETIC NO DIURETIC
(n=27) (n=23)
SERUM K+ (mmol/I) 3.3+0.3 4.3±0.3 <0.
VENTRICULAR , %
EXTRASYSTOLES 2 (7%) 1 (4%) NS
(>30 PER HOUR)
VENTRICULAR , .
COUPLETS 3 (11%) 4 (17%) NS
VENTRICULAR t ,lc
TACHYCARDIA 3 (11%) 1 W  r Ns
VALUE
05
VALUE
01
TABLE 32
DIFFERENCES IN THERAPY BETWEEN HYPERTENSIVES WITH AND WITHOUT VT
DIURETIC TREATED 
BETA BLOCKER TREATED
HYPERTENSIVES 
WITH VT 
(n=18)
11 (61%)
14 (78%)
HYPERTENSIVES 
WITHOUT VT 
(n=82)
45 (55%)
58 (70%)
"p" VALUE
NS
NS
SERUM K+ (nmol/l) 3.9+0.1 3.9+0.1 NS
associated with increased ventricular arrhythmic 
activity in either group (tables 30 and 31).
Finally, the treatment details of the patients with and 
without ventricular tachycardia are compared in table 
32. There were no significant differences in the 
proportion of patients treated with diuretics, or in 
the serum potassium concentration, between the two 
groups. Interestingly, there was also no significant 
difference in the proportion of patients taking regular 
beta blocker therapy and thus, indirectly, no 
suggestion that beta blockade protected against 
ventricular tachycardia in this group of patients.
Discussion
Thus we found no evidence that diuretics increase 
ventricular arrhythmias in hypertensives with or 
without left ventricular hypertrophy. This is in 
keeping with the results of Papademetriou et al (202) 
who demonstrated in a controlled prospective study that 
thiazide diuretic therapy did not increase ventricular 
ectopic activity in hypertensive patients with and 
without LVH. Leif et al also demonstrated in a study of 
thirteen hypertensives that hydrochlorothiazide 100 mg 
once daily for one to six months does not increase 
either ventricular ectopic rate or the prevalence of 
complex ventricular arrhythmias (203); similar findings 
have been reported by Madias in a placebo controlled
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crossover study (204).
Other studies, however, have produced conflicting 
results. Holland et al (198) carried out twenty-four 
hour ambulatory ECG monitoring before and after 
hydrochlorothiazide 100 mg once daily and reported an 
increase in both simple and complex ventricular 
arrhythmias. However, the study design excluded 
patients with either multifocal extrasystoles or 
complex ventricluar arrhythmias during the initial 
assessment. Since ventricular ectopic activity varies 
markedly from day to day (192), this exclusion would 
increase the chance of finding greater ectopic activity 
during the second assessment whether or not there had 
been any change in therapy. Although the authors argue 
that subsequent potassium repletion reduced ectopic 
activity, this third period of assessment was carried 
out only on a group of seven patients (21% of the 
original group) who had demonstrated the highest grades 
of ventricular ectopy while on thiazides. By selecting 
those with the highest rate of ectopic activity, we 
might again expect some reduction in ectopic frequency 
by chance alone. Hollifield and Slaton (199) also 
reported that hydrochlorothiazide 50-100 mg once daily 
increased arrhythmia frequency; however, ECG monitoring 
in this study was carried out over very short time 
periods (five minutes only) before and during exercise 
testing and the study was not placebo-controlled.
The MRC Mild Hypertension Trial included two substudies
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of the effects of thiazide diuretics on ventricular 
ectopic activity which also produced conflicting 
results (205). In the first, one hundred and ten 
patients were randomly allocated to either placebo or 
bendrofluazide with or without potassium 
supplementation and were studied by twenty-four hour 
ambulatory ECG monitoring at baseline and again at ten 
weeks; none of the groups showed a significant change 
in ectopic activity. In the second, longer-term study, 
ventricular extrasystoles occurred more commonly in 
those taking thiazides than in the placebo group but no 
baseline assessment was carried out and there was no 
significant association between the number of 
ventricular extrasystoles and serum potassium 
concentration within the thiazide treated group. 
Interest in the relationship between thiazide diuretics 
and ventricular arrhythmia has been stimulated by the 
sub-group analysis from MRFIT suggesting that diuretic 
therapy may predispose to ventricular arrhythmia and 
thus increase mortality in hypertensives with abnormal 
ECGs (201). This form of analysis, however, has been 
much criticised and other major studies have failed to 
provide confirmatory evidence. Data have recently been 
published from the Glasgow Blood Pressure Clinic 
demonstrating that diuretic-induced hypokalaemia is not 
a risk factor for mortality either in the clinic as a 
whole or in a subgroup of patients with left 
ventricular hypertrophy (206). In addition, the
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Hypertension Detection and Follow-up Program (HDFP), 
which included one thousand, nine hundred and 
sixty-three patients with mild hypertension and minor 
ECG abnormalities, found that diuretic therapy (usually 
chlorthalidone 50 mg once daily) reduced cardiovascular 
mortality (207). In other studies, including the 
Veterans Administration Study (208) and the Australian 
Mild Hypertension Study (209), there was again no 
evidence that thiazides predisposed to sudden death, 
the incidence of both fatal myocardial infarction and 
sudden death being lower in thiazide treated groups 
than in controls.
In summary, we found that although left ventricular 
hypertrophy was associated with an increased prevalence 
of simple and complex ventricular arrhythmias, 
arrhythmia frequency was not increased by 
diuretic-induced hypokalaemia.
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CHAPTER 9
RELATIONSHIP OF VENTRICULAR ARRHYTHMIAS TO CORONARY 
ARTERY DISEASE.
Introduction
In chapter four, ECG LVH was shown to be associated 
with a risk of cardiovascular mortality that was in 
excess of that attributable to associated risk factors 
such as cigarette smoking and hypertension. It was 
suggested that this excess risk might be explained by 
the high prevalence of ventricular arrhythmias in 
hypertensive patients with LVH. It is possible, 
however, that the risk is associated with, but not 
directly attributable to, arrhythmia and that 
ambulatory ECG monitoring was simply detecting those 
patients with coronary artery disease who were already 
at increased risk.
It was considered important, therefore, to determine 
whether high grade ventricular arrhythmias occurring in 
this group of patients are simply a manifestation of 
asymptomatic coronary artery disease. The question has 
therapeutic implications; if severe and extensive 
coronary artery disease was prevalent in a group of 
middle aged individuals known to have a five year 
mortality rate in excess of 35%, there may be a case 
for more intensive investigation and treatment of the
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coronary disease either by aorto-coronary bypass 
grafting or other techniques. If, however, the 
arrhythmias were related to the process of hypertrophy 
itself, or to other myocardial (as opposed to coronary) 
abnormalities, treatment should be aimed at either 
preventing hypertrophy and its complications or perhaps 
treating the arrhythmia.
Thus the aim of this analysis was to determine the 
prevalence and severity of coronary artery disease in 
those patients with LVH and ventricular tachycardia.
Materials and methods
Study group
Seventeen hypertensive patients with both 
electrocardiographic and echocardiographic evidence of 
LVH underwent cardiac catheterisation and coronary 
arteriography. Two patients had definite Q wave 
evidence of previous infarction but were asymptomatic 
at the time of catheterisation. None had experienced 
chest pain within one year of cardiac catheterisation. 
The indication for coronary arteriography was that all 
seventeen had shown at least one episode of ventricular 
tachycardia during 48 hour ambulatory ECG monitoring. 
The baseline characteristics of the study group are 
summarised in table 33.
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TABLE 33
BASELINE CHARACTERISTICS OF PATIENTS UNDERGOING CORONARY ARTERIOGRAPHY
INITIALS SEX AGE (YRS) SMOKER
JC M 58 NO
MO F 68 NO
JK M 61 NO
CP M 66 NO
WH M 63 YES
AM M 30 YES
JM M 52 YES
JB M 69 YES
MP F 46 NO
TC M 61 NO
MM F 67 NO
RS M 44 YES
AN M 56 NO
LM M 43 YES
DD M 48 NO
TD M 61 NO
WJ M 61 NO
Methods
Written informed consent was obtained from all 
patients. Standard left heart catheterisation was then 
carried out under local anaesthetic via the right 
femoral artery using a modified Seldinger technique. A 
long J-shaped guide wire was passed into the femoral 
artery and a 7F pigtail catheter was threaded over the 
guide wire and into the aorta. Heparin 5000 
International Units was given as an intra-arterial 
bolus. A left ventricular angiogram was then performed 
using 40-50 ml contrast medium (NIOPAM) injected 
mechanically over 1-2 seconds, the angiogram being 
recorded onto 35 mm film at a film speed of 50 frames 
per second. The pigtail catheter was then replaced by 
appropriate coronary catheters, usually size 7 shape 4 
Judkins left and right coronary catheters, but variable 
according to local anatomy. Four views of the left 
coronary artery (30 degrees right anterior oblique, 60 
degrees left anterior oblique, craniocaudal and 90 
degrees left lateral) and two views of the right 
coronary artery (60 degrees left anterior oblique and 
30 degrees right anterior oblique) were recorded. At 
the end of the procedure, heparinisation was reversed 
by a slow intravenous injection of protamine sulphate 
(5 millilitres).
The coronary arteriograms were then reviewed 
independently by myself and by a consultant
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cardiologist (HJD); any discrepancies in reporting were 
settled by discussion. The arteriograms were classified 
according to whether or not they demonstrated occlusion 
or stenosis, the latter defined as a reduction of the 
luminal diameter by <30%, 30-50%, 50-70% or >70% in one 
or more of the major epicardial coronary vessels.
Results
The results of coronary arteriography in those patients 
with left ventricular hypertrophy and ventricular 
tachycardia are shown in table 34. Of the seventeen 
patients, seven (41%) had no significant coronary 
artery disease. When the two patients with both history 
and ECG evidence of previous infarction are excluded 
(JK and WH), only five of the fifteen remaining (33%) 
had either an occluded vessel or a stenosis of greter 
than 70% and none had triple vessel disease.
Discussion
A limitation of this analysis was the lack of a 
suitable control group. Nonetheless, the high 
prevalence of ventricular arrhythmia in hypertensive 
left ventricular hypertrophy cannot be attributed 
solely to "conventional1 epicardial coronary artery 
disease since almost one half of the study group were 
free of severe stenoses. This does not necessarily
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TABLE 34
FINDINGS AT CORONARY ARTERIOGRAPHY IN PATIENTS WITH V.T.
INITIALS L.M. L.A.D. CX R .C.A.
JC N >70% N <30%
MO N OCC <30% >70%
JK N <30% N OCC
CP N N N N
WH N OCC <30% OCC
AM N N N N
JM N N N N
JB N >70% >70% N
MP N N N N
TC N N N N
MM N >70% >70% <30%
RS N N N N
AN N N N 30-50%
LM N 30-50% N >70%
DD N N N N
TD N N 30-50% N
WO N >70% <30% OCC
L.M. = LEFT MAINSTEM
L.A.D. = LEFT ANTERIOR DESCENDING
CX = CIRCUMFLEX
R.C.A. = RIGHT CORONARY ARTERY
N = NORMAL
<30% = <30% STENOSIS
30-50% = 30-50% STENOSIS
50-70% = 50-70% STENOSIS
>70% = >70% STENOSIS
OCC = OCCLUDED
imply, however, that ventricular arrhythmias in 
hypertensive patients with left ventricular hypertrophy 
are unrelated to myocardial ischaemia. As discussed in 
chapter 2.8, it is clear that patients with left 
ventricular hypertrophy can develop typical 
exercise-induced angina pectoris and
electrocardiographic evidence of myocardial ischaemia 
even when the major coronary vessels are patent 
(118,119). This presumably reflects the inability of 
the coronary supply to keep pace with the increased 
demand of the hypertrophied left ventricle and at least 
one clinical study has demonstrated a reduced coronary 
vascular reserve in patients with left ventricular 
hypertrophy secondary to hypertension (136).
It is possible, therefore, that coronary stenoses less 
severe than those considered "critical" in an otherwise 
normal heart may result in ischaemia in the presence of 
an already reduced coronary reserve. We have, however, 
not investigated this further, partly because of the 
lack of suitable "in vivo" techniques for assessing the 
functional significance of coronary stenoses in 
patients with left ventricular hypertrophy.
The relationship between hypertrophy, coronary artery 
disease and ventricular arrhythmia has not previously 
been studied in hypertension but there has been some 
corroborative evidence from other forms of left 
ventricular hypertrophy. Klein recently reported on the 
prevalence of ventricular arrhythmias in one
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and twelve patients with aortic valve disease and the 
relationship of arrhythmia to the presence or absence 
of associated coronary artery disease (210). Complex 
ventricular arrhythmias occurred in 40 of 102 patients 
(39%) but the presence of arrhythmia bore no 
relationship to the presence of coronary artery 
disease.
In summary, therefore, the occurrence of ventricular 
tachycardia during ambulatory monitoring was not simply 
an indicator of severe but otherwise "silent" coronary 
disease. This would be in keeping with the suggestion 
that a tendency to ventricular arrhythmia might explain 
the "excess" mortality associated with LVH over and 
above that attributable to associated risk factors such 
as cigarette smoking and hypertension. As noted in 
chapter seven, the occurrence of such arrhythmias is 
related to the degree of cardiac hypertrophy assessed 
by echocardiography and to the presence of 
repolarisation changes on the ECG; it does not appear 
to be closely related to the presence of coronary 
disease.
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CHAPTER 10
HISTOLOGY OF HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY 
Introduction
Having shown that high grade ventricular arhythmias 
occur with increased frequency in those hypertensives 
with left ventricular hypertrophy, and that this 
tendency to arrhythmia is not wholly explained by 
coronary artery disease, we next investigated 
myocardial factors that might be related to ventricular 
arrhythmia. It has been shown previously that marked 
cardiac hypertrophy is associated with subendocardial 
ischaemia (125) and myocardial fibrosis (92).
The aim of this analysis was to quantify, using a point 
counting system, the ischaemic myocardial changes 
present in the left ventricular subendocardium of 
hypertensive patients with LVH and ventricular 
tachycardia and to compare this with a control group.
A further aim was to investigate the association 
between myocardial changes seen on biopsy and left 
ventricular mass, as determined by echocardiography, 
and left ventricular function, as determined by 
estimation of the left ventricular ejection fraction 
from the cineangiogram.
PAGE 149
Materials and Methods
Patients
Over a two year period, we carried out left ventricular 
endomyocardial biopsy as an extension of the cardiac 
catheterisation investigation if catheterisation, 
angiography and coronary arteriography had not provided 
an explanation for the patient's symptoms or for the 
results of non-invasive investigations.
During this period, forty-eight hour ambulatory ECG 
monitoring was performed on all patients with left 
ventricular hypertrophy undergoing cardiac 
catheterisation. Thirty-seven patients were 
investigated but satisfactory biopsies were achieved in 
only twenty-seven. In the remainder, either the 
bioptome could not be manouvred into a suitable 
position, or the biopsy obtained was too small for 
quantitative analysis.
The twenty-seven patients comprised two groups:
1. A study group of eleven patients in whom forty-eight 
hour ambulatory ECG monitoring had demonstrated at 
least one episode of ventricular tachycardia. Six of 
the eleven came from the original group of one hundred 
hypertensives described in chapter five. The remainder 
were detected after we had completed the study of 
arrhythmia prevalence. In addition to ventricular
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tachycardia during ambulatory monitoring, all had left 
ventricular hypertrophy by both ECG and 
echocardiographic criteria.
2. A control group of sixteen patients. As in the study 
group, all had ECG and echo evidence of left 
ventricular hypertrophy. The principal difference 
between the two groups was that none of the control 
group had demonstrated either ventricular tachycardia 
or ventricular couplets during forty-eight hour 
ambulatory ECG monitoring. Left ventricular biopsy was 
only carried out if the catheterisation procedure had 
not provided an explanation for the patient's symptoms. 
Thus nine patients who were investigated because of 
chest pain and an abnormal non-invasive test (either 
treadmill exercise test or exercise radionuclide 
ventriculogram) were found to have no significant 
coronary artery disease and underwent left ventricular 
biopsy. In addition, seven patients with hypertension 
and a systolic aortic valve murmur were found to have a 
non-significant aortic valve gradient at 
catheterisation; left ventricular biopsy was also 
carried out on these patients.
Methods
1. Left ventricular mass was calculated in all patients 
from the M-mode echocardiogram using the cube formula
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and the "Penn" convention as described in chapter 5.
2. Left ventricular ejection fraction was estimated 
from the left ventricular cineangiogram taken in the 30 
degree right anterior oblique projection. The angiogram 
was recorded onto 35 mm film as described in chapter 9. 
The image was then projected onto a screen and the 
outline of the ventricle at both end-systole and 
end-diastole traced onto transparent paper. Left 
ventricular volumes at end-systole and end-diastole 
were then calculated according to the method described 
by Greene et al (211):
3.14
v = --------LM2
6
where,
V = volume
L = long axis of the ventricle 
M = short axis taken at right angles to the 
midpoint of L
Ejection fraction was then calculated as follows.
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percutaneously for biopsy of the right or left 
ventricle. The tissue obtained can then be analysed by 
histological, immunochemical, virological or enzymatic 
techniques.
In our routine practice, biopsy is carried out at the 
end of cardiac catheterisation. Since formation of 
mural thrombus with subsequent embolism seems 
potentially a greater hazard than perforation of an 
already thick left ventricular wall, all biopsies are 
carried out with the patient heparinised, and the 
heparin effect reversed with protamine sulphate at the 
end of the procedure. Using the Seldinger technique, 
the coronary catheter and short sheath are replaced by 
a size 7F "pigtail" catheter and long sheath with a 
valve at the proximal end. The guide wire is removed 
and the catheter flushed and connected to the pressure 
transducer. The catheter tip is manipulated into the 
left ventricle using both the pressure recordings and 
the X-ray screening unit to determine its position. The 
catheter is then withdrawn, leaving the distal end of 
the sheath in the ventricle. The lumen of the sheath is 
then flushed with saline via a side-port. Finally, the 
biopsy forceps (shown in figure 10) are advanced and 
the jaws opened as soon as the forceps project out of 
the sheath. The open forceps are then advanced against 
the ventricular wall, closed and withdrawn. The 
procedure is repeated from three to five times, the 
angulation of the sheath being adjusted after each
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Figure 10
Biopsy forceps as used for left 
ventricular biopsy.
(shown with jaws open)
biopsy so "that samples are taken from different areas 
of the ventricle. The biopsy samples are then prepared 
for light microscopy in the standard way.
B. Risk of biopsy
At the Western Infirmary, over one hundred patients 
have now undergone cardiac biopsy. There have been no 
deaths, and, among the twenty-seven patients described 
in this analysis, no side-effects with the exception of 
short-lived ventricular arrhythmias (usually five to 
ten complexes) as the biopsies are taken. In other 
patients undergoing endomyocardial biopsy, the most 
serious complication has been haemopericardium which 
has occurred twice following attempted right 
ventricular biopsy and once during left ventricular 
biopsy on a patient with a dilated ventricle and active 
myocarditis. In all three cases, the haemopericardium 
was confirmed by echocardiography; surgical 
intervention has not been required. In addition, one 
patient developed a transient ischaemic episode 
approximately twelve hours after biopsy, presumably as 
a result of embolism from a mural thrombus; fortunately 
this resolved completely.
In 1980, Richardson reviewed the published world-wide 
complications of endomyocardial biopsy (213). Of a 
total of 2337 biopsies, haemopericardium occurred in 
nine patients (0.38%) requiring surgery in six (0.26%).
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Dysrhythmia occurred in 0.81% and other complications 
were rare. No deaths were reported.
Thus left ventricular biopsy appears to be a relatively 
safe procedure which adds little to the risk of 
standard cardiac catheterisation.
C. Biopsy analysis - theory and practice
1. Theory
The principle of point counting is as follows: if we 
superimpose a grid containing a number of dots or 
points on a transected area, we can count the number of 
points overlying a given "area of interest" and divide 
this by the total number of points to derive the "area 
fraction" occupied by our region of interest. This is 
illustrated in figure 11. Having calculated the area 
fraction in two dimensions in this way, it has been 
shown that this approximates to the volume fraction in 
three dimensions (214).
The major problem with this technique is in deciding 
how many points to count and this has been the subject 
of some controversy. There are two issues to consider:
1. The greater the number of points counted, the 
greater will be the accuracy of the technique.
2. The smaller the area fraction of the substance or 
tissue being measured, the greater will be the total
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Figure 11
Principle of point counting
The square grid contains 64 points, each one 
at the centre of a square. We can estimate 
the "volume fraction" of the area of interest 
(shaded area) by expressing the number of 
points inside this area as a fraction of the 
total number of points, 
i.e. volume fraction of shaded area = 11/64 = 
0.172.
number of points required for a given degree of 
accuracy.
The optimum number of points to count can be expressed
1-Vv
RSE
where RSE = relative standard error
Vv = volume fraction of interest 
n = number of points falling on an
area of interest (number of "hits")
If the area fraction under investigation does not vary 
greatly from one specimen to another, then the 
recommended technique is to calculate the number of 
"hits" required for a given error that is considered 
acceptable, say 5%, and then to continue counting until 
this number of "hits" is achieved. All measurements 
will then have a similar error. However, analysis of 
the first myocardial biopsies revealed that the area 
fraction occupied by fibrous tissue could vary between 
0% and 30%. Clearly, if there was no evidence of 
fibrous tissue in a specimen, then there would be no 
"hits" and the optimum number of points to count would
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be infinite. Thus some compromise in the methodology 
was required. Preliminary analysis of the first ten 
biopsies suggested that the mean percentage area 
staining positively with either Masson's connective 
tissue stain or Elastica van Gieson stain might be 
around 5%. If we then consider an error of 5% to be 
acceptable, we can calculate the number of points to be 
counted as follows:
1-Vv
relative standard error = _______
n/ *
1-0.05
0.05 =
0.05
n = 361
However, n represents the number of hits required; 
since Vv = 0.05, the total number of points to be 
counted (N) to achieve a relative standard error of 5% 
is equal to 361 x 20 = 7220. Thus it was decided to 
count 8000 points in each biopsy although we have to
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accept that the relative error increases as the area 
fraction occupied by our area of interest (i.e. the 
percentage fibrosis) falls. Table 35 illustrates the 
relative standard error for different values of Vv 
ranging from 40% to 0.1%. Thus when Vv equals 5%, the 
error of the method is just under 5%; when Vv equals 
1%, the error rises to 11%. When viewed in the context 
of the results section to follow, errors of this 
magnitude appear to be acceptable although clearly it 
would be wrong to discriminate between groups with low 
values for Vv since the error within each measurement 
at this level is large.
2. Practice
Having decided on the number of points to be counted, 
endomyocardial biopsies from 27 patients were analysed. 
Full documentation of left ventricular function 
(ejection fraction measured at angiography), left 
ventricular structure (left ventricular mass estimated 
echocardiographically), coronary anatomy and the 
presence or absence of ventricular arrhythmia during 
ambulatory monitoring was available in all patients. To 
eliminate any bias, biopsies were identified by their 
specimen number only and thus the identity of the 
patient was unknown at the time of microscopy. A 
standard binocular microscope (ERNST LEITZ WETZLAR) 
with 10X eyepiece lenses and a 40X objective lens was
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TABLE 35
CALCULATION OF STANDARD ERROR FOR DIFFERENT VALUES OF "n"
PERCENTAGE HITS 1-Vv n V " RELATIVE STANDARD ERROR
40 0.6 3200 56.6 0.011
20 0.8 1600 40.0 0.020
10 0.9 800 28.3 0.032
5 0.95 400 20.0 0.048
1 0.99 80 8.94 0.110
0.5 0.995 40 6.32 0.157
0.1 0.999 8 2.83 0.353
used. A "Chalkey" graticule with 25 points randomly 
distributed was inserted into the right eyepiece. 
Sections stained with Masson’s connective tissue stain 
and Elastica van Gieson stain were then examined 
separately. The former stains collagen and other 
extracellular protein green while the latter stains 
collagen purple. For each stain, eighty high power 
fields were examined. From each patient, there were 
between two and five biopsies and a variable number of 
slices had been taken serially through each biopsy. To 
count eighty high power fields, I started at a 
preselected corner of the first section of the first 
biopsy and worked diagonally towards the opposite 
corner. The process was repeated on all available 
sections from each biopsy from that patient. If this 
did not result in eighty fields, as might occur if few 
biopsies had been obtained or if the biopsies 
themselves were particularly small, the process was 
repeated starting at a different corner of the same 
sections until eighty fields had been counted. The only 
requirements of a "field" were that it had to be 
completely filled by tissue and that it did not include 
the endocardium since the aim was to measure 
subendocardial connective tissue and thus the normal 
endocardial collagen was excluded. At times, the 
endocardial surface had been cut tangentially causing 
the endocardial connective tissue to appear to lie in 
the deeper subendocardium; fields showing this
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Figure 12
Examples of myocardial histology 
Masson's trichrome connective tissue stain
(a) Normal myocardium (x400)
(b)'Myocardium showing increased fibrous tissue 
(Green staining) - (x400)
Figure 13
Examples of myocardial histology 
Elastica/Van Gieson stain
(a) Normal myocardium (x*t00)
(b) Myocardium showing increased fibrous tissue 
(Purple staining) - (x400)
Figure 14
Illustration of Endocardial Thickening
(a) Normal endocardium (x200) -Masson's Stain
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(b) Abnormally thickened endocardium (x200) - Masson's Stain
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appearance were also excluded.
For each field, a total of 100 counts were made by 
rotating the 25 point eyepiece lens through 90 degrees 
three times thus yielding a total of 8000 points 
counted per patient. The number of ''hits'' was then 
divided by eighty to obtain the percentage fibrosis 
(EVG stain) and the percentage interstitium (Masson). 
Examples of the two stains are shown in figures 12 and 
13. Although no quantitative assessment of endocardial 
thickness was made, it was noted that those patients 
with marked fibrosis also tended to have thickening of 
the endocardium. This is illustrated in figure 14.
Results
Data relating to age, sex, degree of left ventricular 
hypertrophy, and left ventricular function for the two 
groups are shown in tables 36 and 37 and the results 
summarised in table 38. The two groups were of course 
not matched for symptoms or indication for cardiac 
catheterisation, but in other respects they were 
similar. Mean age for those with VT was 56+4 years 
(range 30-69 years) compared to 54+2 (range 30-68 
years) for those without VT (NS). Sex distibution was 
also similar in the two groups. Ejection fraction 
measured at cardiac catheterisation is plotted for both 
groups in figure 15. The group with VT shows a wider 
range of ejection fractions (from 15^ to 80-5) and has a
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mean ejection fraction that is lower, although not 
significantly so, than the group without VT. Values for 
left ventricular mass for the two groups are shown in 
figure 16. Taking 200 g as an approximate upper limit 
of normal for left ventricular mass, all of those with 
VT and 13/17 of those without had LVH. However, the 
degree of left ventricular hypertrophy was more marked 
in those with VT (442+28 g vs 339+<34g, p=0.037).
The results of the histological analysis are shown in 
table 39 and demonstrated graphically in figures 17 and 
18. The biopsy results for the two groups were compared 
using a two-tailed t-test for unpaired data. The area 
fraction, and thus volume fraction, occupied by both 
interstitium (figure 17) and fibrous tissue (figure 18) 
was significantly greater in those with ventricular 
tachycardia than in those without (19+4% vs. 3+1% for 
interstitium, (p<0.001), and 13+3% vs. 2+1% for 
fibrosis, (p<0.001)).
The relationships between myocardial fibrosis and 
hypertrophy, and between myocardial fibrosis and left 
ventricular function, are examined in figures 19 and 20 
respectively. Although most patients with more than 10% 
fibrosis did have marked hypertrophy, the reverse was 
not true and overall there was no significant 
correlation between the two variables (figure 19).
There was, however, a significant correlation between 
ejection fraction and percent fibrosis. Four patients 
had ejection fractions less than 30% (normal range
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TABLE 36
CHARACTERISTICS OF PATIENTS WITH LVH AND VT IN
BIOPSY ACHIEVED:
SUCCESSFUL
EJECTION
INITIALS AGE SEX LV MASS LVEDP FRAC1
(years) (g) (nvnHg) (%)
JC 58 M 362 9 73
MO 68 F 387 12 70
AM 30 F 598 11 54
JB 69 M 401 16 29
MP 46 F 296 12 73
TC 61 M 475 15 70
MM 67 F 417 4 80
RS 44 M 387 20 23
AN 56 M 540 18 15
DD 48 M 442 9 77
MA 66 F 561 20 24
TABLE 37
CHARACTERISTICS OF PATIENTS WITH LVH BUT WITHOUT VT ON 48 HOUR 
AMBULATORY MONITORING IN WHOM SUCCESSFUL BIOPSY ACHIEVED:
EJECTION
INITIALS AGE SEX LV MASS LVEDP FRAC
(years) (g) (nmHg) (%)
IR 42 M 302 8 74
JD 59 M 189 20 50
JW 62 M 612 11 74
JM 61 M 196 9 68
JM 30 M 563 14 64
IM 44 F 261 7 64
RD 60 M 485 12 69
HM 63 M 294 16 66
CM 58 F 175 8 74
JS 68 F 274 7 57
NG 50 M 286 20 40
EO 55 F 170 16 64
JH 59 M 327 11 65
LM 43 M 497 9 65
WM 62 M 375 10 65
EK 43 F 476 9 43
PL 52 M 278 11 59
TABLE 38
HYPERTENSIVES WITH VT 
(n=ll)
HYPERTENSIVES WITHOUT VT 
(n=17)
AGE (YEARS) 
M:F
LV MASS (g) 
LVEF (%)
LVEDP (run Hg)
58+4
8:3
442+28
53+8
13+2
54+2
13:4
i
339+34
62+2
12+1
* p<0.05
TABLE 39
BIOPSY FINDINGS - ALL PATIENTS
INITIALS % INTERSTITIAL PROTEIN % FIE
JC 11.5 12.8
MO 16.2 8.8
AM 11.8 9.0
JB 18.0 9.4
MP 23.0 12.4
TC 5.7 3.4
MM 4.2 5.0
RS 18.6 29.8
AN 43.9 16.4
DD 14.2 6.8
MA 41.4 31.2
IR 15.3 9.6
JD 4.3 3.6
JW 0.2 1.4
JM 8.0 5.4
JM 2.2 1.6
IM 2.2 2.0
RD 3.9 2.2
HM 0.0 0.0
CM 0.6 2.0
JS 1.2 2.4
NG 0.0 0.0
EO 6.2 7.6
JH 0.2 0.4
LM 2.6 1.0
WM 0.5 0.4
EK 0.3 1.6
PL 2.4 1.6
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Figure 15
E je c t ion  f r a c t io n  values f o r  
p a t ien ts  w i th  and w i thout 
v e n t r i c u la r  tachycardia
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L e f t  v e n t r i c u la r  mass fo r  
p a t ie n ts  w i th  and w ithout 
v e n t r i c u la r  tachycardia
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Figure 17
% i n t e r s t i t i a l  volume in pa t ien ts  
w i th  and w i thou t  v e n t r i c u la r  
tachycardia
With Without
V.T. V.T.
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Figure 18
% volume o f  f i b r o s i s  in pa t ien ts  
w i th  and w i thou t  v e n t r i c u la r  
tachycardia
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(n = 17)
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Rela t ionsh ip  between l e f t  v e n t r i c u la r  mass 
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700—, •  Pa t ien t  w i th  V.T. 
o Pa t ien t  w i thout
p = NS
600-
500
300-
00
200-
100 -
% f ib r o s i s
90
80
70
60
50
40
30
20
10
0
:igure 20
Relat ionship between l e f t  v e n t r i c u la r  func t ion  and 
: ib ro s is
•  Pa t ien t  w i th  V.T.  
o Pa t ien t  w i thout V.T.
00
r = 0.57
p = 0.01
0 10 15
nr
20 25 30
% f i b r o s i s
45-70-5); all four had significant amounts of myocardial 
fibrosis and two had approximately 30% fibrous tissue 
by volume. Overall, there was a weak inverse 
correlation between ejection fraction and % fibrosis 
(figure 20) although several patients with up to 12% 
fibrous tissue by volume still had a normal ejection 
fraction.
Discussion
These results demonstrate a relationship between the 
occurrence of ventricular arrhythmias and the amount of 
interstitial and fibrous tissue present on 
endomyocardial biopsy. In addition, there is a positive 
inverse relationship between ejection fraction and 
fibrous tissue content but no significant relationship 
between degree of hypertrophy and fibrous tissue 
content, suggesting that factors other than hypertrophy 
contribute to the development of fibrosis.
No other study has been reported relating quantitative 
histological features with arrhythmias in hypertensive 
patients. Other studies, however, have attempted to 
quantify the amount of fibrous tissue in hypertrophied 
hearts. Oldershaw et al used a similar point counting 
technique on myocardial biopsies taken from 
ninety-seven patients with aortic valve disease (215).
In fifty-five patients with aortic stenosis, they found 
a distribution of values for percentage volume fibrosis
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that was similar to our series, the range being from 0% 
to 30%. They found a positive relationship between 
fibrosis and aortic valve gradient and a negative 
relationship between fibrosis and left ventricular 
ejection fraction. They found no relationship between 
fibrosis and the presence of co-existent coronary 
artery disease. Follow-up analysis showed that 
percentage fibrous tissue was correlated with 
mortality. Hess et al have assessed the fibrous tissue 
content in patients with primary left ventricular 
hypertrophy (hypertrophic cardiomyopathy and congestive 
cardiomyopathy) and hypertrophy secondary to aortic 
valve disease, and related this to cardiac function 
(216). They found morphological alterations to be most 
marked in those with hypertrophic cardiomyopathy and 
least marked in those with aortic valve disease, 
although the latter group still had approximately 20% 
myocardial fibrosis. In both of these groups, systolic 
function remained normal despite fibrosis. In those 
with congestive cardiomyopathy, systolic function was 
impaired, this being attributed to "inadequate 
hypertrophy" by the authors. Diastolic function, 
however, was abnormal in the majority of patients and 
the degree of impairment was related to the extent of 
myocardial fibrosis. Baandrup et al have also 
quantitatively assessed endomyocardial biopsies but 
found no significant relationship between the amount of 
collagen present and either haemodynamic variables or
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symptomatic status (217). Their study group, however, 
comprised a heterogeneous group of patients suspected 
of cardiomyopathy, small vessel disease and 
myocarditis.
In all studies of quantitative histology, reference is 
made to the limitations inherent in the technique. 
First, the pathological process under investigation may 
be patchy and may be missed by the biopsy; this is 
particularly likely to occur in inflammatory or 
infiltrative disorders such as myocarditis or 
sarcoidosis. Even if the process is diffuse, there may 
be considerable variation from one part of the 
ventricle to another. Baantrup et al have studied the 
regional variation in cell diameter, volume fraction of 
interstitium and of collagen in biopsies from 
twenty-three hearts; they found the coefficients of 
variance for these three varibles to be 18.6%, 28.9% 
and 80.5% respectively and suggested that at least five 
biopsies should be obtained before attempting to 
correlate structural changes with the functional state 
of the heart (217,218). A further problem in trying to 
correlate structural changes seen on biopsy with 
cardiac function is in knowing to what extent 
subendocardial changes are representative of changes 
throughout the thickness of the left ventricular wall. 
This relationship between the site and extent of 
fibrosis and left ventricular hypertrophy has recently 
been examined in a post-mortem study by a Japanese
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group (219). They carried out quantitative analysis of 
the entire left ventricular wall in twenty normal 
hearts, ten hearts from patients with hypertrophic 
cardiomyopathy and ten from hypertensive patients. In 
those with hypertrophic cardiomyopathy, they found 
significantly more fibrosis in the septum than in the 
free wall of the ventricle. In the hypertensive hearts, 
the distribution of fibrosis was more uniform, there 
being no significant difference between the septum and 
the free wall. There was, however, a marked transmural 
difference, the surface area of fibrosis being almost 
four times greater in the inner third (subendocardium) 
than in the outer third (subepicardium).
Thus there are good reasons for caution when attempting 
to correlate subendocardial histological changes with 
alterations in global left ventricular function. 
However, these arguments do not invalidate the data 
relating to arrhythmias since the aim of this analysis 
was to identify any structural changes, focal or 
diffuse, that might be associated with ventricular 
arrhythmia and because any abnormalities present were 
likely to be most marked in the subendocardium.
In summary, we found an association between myocardial 
fibrosis and ventricular arrhythmia; ten of eleven 
patients with ventricular tachycardia had >5% fibrosis 
by volume (figure 19) compared with only three of 
seventeen of those without VT (p<0.01). There were 
differences in left ventricular mass between the two
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groups but these were less marked; while all of those 
with VT had left ventricular mass values greater than 
250g, thirteen of seventeen of those without VT also 
had high left ventricular mass. Thus it appears that 
hypertrophy with fibrosis rather than hypertrophy alone 
is important in the pathogenesis of ventricular 
arrhythmia in hypertensive patients.
PAGE 167
CHAPTER 11
VENTRICULAR COMPLIANCE IN HYPERTENSIVE LEFT VENTRICLUAR 
HYPERTROPHY
Introduction
We have demonstrated that ventricular arrhythmias occur 
commonly in hypertensive patients with left ventricular 
hypertrophy and have suggested that the frequency of 
arrhythmia may contribute to the high mortality 
associated with this ECG abnormality. However, factors 
other than the origin and rate of a tachyarrhythmia can 
influence the cardiac response.
In hypertrophic cardiomyopathy, reduced left 
ventricular compliance is the major abnormality of 
cardiac function (167); this becomes important 
particularly at high heart rates and when effective 
atrial contraction is lost, both of which occur during 
ventricular tachycardia.
In hypertensive left ventricular hypertrophy, similar 
abnormalities of diastolic function have been reported 
(220) and, as in hypertrophic cardiomyopathy, they may 
be important determinants of the haemodynamic response 
to a tachyarrhythmia.
For this reason, we have investigated the relationship 
between left ventricular hypertrophy and diastolic 
function in three groups of hypertensive patients
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matched with each other for age and sex but with 
varying degrees of left ventricular hypertrophy. 
Diastolic function was assessed by measurement of the 
left atrial emptying index (LAEI) which has previously 
been shown to be a simple and sensitive assessment of 
diastolic function (116).
Materials and methods
Subjects
Ten normal control subjects and thirty hypertensives 
comprising ten without ECG LVH, ten with ECG LVH and 
ten with LVH and ST-T changes, were studied. All forty 
had been part of the original cohort of fifty normal 
controls and one hundred hypertensives. They were 
selected on the basis of having a high quality M-mode 
echocardiogram of the aortic root and left atrium and 
further selected to allow the four groups to be 
approximately matched for age and sex; in addition, to 
control for any possible effect of high blood pressure 
itself on diastolic function, the three hypertensive 
groups were matched with each other for achieved 
systolic blood pressure.
Left atrial emptying index
As described by Dreslinski (116), the left atrial
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emptying index (LAEI) is estimated from the M-mode 
echocardiogram recorded through the aortic root and 
left atrium. This is illustrated in diagramatic form in 
figure 21. The LAEI is a measure of the proportion of 
total atrial emptying, and thus ventricular filling, 
that occurs during the first one-third of diastole. The 
first third is the rapid "passive" phase of ventricular 
filling before the onset of atrial contraction. A high 
value (0.75-1.0) indicates normal ventricular 
compliance and a low value indicates reduced 
compliance. As with earlier calculations, measurements 
were taken over three consecutive cardiac cycles and 
mean values calculated.
To illustrate the method, two examples are shown in 
figure 22, one from a normotensive subject with normal 
diastolic function (figure 22a) and one from a 
hypertensive patient with marked left ventricular 
hypertrophy and abnormal diastolic function (figure 
22b).
Results
Table 40 shows the blood pressure, left ventricular 
mass index and atrial emptying index for the thirty 
hypertensive patients and ten normal control subjects 
studied; mean values for the four groups are shown in 
table 41. As before, differences between groups were 
calculated using a two-tailed t-test for unpaired data
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Figure 21
Calculation of left atrial emptying index - Diagram
Electrocardiogram
Anterior aortic 
root
Aortic valve 
cusps
Posterior aortic 
root
Left atrium
o = Initial posterior notion of aortic root
A = Aortic root motion after total atrial emptying 
(end of 'P' wave on ECG)
X = Aortic root displacement after 1/3 total atrial 
emptying
Then:- Parallel lines are drawn through 0,A and X
vertical distance 0-XThen:- Atrial emptying index = _ 6.3vertical distance 0-A 7 A
=  0,851
Figure 22
C a l c u lation of left atrial emptying index - Examples
(a) Normal control
Atrial emptying index = vertical distance 0-X _ g,769 vertical distance 0-A
F i g u r e  22 (continued)
C a l c u l a t i o n  of left atrial emptying index - Examples
(b) H y p e r t e n s i v e  patient with left ventricular hypertrophy
:h*=2f*1' r^ rS-j* r;
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TABLE 40
BASELINE AND ECHO DATA FROM THE FOUR GROUPS STUDIED
INITIALS AGE SBP DBP LVMI LAEI
(years) (mmHg) (mmHg) (9/m2)
a) NORMAL CONTROLS
JA 56 132 88 102.7 0.839
AW 32 118 86 112.9 0.950
DM 51 124 80 97.2 0.798
AC 76 132 76 119.6 0.445
MH 67 136 64 82.0 0.847
MH 67 132 82 39.1 0.902
RH 54 134 78 116.0 0.781
JS 69 102 68 98.5 0.698
JP 52 157 84 128.8 0.823
DM 42 118 80 102.4 0.884
b) HYPERTENSIVES WITHOUT ECG LVH
LS 58 165 92 99.0 0.639
MI 63 128 86 54.8 0.817
IM 65 168 86 100.1 0.693
MW 42 161 65 87.1 0.517
AP 60 158 88 58.2 0.746
AM 32 140 80 57.1 0.736
MM 76 212 92 80.3 0.357
DB 62 140 92 114.8 0.558
AM 39 128 92 57.3 0.751
MS 50 128 82 122.5 0.288
c) HYPERTENSIVES WITH ECG LVH
WS 67 160 86 135.7 0.579
MY 71 175 110 148.4 0.581
SD 36 144 82 132.3 0.309
KB 59 160 92 129.2 0.584
AG 55 150 78 253.4 0.593
MM 30 136 84 129.1 0.733
MI 74 120 90 119.5 0.494
MV 77 166 100 105.7 0.628
AG 66 177 86 183.9 0.483
VM 65 174 90 156.2 0.558
d) HYPERTENSIVES WITH LVH AND STRAIN
MK
JM
JB
AM
TD
DJ
ES
JL
MC
AM
60
29
68
60
71
62
52
50
51 
29
138
145
210
132
172
155
168
140
130
154
92
95
104
98
92
85
94
78
110
108
174.5 
304.8
214.7
174.8
178.6
218.8 
247.1
170.8
153.8
369.6
0.379
0.388
0.138
0.581
0.584
0.306
0.497
0.707
0.172
0.402
TABLE 41
SUMMARY OF BASELINE DATA
NORMALS HYPERTENSIVES HYPERTENSIVES HYPERTENSIVES 
CONTROLS WITHOUT LVH WITH LVH WITH LVH+STRAIf
(n=10) (n=10) (n=10) (n=10)
AGE (years) 57+4 55+4 60+5 53+5
* ** **
SBP (mmHg) 129+5 153+8 156+6 154+8
** ***
DBP (mmHg) 79+2 86+3 90+3 95+3
** ** **
HEART RATE (bpm) 75+2 67±3 66±3 67+3
** ***
LVMI (g/m2) 100+8 83+8 149±13 221±22
* p<0.02 
** p<0.01 - COMPARED WITH NORMALS
p<0.001
Results corrected for multiple comparisons 
(normals vs. the three other groups) using 
Bonferroni correction factor.
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Figure 23-
Relationship between left atrial emptying 
index and ECG LVH
1 . O C H
0 . 7 5 -
0 . 5 0 -
0.25-
Normal Hypert. Hypert. Hypert.
controls without with with LVH
ECG LVH ECG LVH and strain
n = 10
* p<0.05
** p<0.001
compared with 
normal controls
n = 10 n = 10
possibility that high pressure itself, by increasing 
systolic wall tension and producing subendocardial 
ischaemia, may reduce diastolic compliance and thus 
atrial emptying index. There is a suggestion in our 
data that this does occur; figure 23 demonstrates that 
atrial emptying index is lower in those hypertensives 
without ECG LVH than in the control subjects despite 
similar left ventricular mass index values in the two 
groups. Thus it may be that high blood pressure itself 
reduces left ventricular compliance. In addition, the 
effects of heart rate and antihypertensive treatment on 
left atrial emptying index have not been studied; since 
all of the hypertensives were on treatment, including a 
beta blocker in over 50%, this may contribute to the 
difference between the controls and the hypertensives 
without left ventricular hypertrophy (figure 23). 
However, neither heart rate nor blood pressure is 
likely to explain the differences between the three 
hypertensive groups (figure 23) since both variables 
were similar for all three groups (table 41).
Thus the implication is that as left ventricular mass 
rises, so left ventricular compliance falls and passive 
left ventricular filling is reduced. The heart then 
becomes increasingly dependent on effective atrial 
contraction to maintain ventricular filling and 
ultimately there is hypertrophy of the atrium with the 
appearance of the so-called "left atrial strain 
pattern" on the ECG. The clinical significance is that
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if effective atrial contraction is lost, by for example 
the development of atrial fibrillation or a ventricular 
arrhythmia, then left ventricular filling and thus 
cardiac output will be markedly reduced. It is for this 
reason that the onset of atrial fibrillation in a 
patient with either aortic stenosis or hypertrophic 
cardiomyopathy is an ominous prognostic sign, usually 
accompanied by the development of cardiac failure.
We have not induced ventricular arrhythmias in 
hypertensive patients with LVH, nor have we measured 
cardiac output during a spontaneous tachyarrhyhmia, but 
it is not difficult to imagine that the onset of a 
ventricular tachyarrhythmia in a patient with a 
hypertrophied, non-compliant ventricle will lead to a 
greater fall in cardiac output than would a similar 
arrhythmia in a normal ventricle.
In summary, we have confirmed the finding of Dreslinski 
et al (116) that ventricular compliance, assessed by 
calculation of the left atrial emptying index, is 
reduced in hypertensives with left ventricular 
hypertrophy. By matching the hypertensive groups for 
blood pressure, we have shown that this reduction in 
ventricular compliance is at least in part related to 
the process of hypertrophy rather than to the 
associated hypertension.
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CHAPTER 12
GENERAL DISCUSSION
The first part of this thesis discusses left 
ventricular hypertrophy as a risk factor for 
cardiovascular mortality. Other known risk factors 
include cigarette smoking, high blood pressure, raised 
plasma cholesterol and obesity. However, risk factors 
are often inter-related; for example, there are known 
direct correlations between cholesterol and obesity, 
blood pressure and obesity, and blood pressure and 
cholesterol as well as an inverse correlation between 
cigarette smoking and obesity. Because of these complex 
inter-relationships, statistical techniques such as 
multivariate analysis are needed to determine the 
individual contribution of each risk factor to the 
total risk. Using this technique, it was shown in 
chapter 4 that electrocardiographic left ventricular 
hypertrophy is a risk factor for cardiovascular 
mortality and that the increased risk is not fully 
explained by its association with other known risk 
factors.
In the first part of the text it was also demonstrated 
that the commonly used ECG criteria for left 
ventricular hypertrophy have low sensitivity. Although 
increased risk in epidemiological studies has so far
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only been demonstrated for ECG LVH, and not for echo 
LVH, it seems reasonable to strive to improve the ECG 
diagnosis of LVH. This should aid in the understanding 
of the natural history of cardiac hypertrophy and it 
may be that treatment will produce more effective 
regression if hypertrophy is detected at an early 
stage. Improved diagnosis could be achieved if 
echocardiography was universally available; however, 
this technique is more time-consuming and more 
expensive than electrocardiography and it is not 
possible to obtain technically satisfactory 
echocardiograms from as many as ten or even twenty per 
cent of patients. Thus an improvement in the ECG 
detection of LVH would be a desirable goal. As 
discussed in chapter 6, this could be achieved by some 
form of stratification of patients using readily 
available data, such as age, sex, height and weight.
The second part of this thesis suggested a mechanism 
that might explain why ECG LVH is an independent risk 
factor for mortality. Although it is generally believed 
that the majority of deaths among hypertensives with 
LVH are due to coronary artery disease, the very 
"independence" of LVH as a risk factor argues against 
this since LVH is "independent" of the known risk 
factors for coronary artery disease including age, sex, 
cigarette smoking and blood pressure. This suggests 
either that LVH per se potentiates coronary artery 
disease or that LVH is increasing mortality via a
PAGE 175
different mechanism. We investigated the prevalence of 
ventricular arrhythmia in hypertensive patients with 
and without LVH and found that complex arrhythmias 
occurred commonly in those with ECG LVH and that the 
prevalence of arrhythmia was related to the degree of 
cardiac hypertrophy.
The relationship between ventricular arrhythmias and 
subsequent sudden death, however, has been the subject 
of some controversy. In the Tecumseh Epidemiologic 
Study of 5,200 individuals, premature ventricular 
extrasystoles were associated with an increased 
incidence of sudden death (224). The Coronary Drug 
Project also reported an increased risk of sudden death 
in survivors of myocardial infarction who demonstrated 
ventricular extrasystoles on the resting 
electrocardiogram (225). However, Fisher et al 
suggested that extrasystoles were merely a marker of 
cardiac disease and were no more predictive of sudden 
death than other ECG abnormalities (226). There is, 
however, some consensus of opinion regarding the 
importance of ventricular tachycardia, which has been 
shown to be more closely associated with sudden death 
in patients following myocardial infarction (227), in 
patients with congestive cardiomyopathy (228) and in 
other forms of cardiac hypertrophy, notably 
hypertrophic cardiomyopathy. Some similarities exist 
between hypertensive left ventricular hypertrophy and 
hypertrophic cardiomyopathy and the two conditions may
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be difficult to differentiate (229). Both are 
associated with sudden death and in hypertrophic 
cardiomyopathy, ventricular tachycardia detected by 
ambulatory monitoring is the most powerful single 
predictor of subsequent sudden death (3); furthermore, 
appropriate anti-arrhythmic therapy can reduce 
arrhythmia frequency and may prolong survival (172). No 
such trials of anti-arrhythmic therapy have been 
reported in patients with left ventricular hypertrophy 
secondary to essential hypertension.
It was possible that ambulatory monitoring was simply 
detecting those patients with otherwise silent coronary 
artery disease who were already at increased risk. 
However, further studies suggested that the frequency 
of these arrhythmias was not attributable to a high 
prevalence of coronary artery disease but was related 
to the extent of subendocardial fibrosis which is 
presumably a reflection of chronic subendocardial 
ischaemia. Clearly, an association between the amount 
of fibrosis and the occurrence of ventricular 
arrhythmia does not imply that fibrosis itself is the 
cause of the arrhythmia. However, when viewed in the 
context of the coronary arteriograms of those patients 
with ventricular tachycardia, it does suggest that 
myocardial factors, such as fibrosis or factors that 
correlate with the amount of fibrous tissue present, 
are more important in the pathogenesis of ventricular 
arrhythmia than is the presence of epicardial coronary
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artery disease. In other conditions in which 
ventricular arrhythmias occur commonly, such as 
hypertrophic cardiomyopathy, myocardial fibrosis is 
common and often extensive; in patients with coronary 
artery disease and ventricular arrhythmias, and in the 
vast majority of victims of sudden cardiac death, 
fibrosis is almost always present, usually as a 
discrete "scar" which is thought to be involved in the 
fatal arrhythmia.
The mechanism of ventricular tachycardia has been a 
source of controversy since Mines first suggested that 
ventricular arrhythmias might be caused by a "re-entry" 
circuit (230). However, it is now generally accepted 
that most episodes of ventricular tachycardia, with the 
exception of those occurring within the first 
twenty-four hours of myocardial infarction, are 
sustained by some form form of "re-entrant" circuit 
(231) rather than by repetitive discharge from a single 
focus. Thus, for an episode of ventricular tachycardia 
to occur, there must be both an initiating arryhthmia 
and an abnormal circuit to sustain the arrhythmia. In 
patients with LVH, it is possible that relative 
myocardial ischaemia, due to increased myocardial 
requirements, may initiate such an arrhythmia and that 
myocardial fibrosis, by disrupting and disorganizing 
the myocardial cells, may result in a micro-reentry 
circuit. Certainly the association between myocardial 
fibrosis and ventricular arrhythmia in this analysis
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appeared strong; ten of eleven patients with 
ventricular tachycardia had >5% fibrosis by volume 
(figure 18) compared with only three of seventeen of 
those without V.T. (p<0.05). Differences in left 
ventricular mass were less marked between those with 
and without VT; thus while all of those with VT had 
left ventricular mass values greater than 250g, 
thirteen of seventeen of those without VT also had high 
left ventricular mass suggesting that hypertrophy with 
fibrosis rather than hypertrophy alone is important in 
the genesis of ventricular arrhythmia in hypertensive 
patients.
Finally, it was demonstrated that increasing 
hypertrophy leads to reduced ventricular compliance and 
suggested that this might "sensitise" the heart to the 
effects of a ventricular arrhythmia which involved loss 
of effective atrial contraction.
To demonstrate that this postulated mechanism is the 
cause of the excess risk associated with ECG LVH, two 
pieces of evidence are required. First, we would need 
to demonstrate that the occurrence of ventricular 
arrhythmia on ambulatory monitoring was an independent 
predictor of outcome in patients with LVH. At the time 
of writing (May, 1987), three of the eighteen patients 
with ventricular tachycardia on ambulatory monitoring 
are known to have died compared with one of the 
eighty-two without ventricular tachycardia. Although 
this represents a statistically significant difference
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when tested by Chi-squared analysis, (3/18 vs. 1/82 
p<0.02), it has to be borne in mind that those with 
ventricular tachycardia were already at increased risk 
on account of their higher prevalence of left 
ventricular hypertrophy and slightly higher blood 
pressure readings. The numbers are clearly too small 
for multivariate analysis.
Ultimately, the only justification for instituting 
treatment that is designed to modify a risk factor is 
the demonstration that such risk factor reduction 
improves prognosis. Although such proof is not 
available for the treatment of ventricular arrhythmias 
in hypertensive left ventricular hypertrophy, there is 
some evidence that, in hypertrophic cardiomyopathy, 
effective anti-arrhythmic therapy with amiodarone can 
prolong survival (177).
In conclusion, a possible mechanism for the excess 
mortality associated with left ventricular hypertrophy 
has been suggested. It is known that hypertensive 
patients, particularly those with left ventricular 
hypertrophy, remain at increased risk of death even if 
blood pressure is apparently well controlled as was the 
case in the patient described in chapter one.
In the past, the aim of the clinician has been to 
control blood pressure in such patients and, if 
possible, to modify other risk factors such as 
cigarette smoking and cholesterol. However, it may be 
that this is not sufficient; other forms of therapy,
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perhaps aimed specifically at regression of cardiac 
hypertrophy, or at suppression of ventricular 
arrhythmia, may be required to reduce mortality in this 
high risk group.
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